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Abstract 
 
Telomeres are fundamental structures found at the end of all eukaryotic chromosomes that 
function to protect the end of chromosomes from end-to-end fusion, erosion and subsequent 
telomere dysfunction. Telomerase and alternative lengthening of telomere (ALT) 
mechanisms maintain the telomeres by compensating natural telomeric loss. ALT is found to 
be present in 15% of human tumours lines and it may be expressed at low levels in the 
normal mouse tissues. However, the exact mechanism behind ALT depression and/or 
activation in the mammalian cells is not fully understood. Previous studies have highlighted 
the role of BRCA1 in telomere dysfunction. Also, it has recently been shown that BRCA1 co-
localises at telomeres in the ALT + human cells through BLM and Rad50. However, it is still 
unclear whether BRCA1 plays a direct role on telomere length maintenance and integrity. 
The aim of this project was to examine the role of BRCA1 in telomere maintenance 
associate with ALT in BRCA1 defective mammalian cells. Therefore to achieve this, we have 
set up series of experiments to look at, (a) hallmarks of ALT activity at the cytological level, 
(b) measuring of ALT activity using biochemical and immunocytochemistry techniques and 
(c) understanding the role of BRCA1 in DNA damage response mechanism and telomere 
dysfunction. 
Firstly, we found elevated levels of recombination at telomeres in the two human BRCA1 
carrier cell lines and mouse embryonic stem cell with deficiency in Brca1-/-. Secondly, our 
data showed that human and mouse BRCA1 defective cells are significantly more sensitive 
to ionizing radiation in line with the DNA repair function of BRCA1. Moreover, we found 
persistent DNA damage at telomeres in the BRCA1 defective environment when after 
exposure of cells to ionizing radiation. Thirdly, we found evidence of ALT activity in some 
mouse cell lines, and elevated ALT in mouse cells defective in Brca1. Finally, we examined 
  III 
some other ALT markers using immunofluorescence. Our data indicate differences between 
human and mouse cells in regulating ALT. 
Taken together data presented in this thesis revealed that (i) BRCA1 plays a major role in 
telomere maintenance and defective BRCA1 mammalian cells show evidence of telomere 
dysfunction and telomere length shortening in line with previous publish data, (ii) BRCA1 
defective mouse cells have elevated levels of ALT, (iii) the mouse lymphoblastoid LY-S cells 
have complete absence of ALT. 
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1 General Introduction 
1.1 Introduction 
 
Telomeres are unique DNA-protein structures at the end of all eukaryotic 
chromosomes that play a critical role in chromosomal end protection and recombination. The 
loss of telomeres causes end-to-end chromosome fusions, cell cycle arrest and/or 
apoptosis/senescence (Blasco et al., 1997, Gilley et al., 1995, Hackett and Greider, 2003, 
Campisi et al., 2001, Maser and DePinho, 2002). In humans telomere dysfunction leads to 
some genetic and common diseases including cancer (Harley et al., 1990, Blackburn et al., 
2006, Donate and Blasco, 2011). The molecular analysis of telomeres began in the 1970s by 
the detection of the DNA sequence of telomeres in a single cell protozoan Tetrohymena 
thermophila (Blackburn and Gall, 1978). Blackburn eventually discovered that the DNA 
sequence at chromosome ends of the T. thermophile contained 50 tandem repeats of the 
(Makarov et al., 1993) hexanucleotide unit CCCCAA/GGGGTT and that these tandem 
repeats ranged from 20 to about 70 suggesting a heterogeneity of the telomeric repeat 
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sequences  (Blackburn et al., 2006). In the subsequent decades (from 1970s to 1990s), it 
emerged that DNA ends of other eukaryotic cells such as Physarum and Dictyostelium 
contained similar tandem repeats including a 3’ overhang of the GGGGTTTT repeat strand 
(Oka et al., 1980, Klobutcher et al., 1981). It was later identified that vertebrate telomeric 
DNA also contained a highly conserved tandem repeat of (TTAGGG)n on all chromosome 
ends (Moyzis et al., 1988, Meyne et al., 1989). Blackburn and Greider also discovered that 
the telomeric DNA is elongated and maintained by an enzyme termed telomerase (Greider 
and Blackburn, 1985). They both received the 2009 Nobel Prize in Medicine and Physiology 
for their discovery. The main function of the telomerase enzyme is to maintain telomere 
length homeostasis in eukaryotic cells but it is shown that telomerase has non-canonical 
function specially in NF-κB and Wnt/β-catenin pathways with critical role in cancer 
development and progression (for review see (Li and Tergaonkar, 2014).  
The problem with telomere replication was noted as far back as 1960’s and prompted the 
Russian scientist Alexsei Olovnikov to propose the end-replication problem hypothesis at 
telomeres that explains telomere shortening (Olovnikov, 1971, Olovnikov, 1973). 
Independently of Olovnikov, Hayflick discovered in the 1960’s that human cells grown in vitro 
have limited proliferative capacity which was later linked to telomere shortening leading to 
the concept of a biological clock (Hayflick and Moorhead, 1961, Hayflick, 1965, Harley et al., 
1990). The discovery of telomere shortening and the function of telomerase enzyme in 
human cells made a link between telomere maintenance and human health from the 
carcinogenesis and aging perspective. It became clear that human cancer cells grown in 
vitro have infinite capacity to proliferate without losing telomere length as a result of 
activation of the telomerase enzyme (Harley et al., 1990, Kim et al., 1994). Telomere erosion 
that occurs in vitro was later linked to cellular senescence termed replicative senescence 
(Wright and Shay, 1992, Shay and Wright, 2005). Cellular senescence is usually interpreted 
as a natural anti-proliferative mechanism operational both in vitro and in vivo (Herrera et al., 
1999, Meeker and De Marzo, 2004) in mammalian cells with a functional role as a barrier to 
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carcinogenesis (Wright and Shay, 1992). Other functional aspect of telomere biology is the 
link to cellular aging (Harley, 2002). Interestingly, it was found that the expression of 
telomerase is suppressed in human diploid somatic cells whereas telomerase activity is 
exhibited in gametes, stem cells and tumour cells. Over 85% of human tumours have active 
telomerase making it a target for future anti-cancer therapy (Harley and Villeponteau, 1995, 
Ducrest et al., 2002). However, the complicating factor is the Alternative Lengthening of 
Telomeres (ALT) pathway active in the remaining 10-15% of cancers functioning 
independent of telomerase-enzyme. The ALT pathway utilises the homologous 
recombination process of DNA replication. The exact mechanism of activation and the roles 
of various proteins involved in the ALT activation and process remain to be fully elucidated.  
Here we will review the biology of mammalian telomeres, look at the key proteins involved, 
highlight the mechanism behind telomere length homeostasis, assess the current knowledge 
on the role of DNA damage response proteins and telomere maintenance and finally review 
the role of BRCA1 (a tumour suppressor) in the maintenance of telomere structural integrity 
in mammalian cells. 
1.2 Structure and Function of Mammalian Telomeres 
1.2.1 Structural biology of Telomeres 
Telomeres are highly conserved repetitive non-coding DNA sequences associated with a set 
of specialized proteins located at the end of linear eukaryotic chromosomes. Telomeric DNA 
is predominantly double stranded with a protruding 3’ overhang that invades the double 
stranded portion of the telomere to form a bigger t-loop and smaller d-loop (Figure 1A). The 
first evidence for the lariat structure of the telomeric loop (t-loop) was provided by (Griffith et 
al.)  (1999) (Figure 1B). It was proposed that these t-loop structures are formed by the 3’ 
overhang strand invasion into the duplex part of the telomere. The main function of the t-loop 
formation was thought to be sequestration of the chromosomal end. Recently, a super-
resolution fluorescence imaging using stochastic optical reconstruction microscopy 
(STORM), verified the formation of t-loop within chromosomes (Doksani et al., 2013) (Figure 
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1C). The t-loop configuration of telomere is maintained by a group of telomeric proteins 
(discussed in section 1.2.4 below).  
 
  
Figure ‎1-1. Proposed structure of the mammalian telomeres.  
A) Telomeric DNA sequences are located at ends of chromosomes. Telomeres can be visualised using 
fluorescently tagged probe specific to the telomeric tandem repeats (TTAGGG)n (Green) whereas genomic DNA 
can be counterstained with fluorescently tagged DAPI (Blue). B) Electron microscopy has revealed the lariat 
structure of the telomeres forming a large t-loop (Griffith et al., 1999). C) These structures was recently shown 
using fluorescence tagged FISH and STORM imaging (Doksani et al., 2013). 
 
The length of telomeric DNA varies in size in different species. For example, telomeres are 
typically found to have a length of about 10-15 kb in human primary cells and 20-50 kb in 
mouse and rats cells (Broccoli et al., 1996). In canine chromosomes the range is 12-23 kb 
A 
B C 
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(Nasir et al., 2001). In all vertebrates telomere sequence consist of a 3` tandem repeat of 
(TTAGGG)n. The double stranded 5’ end and single stranded 3’ end of the telomere 
sequence is attached with a highly conserved protein set known as shelterin (de Lange, 
2005a). The shelterin complex protects the integrity of the telomeres and prevents 
illegitimate recombination, repair and sequence end-fusion thus helping create a stable 
linear chromosomal end. The shelterin complex consists of 6 proteins: telomere repeat factor 
1 and 2 (TRF1/2), POT1, TIN2, Rap1 and TPP1 (see section 1.2.3 for detail). Telomeres 
face another problem due to their unique structure and position at the ends of linear 
chromosome known as end-replication problem first described by (Olovnikov, 1971). 
1.2.2 End replication problem 
Replication of DNA is the process of doubling DNA molecule that occurs in the S-phase of 
cell cycle. It has been recognized that the ends of linear chromosomes are replicated 
differently from the rest of the genome. In 1971 Olovnikov established a theory of telomere 
replication known as the ‘End Replication Problem’. The theory revealed that in somatic cells 
in each round of DNA replication a portion of telomeric DNA is lost because of end under-
replication which contributes to the gradual change in cellular phenotype, from normal and 
young to an old phenotype. The experimental work by Hayflick demonstrated the existence 
of cellular senescence (Hayflick and Moorhead, 1961, Hayflick, 1965) thus providing a 
logical background for the Olovnikov hypothesis. Furthermore, it was confirmed 
experimentally that germline and tumour cells are able to protect their telomeric DNA from 
shortening by expression of Telomerase, which is suppressed in normal somatic cells 
(Greider and Blackburn, 1985, Greider and Blackburn, 1989). 
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Based on this idea the traditional DNA replication machinery, which replicates the middle 
regions of chromosomes, is naturally unable to replicate their termini. Conventional DNA 
polymerases extend RNA primers, which are subsequently removed, thus creating gaps at 
lagging DNA strands (Figure 1.2).  
However, DNA sequence loss at telomeres is not consistent with the RNA primer size which 
is in the region of 10 base pairs (Okazaki et al., 1967). Measurements indicate that the size 
of DNA sequence loss at chromosome ends is in the region of 150-200 bp suggesting the 
involvement of mechanisms such as exonucleolytic degradation (Makarov et al., 1997). 
 
Figure ‎1-2. The end replication problem at telomeres.  
The end replication problem is associated with the lagging strand during DNA replication process. A) The leading 
strand is replicated in continues fashion. B) The lagging strand on the other hand is encountered with gaps as a 
result of the primers (grey boxes) known as Okazaki fragment. At ends of chromosome this leaves a gap where 
the cell is not able to fully replicate. C) This model was first proposed by Makarov et al. 1997 following Olovnikov 
‘end replication problem; theory. In here Makarov proposes that there is a greater degradation at the 5’ end of 
both DNA strands (lagging and leading), leaving a long 3’ overhang at both ends (Makarov et al., 1997). 
1.2.3 The G-quadroplex structure of telomeres 
Interestingly, the unique sequence repeats of the telomeric structure containing three or four 
guanines on the single stranded overhangs gives the structure the ability to form G-
quadruplexes (Rhodes et al., 2006). These structures in theory can provide additional end 
protection and have the ability to be self-recognised due to its unique sequence. These 
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unique G-quadruplexes are shown to form in vivo and have a biological function (Henderson, 
1995). These G-quartets arise from the association of four guanines into a cyclic hydrogen 
bonding arrangements (Fig. 1.3 c). In human cells, the G-quadruplex structure will form 
without any kinetic barriers as a result of long G-overhangs (50 – 200 nucleotides) since it is 
strand concentration independent. It was found that one of the functions of the telomeric 
proteins, TPP1 and POT1 is to prevent the formation of G-quadruplexes (Xin et al., 2008). 
The structure of the G-quadruplex human DNA was first described by Parkinson et al. 
(2002). It was shown that the polymorphic structure of the G-quadroplex is affected by the 
concentration of the K+ and Na+ (Rhodes, 2006). However, the most likely structure is 
thought to be the one affected by the K+ concentration as it exceeds the Na+ concentration in 
vivo (Rhodes, 2006). G-quadruplexes in human cells are shown to inhibit the action of 
telomerase thereby preventing telomere elongation, by sequestering the 3’ overhang and 
preventing telomerase access. This interesting observation provided a possible anti-tumour 
strategy whereby a specific G-quadruplex ligand can be used in human telomerase positive 
tumours to prevent telomere elongation and hence initiate cellular senescence (Riou et al., 
2002) (Cao et al., 2003). 
 
Figure ‎1-3. The G-quadroplex structure of telomeric DNA (Phan et al., 2007).  
Structure of two intramolecular G-quadruplexes formed by natural human telomere sequences in K
+
 solution.  
  Chapter 1: Introduction 
8 
 
  
1.3 Proteins associated with telomeric DNA 
Mammalian telomeres are associated with three types of factors that collectively protect the 
structural integrity of the telomere. These factors are: nucleosomes, the shelterin complex 
and factors/proteins associated with the shelterin complex, known as telomere associated 
proteins. 
1.3.1 Telomeric nucleosome 
It has been shown that telomeres in rat cells are packaged in nucleosomal chromatin 
containing histone H1 (Makarov et al., 1993). The t-loop electron microscopy analysis also 
shows the nucleosomes throughout the tail and the circle very similar to the nucleosomal 
array of the genome. The telomeric chromatin also contains histone H3 that is di- and tri-
methylated on lysine 9 and these methylation patterns of telomeric and sub-telomeric 
regions within the heterochromatin are shown to be regulated epigenetically and function to 
maintain normal telomere length (Blasco, 2007). An important action of demethylation of the 
genome has its effect on telomere stability in cancer. Most cancers have deregulated 
methylation pattern (Baylin, 2005) and these are thought to have an impact on telomere 
length stability and therefore contribute to disease phenotype (Blasco, 2007). Subsequently, 
telomere shortening leads to epigenetic defects at mammalian telomeres and sub-telomeres 
as shown by a decrease in DNA and histone methylation and increase in histone acetylation 
(Blasco, 2007). 
1.3.2 Shelterin   
Over that last 15 years research on telomere structure indicated strongly the existence of the 
shelterin complex contributing to the structural integrity of telomeres. The members of the 
complex, TRF1 and TRF2, directly bind the double-stranded telomeric DNA whereas 
protection of telomeres 1 (POT1) binds to the singe-stranded form of TTAGGG repeats 
(Palm and de Lange, 2008). These three proteins held together via protein interactions 
provide a strong protective role for the telomere structure (Celli et al., 2006). The shelterin 
complex is ubiquitously expressed throughout the cell cycle and does not accumulate 
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elsewhere in the nucleus suggesting that the function of shelterin is limited to telomeres 
(Celli et al., 2006). There are hundreds of copies of shelterin proteins within telomeres and 
their concentration increases with increased telomere length (Smogorzewska et al., 2000, Li 
and de Lange, 2003).   
The shelterin complex plays a number of important functions: (i) the t-loop formation, (ii) the 
structure of the telomeric terminus, (iii) the control of the synthesis of telomeric DNA by 
telomerase, (iv) protection of chromosome ends from DNA damage surveillance and repair 
pathways (Celli et al., 2006). The latter protective function of shelterin will be analysed in 
subsequent sections, but first a detailed look at each of the subunits of the shelterin complex 
will be provided below. 
1.3.2.1 TRF1 
Zhong and colleagues identified the first shelterin component, TRF1, from HeLa cell extracts 
as a DNA-binding activity that associates specifically with duplex TTAGGG sequence 
(Zhong et al., 1992). TRF1 is also found to be expressed in vivo and binds TTAGGG repeats 
independently of their location within the chromosome (Smogorzewska et al., 2000). The 
core domain of the TRF1, TRF homology domain (TRFH) is evolutionary conserved. In 
human cells there are two variants of TRF1 due to splice variants, whereas in mouse cells 
there is only one functional form of the TRF1 (Broccoli et al., 1996). It was revealed, through 
immunofluorescence and chromatin immunoprecipitation (ChIP), that TRF1 is localised 
within telomeres at all stages of the cell cycle during both mitosis and meiosis (Crabbe et al., 
2004). Two-hybrid protein-protein screening revealed other proteins that directly interact with 
TFR1 in human cells. These proteins are TRF1- and TRF2- interacting nuclear protein 2 
(TIN2), tankyrase, ku70/80 heterodimer, the bloom’s syndrome (BLM) helicase and Ataxia 
telangiectasia mutated (ATM) kinase that can phosphorylate TRF1 at ser-219 (Celli et al., 
2006). 
TRF1 is also shown to act as a negative regulator of telomere length through inhibition of 
telomerase. Knocking-down of TRF1 protein activity leads to telomere elongation (Iwano et 
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al., 2004). Interestingly, TRF1 is shown to be essential in the mouse during development as 
Terf1-/- mouse embryos die early during maturation at E5-E6 with apoptosis activated within 
the inner blastocysts (Karlseder et al., 2003), most likely because of the p53-dependent 
telomere deprotection. 
1.3.2.2 TRF2 
Another protein that directly binds the telomeric double stranded sequence is TRF2. Both 
TRF1 and TRF2 have a conserved Myb domain that mediates sequence-specific binding to 
telomeric DNA (Bilaud et al., 1997) (Hanaoka et al., 2005). Structurally, TRF1 and TRF2 are 
similar (a central TRFH domain and C-terminal DNA binding domain) but functionally they 
have distinct roles in protection of telomeric ends and t-loop formation. TRF2 interacts with 
TIN2 and Rap1, as well as POT1, and other DNA repair proteins such as Ku70, ATM, 
Apollo, MRN complex, WRN, PARP1 and PARP2 (Arat and Griffith, 2012, Celli et al., 2006). 
TRF2 is essential for the formation of the large t-loop and TRF2-/- mice die early in the 
developmental embryogenesis. Conditional knock-down of TRF2 in mouse embryonic 
fibroblasts (MEFs) results in p53-mediated senescence, chromosomal end fusions and DNA-
damage response activation, suggesting the critical functional role of TRF2 in chromosomal 
end protection (Celli et al., 2006). 
1.3.2.3 TIN2  
TIN2 is a small protein factor (40kDa) that binds to TRF2 and to TPP1, as well as to TRF1 
(Kim et al., 1999). It binds to the TRF1 through the TRFH domain, whereas it binds to TRF2 
and TPP1 through central domain of the protein and the amino terminal half respectively. 
Immunofluorescence and ChIP analysis has shown accumulation of TIN2 with TRF1, TRF2 
and TPP1 in vivo at telomeres (Kim et al., 1999). TIN2 has a central role in the shelterin 
complex as it connects TRF1, TRF2 with POT1 (through TPP1) and can bind to both TRF1 
and TRF2 in vivo simultaneously resulting in stabilisation of TRF2 binding to telomeres (Kim 
et al., 2004). 
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1.3.2.4 Rap1  
Rap1 protein was identified through homology search and was found unexpectedly to 
interact with TRF2 in yeast (Li et al., 2000, Zhu et al., 2000). Rap1 is a 49kD, with a single 
Myb domain and has a nuclear localisation sequence and evolutionary is very diverse 
compared to the budding yeast Rap1. The Myb domain of human Rap1 does not have 
enough positive charge to bind to DNA and therefore it is more likely to mediate protein-
protein interactions. Interestingly, when TRF2 is absent from cells Rap1 does not bind to 
telomeres suggesting a close interaction between TRF2 and Rap1. Functionally, Rap1 has a 
role in telomere length regulation and is shown to affect telomere length heterogeneity (Li et 
al., 2000) and (Li and de Lange, 2003). Similar to TRF1 and TRF2, mice cells lacking Rap1 
are not viable suggesting an important role of Rap1 to the shelterin activity and protection of 
telomeres (Celli et al., 2006). 
1.3.2.5 TPP1 
Another recently identified shelterin protein is TPP1 that was identified through mass 
spectrometry of TRF1/TIN2- associated proteins and a two-hybrid screen with TIN2 (Celli et 
al., 2006). TPP1 binds to POT1 through the carboxyl-terminal half. TPP1 has the role of 
recruiting POT1 to the telomeres and short hairpin knock-down of TPP1 is associated with 
inappropriate telomere elongation that is consistent with reduced POT1 activity at telomeres.  
1.3.2.6 POT1 
Another shelterin protein, POT1, was identified through homology search with the DNA-
binding domain of TEBPα (a ciliate telomere binding factor). POT1 binds to the single-
stranded telomeric sequence through the oligonucleotide/oligosaccharide-binding (OB) folds 
and is highly specific for the 5’-(T)TAGGGTTAG-3’(Lei et al., 2004, Loayza and De Lange, 
2003). POT1 is shown to have a favourite target site such as TAG-3’ ends of telomeres but 
has the capacity to bind to any site along a single stranded TTAGGG repeat arrays (Lei et 
al., 2004),(Loayza and De Lange, 2003). The binding of TPP1 to POT1 helps it to localise 
and binds to telomeres whereas the DNA-binding site of POT1 does not have any effect in 
this sense (Loayza and De Lange, 2003). The main function of POT1 is in telomere 
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homeostasis and end-protection. Interestingly the interaction between POT1 and TPP1 
and/or TIN2 creates together with TRF1/2 and RAP1 a bridge that makes the t-loop 
inaccessible to telomerase and it forms a protective loop at the telomeric end. Two reports 
provided contradictory findings – in one report a knock-down of POT1 expression resulted in 
telomere elongation therefore suggesting telomerase inhibitory function of POT1 (Ye et al., 
2004) whereas overexpression of POT1 also resulted in telomere elongation (Colgin et al., 
2003). The question is: how is it possible that both overexpression and reduction of POT1 
activity results in telomere elongation? Two reports provide contradictory findings: in one 
report POT1 knock-down resulted in telomere elongation therefore suggesting telomerase 
inhibitory function of POT1. In addition to the role of POT1 in inhibition access of telomerase 
to the telomere other observation explain that overexpression of human POT1 also cause 
telomere elongation (Colgin et al., 2003). Basically to explain why increasing and reducing of 
POT1 result in telomere elongation may bring up the key role of TPP1 to interact with both 
TIN2 and POT1 (O'Connor et al., 2006). POT1 links to TRF1, TRF2, and RAP1 through 
TIN2-TPP1, so a bridge, can be formed between the single and double stranded of the 
telomere. This bridge can force the telomere into a closed conformation in which the 3`end is 
inaccessible to telomerase (Palm and de Lange, 2008). However when this bridge (known 
as shelterin) is less stable the telomere is more likely to be open and linear conformation 
accessible to telomerase. Overexpression of POT1 can disrupt the closed conformation 
when different POT1 molecules bind to TPP1/TIN2 and the G-strand overhang, thereby 
breaking the protein bridge. Such a mechanism implies that a closed conformation of the 
telomere rather than simple POT1 binding to single-stranded telomeric DNA is required to 
inhibit telomerase in vivo (Baumann and Price, 2010). Figure 1.4 shows interacting partners 
of shelterin proteins. 
  Chapter 1: Introduction 
13 
 
 
Figure ‎1-4. The schematic diagram of mammalian telomeric complex containing shelterin units (Verdun 
and Karlseder, 2007). 
1.4 The role of shelterin in chromosomal end protection 
The six proteins discussed above form a unique complex that is only found accumulated at 
telomeres and not anywhere else in the cell. This is due to a high affinity of the shelterin 
proteins such as TRF1/2 to the TTAGGG telomeric sequence through a Myb-specific DNA 
binding domain. Similarly, POT1 has a strong affinity to the 3’ end of telomeres with 5’-
(T)TAGGG TTA-3’ and at internal positions. The three proteins are then connected through a 
protein-protein interaction giving a strong five DNA-binding domain (two TRF1/2 and one 
POT1) giving shelterin complex a specific ability to recognise only telomeric sites and no 
other regions within the genome (de Lange, 2005). The unique structure of the shelterin 
complex gives it a specific functional role at protecting telomeres. These functional roles of 
shelterin are: (i) determination of the structure of telomere ends, (ii) generation of t-loops, 
and (iii) control of synthesis of telomeric DNA by telomerase (Table 1-1) (de Lange, 2005a). 
The formation of t-loop lariat structure in mammalian telomeres is thought to be a critical 
aspect of shelterin complex. It is thought that shelterin complex helps the formation of t-loop. 
Conditional knock-down of shelterin components have shown that TRF2 is required for the 
  Chapter 1: Introduction 
14 
 
formation and maintenance of t-loops whereas TRF1, Rap1 or POT1 do not significantly 
affect t-loop formation (Doksani et al., 2013).  
Table ‎1-1. Summary of proteins involved directly with the telomere (the shelterin unit) (de Lange 2006). 
Shelterin proteins Function References 
TRF1 Telomere length regulation Zhong et al., 
1992  
TRF2 Protect chromosome end Bilaud et al., 
1997 
POT1 Modulate telomere length McKay and 
Cooke 1992 
TPP1 Regulating and protecting of telomere length Houghtaling et 
al., 2004 
TIN2 Providing the bridge between single strand and 
double stranded telomeric 
Kim et al., 1999 
hRAP1 With TRF2 inhibiting homologous recombination Li et al., 2000; 
Zhu et al., 2000 
Tankyrase1 Positive regulator of telomere length Smith et al., 1998 
Tankyrase2 Positive regulator of telomere length Smith et al., 1998 
EST1A Positive regulator of telomerase Reichenbach et 
al., 2003 
 
Inhibition of TRF1 or POT1 diminishes the overall repeats of TTAGGG, suggesting a direct 
effect of TRF1 or POT1 on the 3’ end of telomeres (Hockemeyer et al., 2005). Interestingly, 
when TRF1 is inhibited ERCC1/XPF (an endonuclease) cleaves the 3’ end of telomeric DNA 
and the telomere can lose all of the ssDNA. Similarly, POT1 binding to the 3’ end can protect 
the ssDNA from CRCC1/XPF degradation (de Lange, 2005a). 
The effect of shelterin complex on telomere length is through the cis-acting inhibition, 
influenced by the total amount of shelterin proteins. The longer the telomere lengths the 
more shelterin is abound to the telomere and this inhibits the access of telomerase whereas 
shorter telomeres with fewer shelterin units have a relaxed structure therefore allowing 
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access of telomerase to the telomeric site. This control of the telomerase by shelterin is 
mediated by POT1 on the ssDNA. In cells where POT1 activity is diminished through knock-
downs irregular telomere length maintenance is apparent as evidenced by formation of very 
long telomere tract by telomerase despite heavier loads of shelterin proteins (Hockemeyer et 
al., 2006).  
The shelterin complex also interacts with some proteins involved in DNA damage response 
as shown in Table 1-2. The focus of this dissertation is the role that BRCA1, a DNA damage 
response protein, plays in the functional interplay between telomere maintenance and DNA 
damage response.   
1.5 BRCA1 gene and protein structure 
The breast and ovarian cancer susceptibility gene 1 (BRCA1) was first identified and cloned 
in 1994 by Miki and colleagues. One year later the second breast and ovarian cancer 
susceptibility gene 2 (BRCA2) was identified and cloned (Wooster et al., 1995). BRCA1 
gene was shown to contain 24 exons with 22 of it having coding sequences and 2 non-
coding sequences (Miki et al., 1994). Exon 11 was the biggest exon encoding 60% of the 
BRCA1 protein. The BRCA1 gene produces 1863 amino acid long protein with a molecular 
weight of 220 kDa. The protein structure of BRCA1 contains various features that are found 
in other DNA repair and cell cycle checkpoints proteins. For example, the N-terminal RING 
domain and a C-terminal BRCA1 domain (BRCT) has a DNA binding capacity similar to the 
C-terminal acidic domain (Monteiro et al., 1996, Bork et al., 1997) (See Figure 1.5). Each 
structural domain of the BRCA1 is important for its various functions within the cell. For 
example, the RING domain activates the E3 ubiquitin ligase activity through its interaction 
with E2 enzyme (Jiang and Greenberg, 2015). The HR and checkpoint function of the 
BRCA1 is performed by the central domain, which is coded entirely by the exon 11, and this 
poorly conserved central domain is shown to also have tumour suppressive activity (Xu et 
al., 1999b). Nearer the C-terminal there resides a coiled-coiled region that interacts with 
PALB2 that forms a bridge between BRCA1 and BRCA2 creating a tumour suppressive 
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supercomplex (Jiang and Greenberg, 2015). Interestingly, mutations in PALB2 is linked to 
high penetrance breast cancer (similar to BRCA1 and BRCA2 mutation) suggesting an 
important biochemical activity of the PALB2 and the coiled-coiled region in the C-terminal 
domain of the BRCA1 (Antoniou et al., 2014). Finally, near the C-terminal resides BRCA1 C-
terminal repeats (BRCT), which bind to phosphopeptides. Many proteins interact with the 
BRCT domain that provide various functions of the BRCA1 protein. For example, interaction 
of BRCA1 with BARD1 stabilises the two proteins and enhances the DNA damage sensing 
capability of the BRCA1. Crystal structure has shown direct interaction of the 
BRCA1/BARD1 with the nucleosome (McGinty et al., 2014). BRCA1/BARD1 also interacts 
with poly (ADP) ribose (Li and Yu, 2013) as well as with HP1 protein that helps to anchor the 
BRCA1/BARD1 complex to the DNA damage sites (Wu et al., 2015). 
 
Figure ‎1-5. The protein structure of the BRCA1 tumour suppressor (Adapted from (Clark et al., 2012).  
When DNA damage occurs, BRCA1 is phosphorylated at various sites by DNA damage sensing proteins such as 
ATM, CHK1 and ATR, which then makes BRCA1 to form complexes that is then recruited to the DNA damage 
sites. BRCT domain can form mutually exclusive interaction with phosphorylated CtIP, BACH11and abraxas. 
BRCA1 can also recruit BRCA2 to sites of DNA damage via PALB2. The interaction between BARC1 with the N-
terminal RING domain produces the tumour suppressive function of the BRCA1 since mutations within this 
domain is shown to lead to cancer. 
 
BRCA1 is also found to regulate the activity of many transcription factors although BRCA1 
itself does not have sequence-specific DNA-binding transcription factor. Examples of BRCA1 
interaction with various transcription factors include p53, estrogen receptor, progesterone 
receptor, androgen receptor, STAT1, c-Myc, NF-κB, octamer-binding transcription factor 1 
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(OCT1), and others (Rosen et al., 2006, Rosen, 2013). The BRCA1 co-transcriptional activity 
can be stimulatory (p53, androgen receptor) or inhibitory (estrogen, progesterone or c-MYC) 
(Rosen et al., 2006) that offers it a role as transcription co-regulator. BRCA1 is now known to 
have various other functions within the cell such as in DNA damage response, DNA repair 
and cell cycle regulation and these are reviewed in detail in the subsequent sections of this 
chapter. 
1.6 The role of telomere and shelterin in DNA damage response 
One of the main functions of the shelterin complex is to hide the telomeric ends from 
recognition by the DNA damage response proteins. Since mammalian chromosomes are 
linear they face a problem of end protection. Unprotected telomeric ends resemble that of 
DNA double strand breaks, lesions that initiate the DNA damage response. It is therefore 
proposed that shelterin complex hides the telomeric ends from been recognised as sites of 
double strand breaks through the interaction of the shelterin proteins. This was shown 
initially through a series of delicate experiments whereby the function of TRF2 was 
conditionally knocked-down in mouse cells or through expression of dominant-negative allele 
of TRF2 (TRF2∆B∆M). Through this dominant-negative allele of TRF2 that lacks functional 
carboxylic terminal forms an inactive heterodimer causing a total loss of TRF2, Rap1 and 
portion of POT1 from telomeres (van Steensel et al., 1998). De-protection of telomeric ends 
from TRF2, Rap1 and part of POT1 but not TRF1 or TIN2 (they remain attached to the 
telomere) are shown to activate DNA damage response factors such as 53BP1, Nbs1, ATM, 
Rad17, Rif1 and MDC1 in mouse cells (d'Adda di Fagagna et al., 2003, Takai et al., 2003). 
The formation of telomere dysfunction-induced foci or TIFs within telomeres is indicative of a 
DNA-damage domain as a result of telomere structural de-protection. When TRF2 was 
deleted in the mouse cells majority of the TIFs were associated with most telomeres (but not 
all telomeres had TIFs) (Celli and de Lange, 2005). In the presence of functional 
ERCC1/XPF or non-homologous-end joining (NHEJ) machinery it has been shown that 
approximately 50% of the single stranded TTAGGG is lost through end-to-end fusion (van 
Steensel et al., 1998). Interestingly the two mechanisms, TIF-associated DNA-damage 
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response and DNA double strand breaks, are not linked meaning that in cells where the 
action of NHEJ is diminished formation of TIFs still persist at telomeres (Celli and de Lange, 
2005). On the other hand, ATM kinase is shown to be the major component of the activation 
of DNA-damage response, as TIF are not formed in AT cells (where ATM in mutated) (Takai 
et al., 2003). In the absence of ATM, another DNA damage response related protein ATR 
(ataxia telangiectasia/Rad3 –related) protein is observed at dysfunctional telomeres in AT 
cells (Herbig et al., 2004). However, when both proteins are inhibited (ATM and ATR) using 
caffeine this results in disappearance of TIFs (Takai et al., 2003) suggesting that signalling 
of DNA damage performed by the two proteins is made through phosphatidyl inositol 3' 
kinase-related kinases (PIKK). Other factors that seems to be involved during telomere 
deprotection, e.g. DNA damage sensor such as the Mre11 complex (Mre11/Rad50/Nbs1), 
most likely contribute to the upstream sensing step in the DNA damage response and 
inhibition of ATM does not affect its accumulation at dysfunctional telomeres. The Mre11 
complex is part of the homologous recombination DNA damage repair and it will be covered 
in more detail in the subsequent chapters.  
When telomeres are deprotected through dysfunction of the shelterin units, the activation of 
ATM leads to downstream events that result in cell cycle arrest and delay in cycle 
progression, apoptosis or senescence (de Lange, 2006).  Depending on the cell type 
apoptosis or senescence is activated and mediated by p53. For example, it has been shown 
that some epithelial cells or lymphocytes activate apoptosis in response to telomere 
dysfunction whereas fibroblasts go through senescence (de Lange, 2006). Stabilization of 
p53 results in increased levels of p21 that inhibits Cdk2 and arrests the cell entry into the S-
phase. Telomere damage also results in p16 mediated cell cycle arrest through inhibition of 
Cdk4/6. This is shown to occur when p21 is displaced (possibly through p53 impairment) 
where p16 takes over the mechanism of entry into S-phase. In this scenario, elevated p16 
act as the back-up mechanism of cell cycle regulation, although it has been shown that in 
mouse cells p16 does not induce G1/S arrest following telomere dysfunction 
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(Smogorzewska et al., 2002). TIN2 and POT1 also activate TIFs when abrogated through 
either overexpression of TIN2 mutants that result in loss of TRF2 from telomeres (Kim et al., 
2004) or shRNA-mediated knock-down of POT1 with similar effect (Hockemeyer et al., 
2005). The one difference observed between TIN2-mediated TIFs formation and POT1 is 
that, in POT1 knocked-down cells undergo a G1 arrest and TIFs largely disappear by the 
time cells enter the S-phase (de Lange, 2006). 
1.6.1 Functional role of BRCA1 within DNA-damage response 
When DNA damage occurs (Figure 1.6) ATM is recruited to the sites of DNA damage and it 
phosphorylates very quickly the variant of histone H2AX on serine-139 producing a 
phosphorylated H2AX, known as H2AX (Burma et al., 2001) (Wang et al., 2005). 
Subsequently, the H2AX is sensed by the mediator of DNA damage checkpoint 1 (MDC1) 
and this rapid recruitment of the MDC1 serves as a scaffold to other DNA damage repair 
proteins (Stewart et al., 2003, Lou et al., 2006, Lee et al., 2005). MDC1 then recruits the 
MRN complex through the binding of the phosphorylated casein kinase 2 (CK2) of the NBS1 
(Spycher et al., 2008). The localisation of BRCA1 to the sites of DNA damage, especially 
within the ionising radiation-induced DNA damage foci, occurs very quickly (Rosen, 2013). 
The focus of this dissertation is the functional role of BRCA1 within the DNA damage 
response (DDR) and its link with telomere maintenance. The earliest evidence implicating 
Brca1 deficiency in DDR emerged through the study of fibroblast cells and tumours that 
showed extensive genomic instability, including aneuploidy, centrosomal amplification and 
chromosomal aberrations (Tirkkonen et al., 1997) (Xu et al., 1999b) (Weaver et al., 2002). It 
was also revealed that BRCA1 is co-localised with Rad51 during S-phase. When DNA 
damage occurs BRCA1 is phosphorylated and translocated to proliferation cell nuclear 
antigen (PCNA)-positive DNA structures containing Rad51 and BARD1 (Scully et al., 1997). 
Similarly, it has been shown that BRCA1-defective cells are sensitive to ionising radiation 
(Shen et al., 1998, Scully et al., 1999, Ruffner et al., 2001), providing evidences for the role 
of BRCA1 as a (i) caretaker gene involved in DNA repair with monitoring and maintenance 
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role within genome stability, and (ii) as a DNA damage response protein involved in 
response to the DSBs (Rosen, 2013).  
 
Figure ‎1-6. DNA is constantly under attack through exogenous agents (Shiloh, 2003). 
1.6.2 How does shelterin repress telomere-mediated DNA damage response? 
Interestingly, a question that comes to mind is that why telomeres containing functional 
shelterin complex are not sensed by ATM kinase pathway. We did argue that this could be 
because shelterin complex creates the t-loop structure that hides telomeric ends hence 
preventing DNA ends to be recognised as DNA DSBs. Another suggested possibility is that 
the shelterin factors at telomeres create a nucleosomal organisation similar to that of intact 
chromosome internal DNA (de Lange, 2006). The latter hypothesis was tested when 
chromatin organisation of telomeric ends was disrupted leading to ATM activation (Huyen et 
al., 2004). Interestingly, it has been shown recently that TRF2 binds to ATM kinase (in vitro 
and in vivo) and suppresses the activity of ATM (Karlseder et al., 2004). TRF2 was 
overexpressed leading to diminished activity of ATM authophosphorylation suggesting that 
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telomere-bound TRF2 could suppress ATM activation on chromosomal terminus (de Lange, 
2006). Similarly, it was shown that the t-loop structure can block the end-loading of Ku 
protein by the NHEJ activation (Celli et al., 2006). POT1 also can inhibit ATR activation 
suggesting that both TRF2 and POT1 are needed for the efficient suppression of DNA-
damage response activation at telomeres and that TRF2 and POT1 function independently 
(Denchi and de Lange, 2007). 
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Table ‎1-2. Interaction of DNA repair and damage response proteins with telomeres ((Slijepcevic, 2006) de Lange 2006)  
Protein Main function  Function at telomeres Shelterin interactions 
Mre11/Rad50/Nbs1 Recombinational repair, DNA damage sensor T-loop formation/resolution? Required for t-loop HR Associated with shelterin 
ERCC1/XPF NER, crosslink repair3`flap endonuclease 
Deficiency leads to formation of TDMs; implicated in 
overhang processing after TRF2 loss 
Associated with shelterin 
WRN helicase Branch migration G4 DNA resolution Deficiency results in loss of lagging-strand telomeres TRF2 
BLM helicases Branch migration crossover repression T-loop formation/resolution? TRF2 
DNA-PK NHEJ Deficiency leads to mild fusion phenotype Associated with shelterin 
PARP-2 BER Not known TRF2 
Tankyrases Role in mitosis (tankyrase 1) 
Positive regulator of telomere length through inhibition of 
TRF1 
TRF1 
Rad51D Unknown (HR) Deficiency leads to mild fusion phenotype unknown 
ATM Damage signaling DNA damage activation at telomeres TRF2 
Ku NHEJ Deficiency leads to telomere shortening TRF1,TRF2 
RAD54 HR 
Activity plays an essential role in telomere length 
maintenance 
TRF2 
FANCA Damage sensing 
Deficiency leads to breakage at telomeres and end-to-end 
fusion. 
Not known 
BRCA1 HR shorter 
Deficiency leads to accelerated telomere shortening and 
mild telomere dysfunction 
TRF1, TRF2 
Rad9 Damage sensing 
Inactivation increases in chromosome end-to-end 
associations 
TRF2 
PARP-1 BER 
Function as capping of normal telomeres and its deficiency 
leads to chromosome end-to-end fusions 
TRF2 
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Other event that leads to DNA-damage response activation is the programmed shortening of 
telomeres during each round of cell cycle. Even when a single telomere becomes 
dysfunctional, as a result of shortening, this leads to activation of DNA-damage response 
and p53-mediated cell cycle arrest (Hemann et al., 2001). Short telomeres contain fewer 
shelterin complex units (Loayza and De Lange, 2003) causing the diminished loading of 
TRF2 and POT1 on short telomeres and activation of ATM and ATR kinases leading to cell 
cycle arrest and inappropriate DNA repair at telomeres (formation of end-to-end fusion) 
(Denchi and de Lange, 2007). Table 1-2 lists all the known proteins that are associated with 
shelterin at telomeres with a brief description of their function. Some of these proteins are 
found to be critical component of DNA DSB repair machinery that is discussed below. 
1.7 DNA repair and response at dysfunctional telomeres – How does 
BRCA1 play a part? 
When telomeres become dysfunctional, either as a result of defective shelterin complex or 
telomere length attrition, this leads to activation of DNA DSB repair pathways. Two main 
DSB repair pathways in mammalian cells are NHEJ and HR (Figure 1.7). NHEJ is 
responsible for the formation of end fusions leading to dicentric chromosomes, and genomic 
instability, whereas HR causes deletion of large segments of telomeric DNA and mediate 
exchange of sequences between sister telomeres (leading to sister chromatic exchange – 
this is reviewed in detail in subsequent sections).  
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Figure ‎1-7. DNA double-strand break repair in mammalian cells (Lans et al., 2012). DNA DSBs are 
predominantly repaired by either non-homologous end-joining (NHEJ) or homologous recombination (HR).  
 
1.8 The role of BRCA1 in non-homologous end joining (NHEJ) 
The human genome receives constant insult from endogenous and exogenous agents that 
cause damage in DNA including DSBs.  Induction of DSBs can be mediated endogenously 
by reactive oxygen species (ROS) generated by cellular metabolism and replication errors 
and by exogenous agents such as ionising radiation (IR) and chemotherapeutic agents. 
Programmed DSBs occur during the T- and B-cell development as part of V (D) J 
recombination. Figure 1.6 in the above section shows a summary of endogenous and 
exogenous agents that cause DNA damage. Unrepaired DSBs can activate cellular 
senescence or apoptosis (mediated by p53), or lead to chromosomal translocations and 
deletions with end result of loss of heterozygosity. Unrepaired carry abnormalities 
accumulate and can contribute to carcinogenesis. The main mechanism of DSB repair in 
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human cell is the NHEJ that takes place throughput the cell cycle. HR also has a role in 
repair of DSBs in the late S-G2 phase with the third mechanism of DBS repair known as 
microhomology-mediated end-joining (MMEJ) details of which are not well characterised. 
The restriction of HR to the late S-G2 phase is because it requires a template that only 
becomes available during the S-G2 phase as a sister chromatid, whereas NHEJ does not 
require homologous template and can, in theory, take place throughout the cell cycle.  
 
Figure ‎1-8. The mechanism of NHEJ (Samarasinghe, 2013). BRCA1 plays an important role in NHEJ 
mechanisms. A double stranded and break is detected by and repair proteins which bring together two ends and 
join them. 
The NHEJ process DNA DSB through a number of proteins and kinases and the process is 
divided into the following sequential steps: (i) DNA end recognition and assembly of DNA 
repair proteins, (ii) bridging of DNA ends and promotion of DNA end stability, (iii) DNA end 
processing by NHEJ factors, (iv) ligation of DNA ends and dissolution of the assembly 
(Figure 1.8).   
The first step in the NHEJ process is the recognition of DNA ends by the Ku heterodimer. Ku 
heterodimer is made up of Ku70 and Ku80 subunits that as a heterodimer have a high 
affinity to the DNA ends. This is shown to occur within seconds of a laser-generated DSB 
(Mari et al., 2006) and shows its abundant occurrence throughout the cell (500,000 units of 
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Ku molecules per cell) (Downs and Jackson, 2004) (Davis and Chen, 2013). The sequence 
independent biding of Ku heterodimer is because of its ability to bind to the sugar backbone 
of the DNA instead of the bases. It forms a ring-shape structure that slides onto the DNA end 
(Walker et al., 2001). The quick formation of Ku heterodimer binding with broken DNA ends 
forms a scaffold-like structure that allows other NHEJ factors to bind. The direct and indirect 
recruiting of other NHEJ factors by Ku heterodimer such as DNA-PKcs, x-ray cross 
complementing protein 4 (XRCC4), DNA-ligase IV, XRCC4-like factor (XLF) and Aprataxin-
and-PNK-like factor (APLF).  
Ku heterodimer directly recruits DNA-PKcs to the DSBs and this recruitment is only possible 
due to extreme C-terminal 12 residues of Ku80 mediating the recruitment (Gell and Jackson, 
1999). Binding of Ku70/80 with DNA-PKcs requires the presence of DNA. Recruitment of 
DNA-PKcs to the ends of the DNA pushes the Ku heterodimer inwards thus activating the 
kinase activity of the DNA-PKcs. Although it is predicted that both N- and C-terminal units of 
the Ku70/80 make contacts with DNA-PKcs it is the N-terminal that is shown to be absolutely 
necessary for the formation of the DNA-PKcs-Ku-DNA complex and subsequent stabilisation 
of the DNA DSB ends (Davis and Chen, 2013). 
The role of BRCA1 within the NHEJ is controversial, as conflicting evidence has been 
reported for a requirement of BRCA1 in NHEJ (Baldeyron et al., 2002) (Zhong et al., 2002b, 
Zhong et al., 2002a, Bau et al., 2004), while others find no defect in NHEJ in BRCA1-
deficient cells (Moynahan et al., 1999) (Wang et al., 2001) (Merel et al., 2002). This may 
possibly be due to the fact that there are several NHEJ processes described; an error-prone 
and an error-free NHEJ mechanism (Durant and Nickoloff, 2005, Gudmundsdottir and 
Ashworth, 2006). BRCA1 is thought to be involved in promotion of the error-free pathway of 
the NHEJ process (Rosen, 2013). BRCA1 is thought to inhibit the nuclease action of the 
MRE11 (part of the MRN complex) when bound to the DNA therefore limiting the DNA end 
resection activity (Durant and Nickoloff, 2005). It is therefore, still unclear as to how exactly 
BRCA1 is involved in the NHEJ, since levels of BRCA1 during G1 phase of the cell cycle are 
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low and slowly increase during the S- and G2-phases of the cell cycle. Accumulation of 
BRCA1 during the S- and G-2 phases counteracts the ability of the 53BP1-RIF1 to stimulate 
NHEJ and therefore this pathway is inhibited in favour of HR, whereas in the G1-phase with 
low levels of BRCA1, 53BP1-RIF1 is able to accumulate at sites of DNA DSB to promote 
NHEJ (Escribano-Diaz et al., 2013, Feng et al., 2013) The tussling between NHEJ and HR is 
partly controlled by levels of BRCA1 and does explain the cell-cycle dependent activation of 
NHEJ during DNA DSB repair.  
1.9 BRCA1 and HR 
Another mechanism of DNA DSB repair in mammalian cells is HR, characterised by high-
fidelity and template-dependant repair of complex DNA damages. HR also provides repair to 
DNA intra-strand cross-links and DNA gaps. In addition of providing genomic stability and 
integrity, HR plays a critical role in DNA replication and telomere maintenance. HR is the 
preferred DNA repair pathway during S and G2 phases of the cell cycle when identical sister 
chromatids are present and HR can access telomeres when the shelterin function is 
suppressed leading to irregular telomere length replication and activation of alternative 
lengthening of telomeres (ALT) in the absence of telomerase. The similarity between 
telomere maintenance and HR is quite striking. For example, the t-loop formation at 
telomeres as a result of 3’ overhang invasion of the duplex telomeric DNA is similar to the 3’ 
single-stranded overhang at the break site that is followed by invasion of duplex DNA 
(Verdun and Karlseder, 2007). Other similarities exist between DNA repair proteins, DNA 
damage responses and telomeres suggesting that the mechanism of telomere homeostasis 
and DNA repair/damage proteins are very similar (Verdun and Karlseder, 2007). 
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Figure ‎1-9. The HR repair pathway in the mammalian cells (Bugreev et al., 2011). Stalled replication forks 
can be rescued by HR via a mechanism that relies on DNA strand exchange activity of RAD51. 
 
HR is activated following a replication fork stalling, at crossovers at meiosis and it is linked to 
telomere maintenance. In any case when HR is activated through DNA damage sensory 
proteins (ATM and ATR) the search for homology begins. This process is dependent on 
Rad51, a recombinase enzyme (Li and Heyer, 2008). Rad51 binds specifically to the ssDNA 
and promotes strand invasion of the template strand which creates the holiday junction 
(Figure 1.9). BRCA2 is needed for this process as it functions to deliver Rad51 to the DNA 
using shared motifs between the evolutionary conserved BRC motifs of BRCA2 and the 
RecA-homology domain of Rad51 (Pellegrini et al., 2002). Similarly, BRCA1 plays a central 
role in the HR process possibly in a regulatory capacity but the exact biochemical role of 
BRCA1 in HR is still unknown (O'Driscoll and Jeggo, 2006, Zhang, 2013). Moynahan 
provided the earliest evidence for the role of BRCA1 in the HR by clearly demonstrating that 
a Brca1- deficient reporter mouse embryonic stem (ES) cell line failed to accurately repair a 
chromosomal DSB created by the I-Sce 1 endonuclease (Moynahan et al., 1999). They also 
showed that BRCA2 was required for HR as well and provided evidence that Brca1-deficient 
cells could recover HR activity when a WT BRCA1 is transfected (Moynahan et al., 2001).  
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Figure 1.9 provides an overview of the main processes involved in the HR repair pathway in 
mammalian cells. In brief, following formation of DNA DSBs and resection of the ends to 
form the 3’ overhang, the ssDNA is coated with replication protein A (RPA), that aids the 
binding of Rad52 (a protein homologous to Rad51), which in turn interacts with Rad51 to 
recruit it to the ssDNA with BRCA2 shown to have binding specificity to this structure. This 
forms the active nucleoprotein filament and enables the strands invasion of the ssDNA with 
the homologous dsDNA and formation of Holliday junction (West, 2003). After formation of 
the Holliday junction, the two strands function as a primer for DNA re-synthesis following 
assembly of the DNA polymerases. Following this the site of Holliday junction must be 
resolved after recombination and in eukaryotes this is done by the Rad51 paralog, XRCC3 
and Rad51C that is associated with the resolvase activity (Wyman and Kanaar, 2006). It is 
thought that BRCA1 forms a complex with the CtBP-interacting protein (CtIP) facilitating the 
end resection by allowing the recruitment of replication protein A (RPA), a ssDNA-binding 
protein to the site of the DNA damage (Sartori et al., 2007, Buis et al., 2012, Escribano-Diaz 
et al., 2013). It must be noted that the role of BRCA1 is much broader than BRCA2 in the HR 
repair pathway since BRCA1 is also involved in cell-cycle checkpoint activation (Rosen, 
2013). 
The types of proteins involved in the HR depend on the origin of DSBs: whether they result 
from replication fork stalling or IR or cross linked-induced damage.  
1.9.1 HR at telomeres 
As mentioned previously, the t-loop at the telomere closely resembles a structure formed 
during HR with a 3’ overhang generated that is used to make the invasion within the dsDNA 
portion of the telomeric region. In the absence of TRF2 domain, it is shown that the 
formation of the t-loop is altered to form a single or double HR that is subsequently resolved 
by the HR resolvase (such as XRCC3 or Rad51C) (Wang et al., 2004) de Lange, 2006). This 
results in the formation of telomeric circle (t-circle) and causes telomere shortening that 
could lead to DNA-damage signal or a reformation of another t-loop (See Figure 1.10 in 
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section 1.12.1). These (formation of t-circles and heterogonous telomeric lengths) are all 
hallmarks of ALT activity in telomere length maintenance and suggest that this type of HR is 
derepressed in ALT positive cells. This is further discussed in sections below. However, 
studies have shown that, HR-mediated telomere replication is dependent on the 
MRE11/RAD50/NBS1 (Mre11 complex), as mutations in the Nbs1 fail to show loss of 
telomeric DNA after TRF2 mutant overexpression (Helt et al., 2005b) de Lange, 2006). 
Another problem associated with the activation of HR at dysfunctional telomeres is the 
formation of post-replication exchanges that can be visualised using chromosome-
orientation FISH (CO-FISH), also referred to as telomere-sister chromatic exchanges (T-
SCE). The formation of double telomeric signals observed with CO-FISH experiment is likely 
to occur subsequent to DNA replication (Londono-Vallejo et al., 2004, Bailey et al., 2004b). 
1.9.2 NHEJ and HR in cell cycle  
The most dangerous type of DNA damage, in which both strands in the DNA double helix 
are severed is termed DSB. It is clear that DSBs, which are unrepaired or are repaired 
incorrectly, result in loss of genetic material and subsequently cause genomic 
rearrangements or cell death (Mao et al., 2008). Therefore, cell cycle checkpoints become 
activated as a first response to DNA damage (Sancar et al., 2004). Depending on the cell 
cycle phases at which the damage is occurred, cells can be blocked at either G1/S or G2/M 
(Sancar et al., 2004). However, if the damage is permanent or cell cycle checkpoint is 
dysfunctional, apoptosis may be triggered to remove the injured cells (Sancar et al., 2004). It 
is now well known that the G1 checkpoint is defective in most cancer cells, due to 
mutations/alterations of key regulators of the G1 checkpoint (p53, Cyclin D, etc.) (Kastan et 
al., 1991), whereas the G2 checkpoint is rarely impaired in cancer cells, as this checkpoint 
operates primarily via a p53-independent mechanism (Figure 1.10)(O'Connell and Cimprich, 
2005). In fact, in cancer cells absence of G1 checkpoint abrogation of the G2 checkpoint 
often sensitises the cells to radiation (Chen et al., 2012). Mao et al., 2008 measured the 
efficiency of NHEJ and HR at all stages of cell cycle in hTERT-immortalized diploid human 
fibroblasts. The results indicated that NHEJ is active throughout the cell cycle, and its activity 
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increases from G1 to G2/M. HR is nearly absent in G1 and most active in the S phase, and 
decline in G2/M. Therefore this is in contrast with the notion that NHEJ is most active in G1, 
while HR is active in S, G2 and M. Overall, the efficiency of NHEJ was higher in all cell cycle 
stages than the HR. As a result, human somatic cells utilise error-prone NHEJ as the major 
pathway at all cell cycle stages, whereas HR is used primary in the S phase (Mao et al., 
2008). 
 
 
Figure ‎1-10– Irradiation induces G1 and G2 cell cycle checkpoint activation and DNA repair. Most cancer 
cells are defective in G1checkpoint, commonly due to the mutation/alterations of the key regulators of the G1 
checkpoint (in blue), but contain a functional G2 checkpoint (Hein et al., 2014). 
 
 
1.10 The role of BRCA1 in telomere maintenance 
BRCA1 plays an important role in DDR by being involved in HR and NHEJ (see sections 1.8 
and 1.9). BRCA1 is recruited to the sites of DNA damage by the MRN complex and it is 
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critical in recruitment and assembly of further recombination proteins to the site of DNA 
damage.  
BRCA1 was identified as a tumour suppressor in the breast cancer and ovarian cancer in the 
early 1990s through positional cloning and was linked to chromosome 17q21 (Hall et al., 
1990) (Miki et al., 1994). In the subsequent years evidence linked inactivating mutation in the 
BRCA1 gene to increased risk of familial breast and ovarian cancer (for reviews see(Narod 
and Foulkes, 2004). Because of its important role in various aspects of DSB repair, S-phase, 
G2/M and spindle checkpoints, as well as in centrosomal regulation (Zhang and Powell, 
2005), (Roy et al., 2011) any perturbation in its function can have severe consequences for 
the cell. For example, biallelic inactivation of the BRCA1 leads to genomic instability and 
cancer development. Indeed, mutations in the high penetrance genes, BRCA1 and BRCA2 
are linked to an increased risk of familial breast cancer (King et al., 2003). Considering 
BRCA1’s various essential roles in the cell, it is still unclear as to why BRCA1 mutation 
preferentially leads to a subset of ovarian and breast cancer and not other types of cancers, 
even when important cancer-causing genes such as p53 and ATM are intact (Musolino et 
al., 2007) (Tlsty, 2011). Mutations in other DNA damage genes such as p53 and ATM is 
found in many cancers (Musolino et al., 2007) (Tlsty, 2011). For instance, p53 mutation is 
found in almost 50% of all cancers (Vogelstein et al., 2000). Similarly, it is not known why 
BRCA1 mutation in one allele (leading to haploinsufficiency) early in the life causes rapid 
onset of the breast cancer (Whittemore et al., 1997), (Komenaka et al., 2004), whereas total 
inactivation of both alleles only occurs as a late event in the tumour development (Clarke 
and Sanderson, 2006, Martins et al., 2012). The exact role of the BRCA1 in genome integrity 
and DDR is not fully elucidated and probably involves other proteins that act as partners of 
BRCA1 in various pathways. In a recent study it was shown that cells from primary 
mammary epithelial cells (HMECs) with mutations in BRCA1mut/+, show premature 
senescence as a result of genomic instability (Sedic et al., 2015). This unique type of cellular 
senescence caused by haploinsufficiency of a tumour suppressor such as BRCA1 is termed 
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haploinsufficiency-induced senescence (HIS). The spontaneous bypass of this senescence 
which is triggered by pRb pathway activation rather than p53 induction is thought to be 
involved in the early onset of breast cancer development in individuals with BRCA1 mutation 
(Sedic et al., 2015). Although these immortalised non-tumourigenic BRCA1mut/+ HMECs 
showed rapid genomic instability, increased DNA damage, increased telomere length rate 
the exact mechanism by which the telomere maintenance is affected is not known (Sedic et 
al., 2015). Indeed it is not known whether BRCA1 haploinsuficiency leads to activation of 
telomerase or ALT mechanism as these experiments have not been performed. Recent 
findings suggest that BRCA1 does accumulate at telomeres in the ALT-positive cancer cells 
but not in telomerase-positive cancer cells most likely with the help of BLM and PML bodies 
(Acharya et al., 2014). One of the aims of this dissertation is to elucidate some of 
uncertainties surrounding the BRCA1 role in telomere homeostasis.  
1.11 Telomere length regulation by telomerase 
The linear genome in all mammalian cells requires a special mechanism to (i) fully replicate 
the DNA ends due to the DNA end replication problem as described earlier (1.2.2 above) 
and (ii) the nucleolytic processing of telomere ends after semiconservative DNA replication 
(Cristofari and Lingner, 2006). The end-replication problem is most commonly overcome 
through the ribonucleoprotein reverse transcriptase telomerase enzyme discovered by 
Greider and Blackburn in Tetrahymena thermophila (Greider and Blackburn, 1985). 
Subsequently, Greider and Blackburn received the 2009 Nobel Prize in Physiology or 
Medicine for their discovery of this unique RNP enzyme that has important physiological 
implication to human health as seen cancer and aging. Telomerase was subsequently 
demonstrated to have an RNA moiety, which co-purifies with enzymatic activity (Greider and 
Blackburn, 1989). Subsequent experiments revealed a highly conserved reverse 
transcriptase sequence motifs within the enzyme (Lingner et al., 1997).  
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1.11.1 The human telomerase structure 
1.11.1.1 Human TR (hTR) 
The telomerase enzyme has two major structural features: an RNA moiety of telomerase 
(TERC) and the telomerase reverse transcriptase (TERT). The TERC component of 
telomerase act as a template for telomere elongation and it is shown to be conserved in the 
secondary structures in all species, but the primary structure (length and sequence) diverge 
between species (153-192 nucleotides in ciliates and 1.3kb in Saccharomyces cerevisiae 
(Romero and Blackburn, 1991, Lingner et al., 1994). For example, the template of all 
telomerases is single stranded allowing conventional Watson-Crick base-pairing with the 3’ 
single stranded overhangs of telomere with the active site of the TERT closely linked 
(Cristofari and Lingner, 2006). The whole RNA template is approximately 1.5–2 times the 
telomeric repeat length providing access to both annealing of the telomeric 3’ end and the 
template providing the addition of one telomeric repeat per elongation cycle (Cristofari and 
Lingner, 2006). The TERC component of telomerase also has a pseudoknot domain at the 5’ 
end that is conserved in all species. The hTERC is ubiquitously expressed in both the 
normal and tumour cells (Feng et al., 1995) but it is shown to be up-regulated in tumour cells 
by almost five-fold when measured by in situ hybridisation (Heine et al., 1998) possibly due 
to longer half-life of the transcribed RNA. 
1.11.1.2 Human TERT (hTERT)   
The second structural unit of telomerase is the TERT that has the reverse transcriptase 
activity. TERT was initially identified through biochemical purification of telomerase in E. 
aediculatus (Lingner and Cech, 1996) and S. cerevisiae (Lendvay et al., 1996) that 
eventually led to the full identification of the structure (Lendvay et al., 1996). Subsequently, 
hTERT was identified through homology search and the cDNA prepared and cloned 
(Meyerson et al., 1997). In humans, the hTERT was mapped to Chr 5p15.33 near the tip of 
the chromosome 5 and the hTERT gene spanned 40kb in size containing 16 exons. The 
hTERT protein is 127kDa in size and has a conserved telomerase-specific motif (T), seven 
reverse transcriptase (RT) motifs in their carboxyl-terminal half (1, 2, A, B′, C, D and E) 
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forming a finger-palm-thumb structure (Nakamura and Cech, 1998). Phylogenetic studies 
have suggested that the TERT is most related to RTs encoded by the non-long terminal 
repeat retrotransposons and viruses therefore providing evidence that telomerase is among 
the most ancient eukaryotic RTs (Eickbush, 1997). The RTs are very important in the 
function of the reverse transcriptase as mutations in the RT motifs prevent telomerase 
activity (Harrington et al., 1997, Nakayama et al., 1998). Through the RT motifs the hTERT 
protein recognises the RNA template and transcribes the telomeric sequence leading to 
telomere length elongation.  
Other molecular chaperons such as p23 and heat-sock proteins (Hsp90) associate with 
hTERT to promote hTERC and hTERT assembly in vitro in rabbit retinulocyte lysates 
(Weinrich et al., 1997). It is also shown that both chaperons are associated with the mature 
telomerase in cell extracts as inhibition of Hsp90 leads to blocking of telomerase formation 
(Holt et al., 1999). Interestingly, Weinrich and colleagues have shown that hTERT is the rate 
limiting factor for the telomerase absent in normal somatic cells but actively expressed in 
tumour-derived tissues and cells (Weinrich et al., 1997).  
1.11.2 Telomerase assembly and regulation at telomeres   
The large telomerase complex (~1000kDa) in human cells have the ability to form dimers or 
higher order multimers and the hTERT is implicated in multimerization (Cristofari and 
Lingner, 2006). This dimerization is mediated by the RNA-RNA interaction involving 
pseudoknot formation in trans (Ly et al., 2003). Biochemical analysis has shown that the 
telomerase enzyme is associated with many chaperons and proteins including telomerase 
associated protein 1 (TEP1), Hsp23, Hsp90, hStau and dyskerin but the exact function of 
these and other associated chaperons and proteins are not fully understood. For example, it 
is known that Hsp23 and Hsp90 are required for the assembly of the telomerase in the 
nucleus and mutations in dyskerin lead to the congenital disorder dykeratosis congentia 
(DC) (Pendino et al., 2006). 
  Chapter 1: Introduction 
36 
The telomerase activity is limited to the nucleus and its function on telomeres is regulated by 
several shelterin proteins. TPP1 and TIN2 recruit telomerase and retain it at telomeres as 
their depletion is shown to lead to diminished activity of telomerase at telomeres (Abreu et 
al., 2010). On the other hand POT1 is shown to inhibit telomerase binding to the 3’ single 
stranded telomeric DNA through its OB1 motif as studies have shown that lack of POT1 OB1 
domain induces rapid telomere elongation (Loayza and De Lange, 2003). Therefore, POT1 
is a negative regulator of telomerase as it acts as a terminal transducer that converts 
telomere length information into a regulatory signal at the telomere terminus (de Lange, 
2006). 
1.11.3 BRCA1 inhibition of telomerase activity 
It must be noted that a single study suggested inhibition activity of BRCA1 overexpression 
on telomerase in cells grown in vitro with the consequence of telomere shortening (Xiong et 
al., 2003). This inhibition occurs through reduction of the hTERT activity and had no effect 
on other components of the telomerase holoenzyme (e.g. TP1, HSP90, hTR, and dyskerin), 
the hTERT transcriptional activator c-MYC or the shelterin components TRF1 and TRF2 
(Xiong et al., 2003). The WT BRCA1 overexpression caused c-myc-induced hTERT 
repression, which was consistent with previous findings (Wang et al., 1998) (Li et al., 2002). 
Inhibition of the telomerase activity resulted in shortening of telomeres in the subclones of 
the overexpressed WT BRCA1 cells, but this telomere shortening did not result in 
senescence or apoptosis as the cells were able to maintain short telomere lengths. The 
mechanism behind the maintenance of the short telomeres is not known by the author but 
predicted to be due to low-levels of telomerase activity (Xiong et al., 2003). However, the 
authors failed to assess alternative telomere length maintenance activity in these cells 
(discussed in more detail below). 
Overall, limited evidence thus far has been provided that have shown non-physiological 
overexpression of WT BRCA1 in cells with mutant BRCA1 activity leading to telomerase 
inhibition and rapid telomere shortening. However, the study but failed to identify the 
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potential mechanism for the short telomere length maintenance or indeed assess the ALT 
mechanism. 
1.12 Telomere length regulation through Alternative Lengthening of 
Telomere (ALT) and the role of BRCA1 
Immortalised mammalian cells which proliferate for many population doublings (PD) without 
telomerase activity (measured through the conventional telomerase repeat amplification 
protocol or TRAP assay) maintained telomeres through ALT (Bryan et al., 1995, Reddel et 
al., 1997, Hande et al., 1999). Evidence for ALT activity have so far only been found in 
human immortalise cancer cell lines and telomerase-null mouse cell lines (Bryan et al., 1995, 
Henson et al., 2002).  Although, ALT activity has been found in breast carcinoma and other 
human cancers including glioblastoma multiforme, osteosarcoma and some types of soft 
tissue cancer, it is more prevalent in tumours of mesenchymal origins (Cesare and Reddel, 
2010). The exact reasons for ALT preference in tumours of mesenchymal origin is not 
known. The human mesenchymal stem cells are shown to have a preference for ALT activity 
(Lafferty-Whyte et al., 2009). ALT cells have distinct phenotype that makes it unique to its 
mode of telomere length maintenance. Therefore, understanding the mechanism of ALT 
activation in the cancer setting offers particular clinical significance through development of 
ALT-targeted treatment.  
1.12.1 Telomeric phenotype of ALT positive cells 
Telomeres in ALT-positive cancer cells have the exact features of telomerase-positive cells: 
telomeres are able to form the t-loop structure with shelterin protection and have TTAGGG 
telomeric repeats and the overhang of the G-rich strand (Cesare and Reddel, 2010). 
However, ALT-positive cancer cells are shown to have heterogeneous telomere length 
ranging from <3kb to >50 kb with an average of  20 kb (Bryan et al., 1995, Bryan et al., 
1997a, Grobelny et al., 2000, Murnane et al., 1994, Opitz et al., 2001). To put this in 
perspective, telomerase-positive human cancer cells have on average telomere length of 
<10 kb (de Lange et al., 1990). In some breast cancer cells telomeres are only 2-3 kb in 
length (Motevalli et al., 2014). In human germline cells the telomere length are averaged at  
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15 kb (de Lange et al., 1990). In normal human somatic cells, in the absence of telomerase 
and ALT activity, telomeres get progressively shorter with every cell division at a rate of 40 – 
200 bp until the telomere length gets to 5 – 8 kb at which point the cell triggers the p53-
dependant cellular senescence mechanism and ceases proliferation (Harley et al., 1990, 
Wright et al., 1997, Shay and Wright, 2005) Neumann and Reddel 2006).  
The heterogeneity in telomere size in ALT-positive cells is observed using in situ 
hybridization (FISH). Some chromosomes have no telomeric signal whereas others have 
strong telomeric signal reflecting the heterogeneity in the telomere lengths observed (Blasco 
et al., 1997, Perrem et al., 2001). Interestingly, fluctuations in telomere length measured 
using Flow-FISH method, were observed in an ALT-negative mouse lymphoma cell line 
(L5178Y also known as LY-R) with emergence of a subpopulation of cells after 20PDs 
(Cabuy et al., 2004). This unusual event in the telomerase-positive LY-R cells reveals 
significant gains and losses of telomeric DNA for which the mechanism of changes has not 
been elucidated (this observation is discussed in more detail in Chapter 6). 
The second most striking feature of telomeres in ALT positive cells is the presence of 
extrachromosomal telomeric DNA which takes many forms including double-stranded 
telomeric circles (t-circles) (Cesare and Griffith, 2004, Wang et al., 2004), the single 
stranded circles referred to as C- or G-circles depending on whether the strand is C- or G-
rich (Nabetani and Ishikawa, 2009, Henson et al., 2009) (the mechanism of C-circle 
formation is discussed in detail in Chapters 2 and 6), linear double-stranded DNA (Tokutake 
et al., 1998, Ogino et al., 1998) and very high molecular weight ‘t-complex’ DNA containing 
abnormal and branched structures (Nabetani and Ishikawa, 2009).  
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Figure ‎1-11. Evidence of telomeric copying via HR in the ALT cells.  
A) The detection of telomere copying using FISH of an intratelomeric plasmid DNA tag (yellow) in a clonal ALT 
cell lines in early and B) late passage cells (Dunham et al., 2000). C) The four proposed model of ALT 
recombination in human cells (Henson et al., 2002). 
The third hallmark common in all human ALT positive cell lines is the occurrence of specific 
nuclear structures, referred to as ALT-associated promyelocytic leukaemia nuclear bodies 
(PML nuclear bodies) or APBs (Yeager et al., 1999). These are PML nuclear bodies (PNBs) 
that are PML aggregates bound to the nuclear matrix (Henson et al., 2002). PNBs have a 
vast array of functions including tumor suppression, cell cycle regulation, senescence, 
apoptosis and immune response just to name a few (for detailed review of PNBs see 
(Lallemand-Breitenbach and de The, 2010). PNBs perform their function by sequestering 
and releasing proteins and localising proteins to their site of action – be it on the chromatin, 
on the DNA or through interactions with other proteins (Henson et al., 2002). However, APBs 
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differ from other PNBs in that they contain telomeric DNA, as well as having TRF1 and TRF2 
proteins association (Yeager et al., 1999). It has recently been shown that APBs contain 
many other proteins involved in DNA recombination and replication such as RAD51, RAD52, 
RPA, MRE11, RAD50, NBS1, BLM, WRN, ATM and ATR (Henson et al., 2002, Cesare and 
Reddel, 2010, Nabetani and Ishikawa, 2009). APBs formation in ALT-positive cells is cell 
cycle dependant and occurs in specific phases of the cell cycle. Therefore APB frequency 
typically varies between 5 – 10% in ALT-positive cells (Yeager et al., 1999). APBs have 
been observed in all ALT-positive human tumour cell lines (Neumann and Reddel, 2006) 
including human tumour specimen obtained from needle aspirates, frozen sections and 
paraffin-embedded blocks (Henson et al., 2002), Neumann and Reddel, 2006). However 
evidence is emerging that not all ALT-positive human cells have APBs associated with 
telomeric DNA (Cerone et al., 2005). This inconsistent observation was made only in one 
ALT-positive human cell line. This unexpected observation suggests that there may be more 
than one class of APBs; those that accumulate and are involved in cell cycle and cellular 
senescence and those that is involved in the ALT activity and telomere length maintenance 
(Cesare and Reddel, 2010). 
A forth hallmark of ALT cells is the frequent occurrence of post-replicative exchanges 
between telomeric repeats that results in telomere-sister chromatid exchange (T-SCE) 
(Bechter et al., 2004a, Londono-Vallejo et al., 2004). These T-SCEs can only be visualised 
using a strand-specific in situ hybridization technique known as chromosome orientation 
(CO)-FISH (Bailey et al., 2004b) (Bailey et al., 2001) (See Chapter 2 for more detail). With 
this technique it is possible to analyse the frequency of SCEs involving telomeres. However, 
the exact mechanism behind the formation of T-SCEs is not fully known. It is predicted that 
these may occur as a result of recombination mediated repair of replication forks (Wilson 
and Thompson, 2007). Though the exact molecular mechanism of T-SCEs is not 
understood, these features are commonly observed at high frequencies in all ALT-positive 
human cell lines and very rarely in telomerase-positive human cells (Neumann and Reddel, 
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2006; Table 1 p. 170, (Londono-Vallejo et al., 2004). The result of unequal T-SCEs in ALT 
cells is proposed to cause one daughter cell to have elongated telomeres, and therefore 
higher proliferation capacity relative to the daughter cell with shorter telomeres, and hence 
lower capacity for cell division (Bailey et al., 2004b). It must be noted that this is only a 
hypothesis and no evidence of differential segregation of telomeres has been observed in 
human cells (Cesare and Reddel, 2010). It is thought that the high frequency of telomeric 
exchanges in ALT positive cells could be due to the recruitment of proteins involved in HR to 
the sites of telomeres resulting in the accumulation of proteins that results in generating 
telomeric SCEs (Londono-Vallejo et al., 2004). 
1.12.2 Telomeric recombination in ALT cells 
The occurrences of long but heterogeneous telomeres in ALT positive cells suggested that 
their telomeres may be maintained by HR (Murnane et al., 1994) Neumann and Reddel, 
2006). A total of four HR derived mechanisms were proposed (Figure 1.10) suggesting inter-
telomeric recombination as a primary mechanism (Reddel et al., 1997). Dunham and 
colleagues (Dunham et al., 2000) provided evidence for inter-telomeric recombination by 
showing telomere to telomere copying using fluorescently-tagged plasmids targeted into 
telomeres. These experiments showed for the first time that telomeres from one 
chromosome can be used as templates for extending another telomere from a separate 
chromosome (Figure1.10), and that these events were unique to ALT positive cells (Dunham 
et al., 2000). This model of HR-mediated telomere length maintenance is seen as a 
favourable model of telomere length homeostasis in the ALT positive cells (over the unequal 
exchanges and asymmetric segregation model) since recombination can occur both from 
inter-telomeric (Dunham et al., 2000) and intra-telomeric sequences (Muntoni et al., 2009). 
Therefore, telomeres can copy themselves through t-loop formation or template-directed 
DNA-copying of one sister chromatid by another (Cesare and Reddel, 2010).  
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1.12.3 Proteins involved in HR-mediated telomere maintenance in ALT cells 
Several proteins have been shown to be important in recombination at telomeres. These are 
classified into (i) proteins that keep telomere elongated and (ii) proteins that prevent 
telomere loss (Cesare and Reddel, 2010).  
Central to the recombination process is the MRN complex, which includes a trio of MRE11, 
RAD50 and NSB. MRN is shown to be necessary to the recombination in ALT cells (Jiang 
and Greenberg, 2015, Zhong et al., 2007) as MRN recruits ATM and is responsible for 
resection of 5’ to 3’ of the DNA at the DSB sites creating a 3’ overhangs necessary for strand 
invasion during the HR process (Lee and Paull, 2007) (See section 1.9 above). The 
localisation of MRN occurs on telomeres during the S and G2 phases of the cell cycle and is 
bound directly to the TRF2 (Zhu et al., 2000). Since the DNA elongation at telomeres occurs 
at the 3’overhang section it requires DNA polymerases which are though to be recruited to 
the telomeric sites by the ATM after its activation via the MRN complex (Cesare and Reddel, 
2010). This is shown in various experiments whereby the MRN activity was diminished by 
various means (using SP100 protein to sequester NBS1, or shRNA targeting RAD50) 
causing long-term disruption of the MRN complex and massive telomere shortening in the 
ALT positive cells (Jiang and Greenberg, 2015, Zhong et al., 2007). 
Other proteins that are shown to be involved in the ALT mechanism are WRN and BLM, both 
present in APBs (Yankiwski et al., 2000) (Johnson et al., 2001). The BLM RecQ helicase 
functions at telomeres to regulate the D-loop formation following strand invasion and may 
also be involved in resolving recombination events in mortal and telomerase-positive cells 
(Neumann and Reddel, 2002). The 3’ and 5’ exonuclease activity of the WRN is shown to 
function both in recombination repair at telomere and in the dissociation of a 3’ telomeric tail 
from inappropriate recombination event by resolving telomeric D-loops (Opresko et al., 2002) 
(Opresko et al., 2004). Similarly, it is shown that Replication protein A (RPA), RAD51, 
RAD52 and BRCA1 are associated with ALT through APBs (Yeager et al., 1999) (Naka et 
al., 2002, Acharya et al., 2014). Recently, it is shown that BLM and BRCA1 are co-localised 
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with Rad50 at telomeres during S- and G2-phases of the cell cycle in the ALT positive cells 
but not in telomerase-positive cells (Acharya et al., 2014), further highlighting the 
involvement of BRCA1 via BLM and RAD50 in telomere maintenance in the ALT cells. 
1.13 Aim of the thesis and outline of chapters 
Maintaining telomere structure and length in the mammalian cells is extremely important as 
functional telomeres can prevent unwanted genomic instability, an important hallmark of 
cancer. Telomere dysfunction is caused by (i) disrupted shelterin proteins, (ii) telomere 
length shortening and (iii) defective DNA damage repair and sensing proteins. BRCA1 is an 
important DNA damage repair protein that is recruited to sites of DNA DSB damage 
including telomeres and it repairs the damaged DNA mainly through HR and to lesser extent 
through NHEJ. Cells lacking functional BRCA1 suffer from premature senescence but the 
exact role of telomere maintenance in the process is not known.  
Aims of this thesis are: 
(a) To assess the effect of BRCA1 heterozygous mutation on DNA damage repair and 
sensing capacity at telomeres in human and mouse cells;  
(b) To assess whether BRCA1 defects plays a role in ALT in human cells and mouse stem 
cells. 
(c) To elucidate uncertainties surrounding BRCA1 role in telomere homeostasis described 
earlier (see pages 40-41).   
To achieve the above aims we used human lymphoblastoid cell lines derived from patients 
with heterozygous BRCA1 mutations and mouse embryonic stem cells (mESCs) lacking 
both copies of BRCA1. Using a range of techniques we measured DNA damage response 
and telomere maintenance in these cells.  
Chapter 3 describes DNA damage response and telomere maintenance following low doses 
of IR in human lymphoblastiod cells lines.  
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Chapter 4 describes DNA damage response in mESCs.  
Chapter 5 focuses on telomere maintenance and searching for evidence of ALT in mECS.  
Finally, in Chapter 6 we used the same mESCs described in chapters 4 and 5 and human 
ALT-positive cell lines U2OS, SKLU-1 and G292, as well as ALT-negative human cells HeLa 
and HCC1937, to further characterise the relationship between BRCA1 wild-type and 
heterozygous mutant with BLM at telomeres, with the aim of identifying the mechanism 
behind ALT activity in the above cells. 
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2 Materials and Methods 
 
2.1 Cell lines and tissue culture conditions 
2.1.1 Human epithelial cancer cell lines 
The HeLa cell line (Table 2-1) was originally established from a patient with cervical cancer. 
HeLa cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Gibco/Sigma), 
supplemented with 10% fetal calf serum (Gibco/Sigma) at 37ᵒC in the atmosphere of 10% 
CO2. The breast cancer cell line HCC1937, which has a truncated, non-functional BRCA1 
was cultured in RPMI 1640 (Gibco/Invitrogen) supplemented with 15% fetal calf serum at 
37ᵒC in a humid atmosphere containing 5% CO2.  In order to avoid contamination, Penicillin 
and Streptomycin were added (1µl per 100ml medium) to both media. 
2.1.2 Human B-lymphocytes 
Normal human B-lymphoblast cell lines GM00893 and GM13705,and GM14090 cell lines 
derived from carriers of BRCA1+/- mutations were cultured in RPMI 1640 medium 
(Gibco/Invitrogen) and 10% fetal calf serum and antibiotics at 37ᵒC in the atmosphere of 5% 
CO2. All these cell lines have been obtained from the Coriell Cell Repository. 
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2.1.3 Mouse lymphoma cell lines 
Mouse lymphoma LY-R (radio-resistant) and LY-S (radio-sensitive) cells were cultured in 
RPMI 1640 medium (Gibco/Invitrogen) supplemented with 10% fetal calf serum and 
antibiotics at 37ᵒC in the atmosphere of 5% CO2 and were used as a reference for 
cytological testing telomeric measurements using interphase Q-FISH (IQ-FISH) technique. 
2.1.4 Mouse embryonic stem cells 
Mouse embryonic stem cell lines E14 and 408 were obtained from Dr Beverly Koller, Duke 
University, USA. They represent undifferentiated embryonic stem cells and were cultured at 
37ᵒC in the atmosphere of 5% CO2 on gelatine coated dishes in KnockOut DMEM medium 
supplemented with 20% KnockOut serum replacement, 2 mM L-glutamine, 0.001% b- 
mercaptoethanol (Sigma-Aldrich, St. Louis, MO), 1000 U/ml ESGRO (Chemicon, Temecula, 
CA), 10 U/ml penicillin, 10 U/ml streptomycin (all purchased, except where stated, from 
Gibco/Invitrogen). Medium was changed every 2 days, and cells were subcultured initially at 
the ratio 1:2. The ratio progressively increased up to 1:8. 
 
Figure ‎2-1. Representative images of cultured mouse ESCs.  
A) Brca1 wild type E14. B) Brca1
(-/-)
 homozygous 408. Images taken at x40 magnification using inverted 
microscope. 
2.1.5 Human ALT+ cell lines 
The human osteosarcoma cell line U2OS and G292 originally derived from a 15 and 9 years 
old female, exhibit epithelial adherent morphology were grown in McCoy`s 5a culture 
medium (Sigma), supplemented with 10% FBS (Gibco/Sigma) and 2mM glutamine (Gibco) 
at 37ᵒC. the lung adenocarcinoma SK-LU-1 cell line derived from 60 years old female 
(ECACC, Cat. No.93120835) was grown in EMEM (Sigma), supplemented with 10% FBS 
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(Gibco/Sigma) and 2mM glutamine (Gibco). In order to avoid contamination, penicillin and 
Streptomycin were added (1µl per 100ml medium) to all media. 
 
Figure ‎2-2. Representative images of ALT
+
 human cell lines.  
A) Human U2OS osteosarcoma cell line. B) Human ALT- HeLa cells. Images taken at 40x magnifications. 
2.2 Tissue culture procedure 
All cell lines were kept frozen in liquid nitrogen. When required vials of frozen cells were 
thawed and set up in either 25cm2 or 75cm2 filter head flasks (Nunc) to prevent any 
contamination. Cells were incubated in a humidified incubator (Heracell 150) at 37ᵒC.  All 
primary fibroblast cell lines were subcultured 1:3 following gentle trypsinization with trypsin- 
EDTA (Gibco/Invitrogen) for about 5 minutes at least every three days at 80 percent 
confluence. After trypsinization cells were spun down using a Megafuge 1.0, Heraeus 
centrifuge for 5 minutes at 1200rpm. 
2.2.1 Cell counting 
Cell counting was carried out using automatic method a Countess Automated Cell Counter 
from Invitrogen was used. A mixture of 10µl of Trypan blue and 10µl of cell suspension was 
prepared. Then a total of 10µl of mixture was taken and added to each slides. The slide is 
then inserted into the allocated slot in the machine. Finally, the result of the total number of 
cells per ml displayed on the screen. 
  Chapter 2: Materials and Methods 
48 
 
 
Table ‎2-1. A detail summary of all cell lines used in this thesis.  
Cell lines Species Origin and gene affected Cell type Sex References 
GM00893 Human Healthy individual (32 years old) B-lymphocyte Female Coriell Institute 
for medical 
research 
GM13705 Human BRCA1 carrier (BRCA1
+/-
) (38 year old) B-lymphocyte Female Castilla LH et al 
1994 
GM14090 Human BRCA1 carrier (BRCA1
+/-
) (43 years old) B-lymphocyte Female Struewing JP et 
al 1995 
U2OS Human Human osteosarcoma (15 years old) Mesenchymal 
adherent cells 
Female Ponten J and 
Saksela E 1967 
HeLa Human Human cervical carcinoma (31 years old) Epithelial 
adherent cells 
Female Gey Go et al. 
1952 
HCC1937 Human Human breast adenocarcinoma (23 years old) Lymphoblast, 
epithelial 
Female Tomlinson GE et 
al. 1998 
L5178Y (referred to as LY-
R) 
Mouse Mouse lymphoma, Normal Lymphoma Unknown Alexander P et al 
1961 
L5178Y-S (referred to as 
LY-S) 
Mouse Mouse lymphoma, Radiosensitive Lymphoma Unknown Alexander P et al 
1961 
E14TG2a (referred to as 
E14) 
Mouse Mouse embryonic stem cells with functional 
Brca1 
Stem cell Unknown Hooper et al. 
1987; Snouwaert 
J et al 1999 
408 Mouse Mouse embryonic stem cells with defective 
Brca1 (Brca1
-/-
) 
Stem cell Unknown Snouwaert J et al 
1999 
SKLU-1 Human Human lung adenocarcinoma (60 years old) Epithelial 
adherent cells 
Female Fogh J et al 1977 
G292 Human Human osteosarcoma (9 years old) Fibroblast 
adherent cells 
Female Peebles P et al 
1978 
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2.2.3 Cell cryopreservation 
Cells were preserved in liquid nitrogen, so before that cell suspension mixed with 1ml of 
freezing medium consisting of 90% foetal calf serum (Gibco/Invitrogen) and 10% DMSO 
(dimethylsulfoxide, Sigma). The cell suspension was aliquot into cryogenic vials for storage 
in liquid nitrogen. Prior to storage in liquid nitrogen the vials were kept in a Nalge nunc cooler 
for 24 hours at -20ᵒC, which contained Isopropyl Alcohol (IPA). 
2.2.4 Thawing of cryopreserved cells  
The cryopreserved cells after taken out from liquid nitrogen, warmed for 2-3 minutes at 37ᵒC 
and then transferred to flasks containing pre-warmed medium. After 24 hours the medium 
was changed to wash away any DMSO residual. 
2.2.5 Irradiation of cells 
Cells were exposed to ionising radiation using a Cobalt-60 source. Adherent cells were 
grown up to 80-90% confluence either in non-filtered tissue culture flasks (Nunc, Fisher) for 
metaphase preparation, or on polyprep slides (Sigma) depending on the relative assay. Cells 
were exposed to different doses of ionizing radiation including: low dose 0.5 Gray (Gy) or 
high dose (1.0Gy, 2.0Gy, and 4.0Gy) which was calculated using datasheets provided by the 
physicists in charge of the facility. 
The formula was used to calculate: 
𝑇𝑖𝑚𝑒 (𝑚𝑖𝑛𝑠) =
𝐷𝑜𝑠𝑒 𝑁𝑒𝑒𝑑𝑒𝑑 (𝐺𝑦)
𝐷𝑜𝑠𝑒 𝑅𝑎𝑡𝑒 (𝐺𝑦 𝑚𝑖𝑛−1)
 
 
The calculation of radiation dosages was measured in Gy per minutes. In our research, cells 
were only subjected to relatively low doses of radiation (0.5Gy and 1.0Gy), however 2.0Gy 
was used as a maximum dose. 
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2.3 Cytogenetic Analysis 
2.3.1 Metaphase preparation using lymphoblastoid cell lines 
All cell lines were treated in the presence of Demecolcine (10µg/ml) for about 1- 12 hours 
depending on the cell line and assays. Demecolcine was used to block the formation of 
microtubules, therefore can arrest the cells in metaphase. Cells were washed with PBS, 
trypsinised for 5 minutes and after spun down at 1000rpm for 5 minutes, treated with 3ml of 
hypotonic buffer (75 Mm KCl) for 15 minutes in a 37ᵒC water bath and this will cause cells to 
increase their fluid intake. The 1ml of fresh fixative (Methanol: Acetic acid 3:1) was gently 
added and the cells were centrifuge at 1000rpm for 5 minutes. The fixation process was 
repeated at least 3 times. Finally, cells were then re-suspended in fresh fixative and 20µl of 
this suspension was dropped on to pre-cleaned slides. The fresh fixative confirmed that 
mitotic cells were spread over the surface of slide effectively. The slides were checked under 
a phase contrast microscope. 
2.3.2 Metaphase preparation using mouse embryonic stem cell lines 
2.3.3 Giemsa staining 
 Next, metaphase cells were stained with 7 percent (v/v) Giemsa (Sigma-Aldrich) for about 5 
minutes in 5 ml of ddH2O. To ensure better staining, Giemsa was filtered using standard 
filter paper (3MM Watman paper). After staining slides were washed gently with ddH2O and 
left to air dry. Slides then were mounted with DPX (BDH laboratories), covered with cover 
slip, and left for maximum 2 hours to dry. Analysis was carrying out using light microscopy 
(Zeiss Axioplan 2) equipped with CCD camera and Metasystem software (Altlussheim, 
Germany). 
2.3.4 Chromosomal aberration analysis 
To detect any damage at chromosomal level, metaphase chromosome was stained using 
either DAPI (fluorescence microscopy), or Giemsa (light microscopy) and were analysed at 
G1 and G2 phases of the cell cycle. For both human lymphoblastoid cell lines and mouse 
embryonic stem cell lines following protocol were performed. 
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For G1 assay, cells were irradiated as confluent, sub-cultured and incubate about 18 hours. 
Then 10µg/ml colcemid was added for 2 hour. The cells were harvested as described above. 
The duration of one single cell cycle in the case of mouse embryonic stem cells is 
approximately 20 hours and incubation for 18 hours plus 2 hours colcemid treatment allow 
capturing of metaphase G1 cells exclusively. 
Semi-confluent cells were exposed to ionizing radiation in G2 assay. Cells were then 
incubated for 20 minutes before adding colcemid and kept them in presence of colcemid for 
1 hour. The cells were harvested at 1.5, 3.0 and 4.0 hours after radiation. 
2.3.5 Micronuclei assay 
Growing cells were treated with 6µg/ml of Cytochalasin B (Sigma) for 48hours. The cells 
were then centrifuge at 800rpm for 8 minutes. After discarding the supernatant, the pellet 
was gently re-suspended in 3ml of hypotonic KCl (75mM) solution and left at 4ᵒC for 3 
minutes. A few drops of fixative (Methanol: Acetic Acid; 3:1) were added to the cells, and 
they were centrifuged at 800 rpm for 5mins. After that the supernatant was aspirated and the 
cells were re-suspended in 3ml of fixative and left for 10 minutes at room temperature. After 
centrifuging the supernatant was aspirated and a total of 500µl of fixative was added, this 
suspension was cyto-spun onto slides at 800rpm for 5 minutes. The slides were then stained 
with the Giemsa as described earlier.  
 
Figure ‎2-3. Schematic diagram showing formation of micronuclei (MN).  
MN is formed when fragments of chromosome does not segregate and results in formation of mini nuclei during 
cellular division (Author’s own representation). 
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2.4 Interphase Quantitative Fluorescence in situ Hybridization (I-QFISH) 
2.4.1 Pre-hybridisation washes 
The slides containing samples were washed with PBS for 5 min on the shaker. After that the 
samples were treated with 4% formaldehyde for 2 minutes, the next step was washing in 
PBS for 3x5 minutes. In order to remove unwanted proteins, 500µl of pepsin (10% pepsin; 
Sigma) was mixed with 50ml of acidified dH2O of pH2 (49.5ml of deionized water added to 
0.5ml HCl) and then added to 50 ml PBS and incubated at 37ᵒC in water bath for 10 minutes. 
Next cells were washed 2x2 minutes with PBS on the shaker, and fixed for the second time 
with 4% formaldehyde for about 2 minutes. Subsequently after washing the slides 3x5 
minutes with PBS, dehydrated with ethanol series (70%, 90%, 100%) and left to dry at room 
temperature (Figure 2.4). 
2.4.2 Hybridisation 
A total of 20µl of the PNA probe specific for the telomeric DNA sequence (CCCTAA)3 
labelled with FITC, was added to the slides. The slides were then heated on the heating 
block for 2 minutes at 70-75ᵒC. Slides were left in a dark and humid chamber for 2 hours to 
allow for hybridisation. 
2.4.3 Post-hybridisation washes 
The slides were washed twice in presence of 70% formamide solution for about 15 minutes 
followed by washing the slides 3x with PBS for 5 minutes. After dehydrated with ethanol 
series (70%, 90%, 100%), a total of 15µl of Vectra-shield anti-fade (DAPI) mounting medium 
was added to each slides and then were sealed with a clear nail varnish. 
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Figure ‎2-4. Schematic representation of the IQ-FISH workflow.  
Cells are dropped and fixed onto a clean microscope slide and is hybridized with a Telomeric probe (see 
materials and methods for detail). The slides are then further treated and washed and images taken using a 
fluorescent microscope. The signal intensity from each telomeric probe is then quantified using image-processing 
software (Author’s own representation). 
 
2.4.4 Image capture and telomere length analysis 
Images of interphase cells were acquired using the Smart Capture software (Digital 
Scientific, Cambridge, UK) and the analysis of telomere fluorescence using the IP lab 
software. The software adapted for this purpose by Digital Scientific. The software produces 
a combined image of the detected telomeres and the cell nucleus boundaries which are 
superimposed onto the telomere image. In order to maintain the accuracy of IQ-FISH 
methodology it was essential to have correct controls for the experiment. This is because the 
fluorescence microscope lamp intensity is not steady. To provide the accuracy of 
fluorescence intensity measurement we used to mouse cell lines, LY-R and LY-S, with long 
and short telomeres respectively, as calibration standards (Mcllrath et al., 2001). In each 
experiment we captured images of LY-R and LY-S cells together with the test samples. After 
capturing images of interphase cells in the Smart capture 2 software, the data was sent to 
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the IPLab program in which telomere fluorescence intensities were measured. The 
procedure for IQ-FISH was described in detail in a PhD thesis by another student working in 
Dr. Slijepcevic’s laboratory (Ojani, 2012). 
 
Figure ‎2-5- Image shows a typical segmented image with cell nuclei stained in green 
 
Figure ‎2-6- Image shows a snapshot of the mathematical manipulations behind the process of telomere 
fluorescence intensity measurement. 
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2.5 Chromosome Orientation Fluorescence in situ Hybridisation (CO-
FISH) 
CO-FISH or the technique which was originally called COD-FISH, is based on standard 
FISH which also has more ability to determine the absolute 5` to 3` orientation of DNA 
sequence relative to short arm to long arm of the chromosome. The principle of the 
technique is based on standard FISH, which allows hybridisation of a single standard probe 
to only one chromatid of a metaphase chromosome (Goodwin et al 1993). Figure 2.7 shows 
the main principle of this technique.  
To examine the telomeric sister chromatid exchange (T-SCE), CO-FISH was used which can 
be seen below. The split signal shown in the image shows a T-SCE. This image was 
adapted and adjusted from (Bailey et al 2004). 
After cell culturing the cells were placed in incubator for 20minutes and then 3µl of 5`-bromo-
2-deoxyuridine (Brdu/Brdc, 3:1) at the concentration of 1x10-5 M (Sigma) was added to the 
cells. Following metaphase preparation slides were made and were aged overnight at 54ᵒC 
to allow better preservation of chromosomes after subsequent DNA denaturing.  
2.5.1 Washing, digestion, and fixation 
The slides were washed with PBS for15 minutes and then stained with 2.5µl of Hoescht 
33258 (0.5µl/ml), which was gently mixed with standard saline citrate (2x SSC) for 15 
minutes. Slides were then exposed to 365 nm UV light for 30minutes, and a total of 100µl of 
Exonuclease III (Promega) (1.5µl Exonuclease III + 10µl buffer + 88.5µl H2O) was added to 
each slide, covered with cover slip and left at room temperature for 10 minutes. Samples 
were then washed with PBS for 2x5 min on the shaker. Subsequently, the slides were 
treated with ethanol series for about 5 minutes for dehydration (70%, 90%, and 100%), and 
left to air dry. Hybridisation and post-hybridisation washes are carried out as described 
earlier (section 2.4.2 and 2.4.3). 
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Figure ‎2-7. Schematic representation of CO-FISH.  
Cells are left overnight in the presence of BrdU and after incooperation into the genome and metaphase 
preparation the slides are UV treated and digested using Exonuclease II. This causes removal of one of the 
strands of chromosome. The slides are then hybridized with telomeric probe and in the presence of sister 
chromatic exchanges three telomeric signals are observed as opposed to normal CO-FISH pattern of two 
telomeric signals on opposing chromatid.   
2.5.2 Image Analysis 
Digital images were acquired using a Zeiss fluorescence microscope equipped with a CCD 
camera and the ISIS captures software (in situ imaging system ISIS. Meta systems, 
Altlusshim, Germany). 
2.6 Immunocytochemistry 
2.6.1 Single‎immunofluorescence‎detection‎of‎γ-H2AX foci 
Ionizing radiation or cytotoxic agents are mechanisms that induced double strand breaks; 
subsequently γ-H2AX foci quickly form and can be used as a biomarker for DNA damage. 
Therefore, γ-H2AX assay is one of the most popular technique for detection of DNA double 
strand breaks. Interphase cells were examined using a monocolonal anti-body against the γ-
H2AX protein. We used a simple cytospin procedure to spreads non-adherent cells onto 
microscope slides using gentle fixative reagents (2% formaldehyde for 10 min). Cells were 
grown in T25cm2 flasks (Nunc) and attached to poly-prep L-lysin slides (Sigma-Aldrich) by 
cytospin centrifuge at 1000 rpm for 5 min. after fixation with 2% paraformaldehyde for 10 
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min, washed with PBS for 5 min, permeabilized with 0.05% Triton X-100 solution (Sigma-
Aldrich) in PBS for 10 min at 4°C. Non-specific sites on the cells were then blocked using 
blocking buffer (0.1 gram BSA + 10ml PBS + 10µl Tween20). A total of 100µl of blocking 
buffer was added to each slide and covered with parafilm for 30 minutes in dark. Cells were 
then incubated with mouse monoclonal anti-phospho-histon H2AX (γ-H2AX, Millipore) at 
1:500 following manufacturer`s instructions in blocking buffer for 1 hour at room temperature. 
Cells were then washed and incubated with a species specific secondary IgG FITC 
conjugated antibody (FITC labelled anti-mouse, Invitrogen) at 1:1000 for 1 hour at room 
temperature. Cells were then washed in PBS several times and covered with vectashield 
mounting medium (Vector Laboratories, California, USA) containing 1.5 µg/ml DAPI. 
2.6.2 Telomere dysfunction-induced foci (TIF) assay 
Combined  immunofluorescence (γ-H2AX) and FISH (telomeric PNA probe) to detect the 
DNA damage at telomeres is named TIF. First, detection of γ-H2AX foci by 
immunofluorescence was performed. Slides were incubated overnight in a dark container at 
room temperature. On the next day the FISH method, described in previous section (2.4) 
was applied with a Cy3-conjugated PNA probe (C3T2A)3, followed by standard formamide 
and SSC washes. Cells were counterstained with DAPI in fluorescence anti-fade medium. 
The slides were then analysed using the computerized Axioskop 2 Zeiss fluorescence 
microscope equipped with a CCD camera and Metasystem software. 
2.6.3 Single immunofluorescence detection of PML foci 
A total of 5x105 cells were grown on poly-L-lysine- coated slides (poly-Prep slides, Sigma- 
Aldrich) for 24 hours prior to immunofluorescence staining. The slides were fixed in 4% 
paraformaldehyde for 10 minutes and were washed three times in PBS. Cells were then 
permeabilised in 0.25% Triton-X 100 (Sigma- Aldrich) for 10 minutes at room temperature 
and were washed in PBS 3X5 min. Cells were blocked with 1% Bovine serum albumin (BSA) 
in PBS for 30 minutes and were covered with parafilm in a humid container. Promyelocytic 
leukemia (PML) primary antibody (Mouse monoclonal antibody against PML, MAB3738, 
Millipore) was added to the slides at the desired concentration (1:100), for 1 hour in humid 
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container covered with parafilm. Slides were washed in PBS three times for 5 minutes. The 
anti-mouse secondary antibody labelled with FITC (Invitrogen) was added to the slides at a 
dilution rate of 1:1000 and slides were incubated for 1 hour in a dark and humid container. 
The slides were washed in PBS 3x5min in the dark on the shaker.15µl of Vectashield with 
fluorescence DAPI mounting medium was then added to the slides and the slides were 
covered with a coverslip prior to sealing with clear nail varnish. 
2.6.4 Immunofluorescence and FISH (Immuno-FISH) 
After immunostaining with anti-PML antibodies, as described earlier. The FISH method was 
applied with a Cy3-conjugated PNA probe (C3TA2)3 followed by standard formamide and 
SSC washes (section 2.4). Cells were counterstained with DAPI, and covered with a 
coverslip and were sealed with clear nail varnish. 
2.6.5 Single immunofluorescence detection of ATRX foci 
Immunofluorescent staining was performed on cells grown on poly-L-lysine-coated slides 
(Sigma-Aldrich), fixed for 10 min at room temperature in a 3% paraformaldehyde-buffered 
solution, and permeabilised 10 min on ice with cold 0.5% Triton X-100 (Sigma-Aldrich). Cells 
then were washed with cold PBS 4x5min and were blocked with PBG (PBS+BSA+ Gelatine 
Fish) for at least 30 minutes at room temperature. Alpha-thalassemia/mental retardation 
syndrome X-linked (ATRX) primary antibody (Rabbit polyclonal antibody against ATRX, 
ab97508, Abcam) was added to the slides at the relevant concentration (1:100) and 
incubated 1.5 hrs at 37ᵒC. the slides were washed in PBS three times for 5 minutes. Cells 
then were incubated for 30 minutes at 37ᵒC with anti-rabbit secondary antibody labelled with 
FITC (Cat no.: F1262, Sigma) (1:100) diluted in PBG. The slides were washed in PBS three 
times for 5 minutes on the shaker and mount on slides using Vectashield containing DAPI.  
Immune-FISH was performed following by immunostained. The FISH method was applied 
with a Cy3-conjugated PNA probe (CCCTAA)3 . Cells were counterstained with DAPI and 
were sealed with clear nail varnish. 
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2.6.6 Single immunofluorescence detection of BRCA1 foci 
Cells were grown on coverslips (Poly-L-lysine-coated slides, Sigma-Aldrich) and fixed for 10 
minutes with 4% paraformaldehyde at room temperature. Cells then were washed in PBS 
three times for 5 minutes and were permeabilised with 0.5% Triton X-100 (Sigma-Aldrich) for 
10 min on ice.  The cells were then blocked with 1% BSA in PBS for 30 minutes at room 
temperature and were covered with parafilm in a humid container. 100µl of mouse 
monoclonal anti BRCA1 (Thermo scientific, 6B4) was added to the slides at the desired 
concentration (1:400) and the slides were incubated for 1 hour in humid container. The 
slides were each rinsed three times for 5 minutes. 100µl of secondary FITC-conjugated anti 
mouse IgG antibody (Invitrogen) was added to the slides at the desired concentration 
(1:500) and the slides were incubated for 1 hour in a dark and humid container covered with 
parafilm. The slides were each washed in TBST (Tris-Buffered Saline with 0.1% Twee20) 
three times for 5 minutes in the dark on the shaker. 15µl of vectashield with fluorescence 
DAPI mounting medium was then added to the slides and the slides were covered with 
coverslip prior to sealing with clear nail varnish. 
2.6.7 Single immunofluorescence detection of BLM foci 
Cells were grown on poly-prep slides (Sigma-Aldrich) for 24 hours before fixation in 4% 
formaldehyde in PBS for 10 minutes and were permeabilised with 0.5% Triton X-100 
(Sigma-Aldrich) for 10 minutes at 4ᵒC. cells were then washed with PBS 3x5 min and were 
incubated  with blocking buffer 1% BSA in PBS for 30 minutes in humid container. 100µl of 
Blooms Syndrome (BLM) primary antibody (Rabbit polyclonal antibody against BLM, PA5-
27384, Thermo Scientific) was added to the slides at the desired concentration (1:100) and 
the slides were incubated for 1 hour in a humid container covered with parafilm. The slides 
were washed in PBS three times for 5 minutes. Then, 100µl FITC secondary anti-rabbit were 
added (diluted 1:100 with 1% BSA) for one hour in dark, damp conditions and washed with 
PBS for five minutes, three times in a dark coupling jar and on an orbital shaker. Cells were 
fixed again with 4% formaldehyde for 20 minutes at room temperature and left overnight. 
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2.6.8 Double immunofluorescence detection of BRCA1 with BLM 
Cells were spread onto poly-L-lysine-coated slides. For the simultaneous visualisation of 
BRCA1-BLM foci, cells were fixed as mentioned in previous section. Cells preparation were 
blocked for 1 h in 10% FBS/PBS, rinsed, and incubated with primary antibodies. Double 
staining with antibodies was performed for 1 hour at room temperature or overnight at 4°C, 
whereas species-specific FITC and Texas Red-conjugated secondary antibodies were 
applied for 1 h at room temperature followed by counterstaining for 5 min at room 
temperature with 0.5µg/ml DAPI. Slides were mounted in vectashield and analysed by 
fluorescence microscopy. All primary antibodies were used at 1: 100-400 dilutions, whereas 
the secondary antibodies were employed at a 1: 100 dilutions.   
2.7 Western Blot 
Cells were grown as described before, and after typsinaisation a total of 15 x105 cells 
centrifuged and washed with ice-cold PBS for 5 minutes at 4°C then lysed on ice for 15 min 
in 60µl of lysis buffer (Tris-HCl (1M,PH7.4), NaCl (5M), EDTA (0.5M,PH8.0), Triton X 
(100%), SDS (10% w/v), Na-deoxycholate (10% w/v), Protease Inhibitor (100x) dH2O) 
(Peplab, Germany). Samples then were centrifuged at 14,000rpm for 15 min and the 
supernatant transfer to new Eppendorf tubes. The total protein extracts were and stored at -
20°C.  
For each samples approximately 30µg of protein was prepared in 2x Laemmli buffer ( 2-
mercaptoethanol 0.1%, Bromophenol blue 0.0005%, Glycerol 10%, Sodium dodecyl sulfate 
(SDS) 2%, and Tris-HCl 63mM (pH6.8)) and boiled in 100°C for 10 min to denature the 
globular structure of the proteins and then loaded onto a 4-20% precast gradient gel (Bio-
rad). The lower the molecular weight of a protein of interest, the higher the percentage of gel 
that is required. 
2.7.1 Protein gel electrophoresis 
30µg of protein were loaded carefully onto each well. The protein marker was normally 
loaded on the first well. The interior and exterior of the tank was filled with 1x running buffer 
made with 3.0g (w/v) of tris base, 14.4g (w/v) of glycine, 1g of SDS, and distilled water to 1 
  Chapter 2: Materials and Methods 
61 
litter. The samples were initially run at 25mA with a constant voltage of 150V until proteins 
were evenly located in the gel for approximately 90 minutes. The samples were checked 
regularly to prevent running off of the protein samples. 
2.7.2 Blotting and transfer 
Once proteins were separated in the gel based on their size and mobility (heavier proteins 
move slower and hence were at the top of the gel, whereas smaller proteins move faster and 
were found near the bottom of the gel), proteins were stained with 0.1% Coomassie Brilliant 
Blue (Thermo Fisher Scientific) (50% methanol, 10% acetic acid and 40% H2O) for 1hr on 
the shaker and then destained with destaining solution (50% methanol, 10% acetic acid and 
40% H2O) with at least two changes until all stains is removed. Coomassie blue dye is a 
colorimetric method that in an acidic condition the dye binds to proteins primarily through 
basic amino acids (arginine, lysine, and histidine) (Syrovy and Hodny 1991). Then proteins 
were transferred onto a blotting paper Polyvinylidine fluoride (PVDF). PVDF is a non-reactive 
membrane that has a non-specific affinity to amino acids. PVDF was activated by soaking in 
100% methanol for 10 seconds. A sandwich of filter pad, 3mm filter paper, activated PVDF 
membrane, gel, 3mm filter paper, and filter pad was assembled according to the 
manufactures protocol (Bio-Rad). A small magnetic stirrer was placed in the tank, topped 
with 1x transfer buffer made with 11.25g (w/v) of glycine, 2.42g (w/v) of tris base, 200ml (v/v) 
of methanol and distilled water to 1 litter. The blotter was placed inside the tank and the tank 
was run at 100V for 90 minutes on a magnetic stirrer to create an even distribution of the 
electrolysis. An ice pack was also placed inside the tank to prevent overheating of the buffer 
solution. Next we stain the blotting membrane using 1x concentration of Ponceau S (Sigma-
Aldrich) for 5 minutes on the shaker to make sure that all proteins have been transferred 
equally across from the gel. Ponceau S is a sodium salt of a diazo dye with a light red color 
that specifically stains proteins on the PVDF blotting paper.  
2.7.3 Blocking and antibody incubation 
Once the transfer of protein from gel onto the PVDF membrane was complete the proteins 
were blocked with 5% blocking reagent containing 5g (w/v) of semi-skimmed milk (Marvel) in 
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100ml of Tris buffer saline-Tween (TBST) made with 16g (w/v) of NaCl, 0.2g (w/v) KCl, 3g 
(w/v) of Tris base, 0.1% (v/v) Tween-20 added to 880ml of distilled water adjusted pH to 7.6, 
and distilled water added to 1 litre. The membrane was left in 30ml of blocking solution for 
about one hour on a shaker at room temperature. The milk mixture blocks the unspecific 
binding of an antibody with the membrane. the membrane was incubated with the primary 
antibody (1:1000 dilution) according to the manufacturer`s recommendation and was further 
optimized by the user. Table 2-2 below shows all antibodies used in our experiment with 
optimized dilution ranges. Primary antibodies were diluted in one in five dilutions in 5% 
blocking buffer in 1x TBST and added to the membrane overnight on a shaker set at medium 
pace (200rpm/minutes) at 4ᵒC. The following day the membrane was washed four times with 
0.1% PBS IGEPAL (IGEPAL CA-630, Sigma) for 10 minutes each and incubated with a 
secondary antibody diluted in one in five dilutions of 5% blocking buffer on a shaker at 4ᵒC 
for at least one hour.  
2.7.4 Protein detection with chemiluminescence 
After one hour incubation with a secondary antibody the membrane was washed four times 
in 0.1% PBS Igpal for 10 minutes. Meanwhile ECL plus (Enhanced chemiluminescence) kit 
(GE Healthcare) was taken out of the fridge and left at RT to warm up. The amount of ECL 
required for detection was based on the size of the membrane and was recommended by 
the manufacturer to be of a final volume of 0.125m/cm2 of membrane. The manufacturer`s 
protocol was consulted for the exact mixture of chemical A and chemical B. as a rule of 
thumb, 2ml of reagent A was mixed with 50µl of reagent B. that is 1 part of reagent A mixed 
with 40 parts of reagent B. The ECL mixture was added onto the membrane and covered 
with Saran wrap for 5 minutes in a dark room. The excess of the ECL was tipped off onto a 
paper towel, wrapped in the membrane facing down onto a piece of clean Saran wrap and 
placed in an X-ray cassette. 
Unexposed ECL plus hyperfilm (GE healthcare) was put on top of the membrane and the 
cassette closed and left for exposure for 5 minutes. The X-ray films were developed using an 
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automatic machine (Xograph). The exposure time was assessed accordingly depending on 
the size of the exposed bands. If the protein bands were faint and could not be visualized 
then a second film was exposed for a longer period. The ECL chemiluminescence was 
active for at least one hour. 
Table ‎2-2. Summary of antibodies used in this thesis.  
WB: western blotting (WB); IF: immunofluorescence; M: monoclonal; P: polyclonal.   
Antibody Cat.No. Type Source Application Concentration 
Anti-BRCA1 MA1-23164 M Thermo Fisher 
Scientific 
WB/IF 1:400 (IF) 
1:1000 (WB) 
Anti-BLM PA5-27384 P Themo Fisher 
Scientific 
IF 1:100 (IF) 
Anti-ATRX Ab97508 P Abcam IF 1:100 (IF) 
Anti-PML MAB3738 M Millipore IF 1:100 (IF) 
Anti-y-H2AX 
(Ser139) 
05-636 M Millipore IF 1:500 (IF) 
Anti-β-actin A-2228 M Sigma WB 1:10,000 
(WB) 
Goat anti-rabbit 
IgG (H+L) 
A-110088 P Thermo Fisher 
Scientific 
IF 1:100 (IF) 
Goat anti-rabbit 
IgG (H+L)  
T-2767 P Thermos Fisher 
scientific 
IF 1:100 (IF) 
Rabbit anti 
mouse IgG 
A-11054 P Thermo Fisher 
scientific 
IF 1:100 (IF) 
Goat anti rabbit 
IgG 
A-11054 P Thermo Fisher 
scientific 
IF 1:100 (IF) 
Goat anti 
mouse IgG  
A-11001 P Thermo Fisher 
scientific 
IF 1:100 (IF) 
1:5000 (WB) 
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2.8 Quantitative telomere-repeat amplification (TRAP) assay  
2.8.1 Protein isolation 
Cell lines to be analysed were grown to 80-90% confluence on a P100 petridish. At this point 
cells were harvested and total cell number was determined. The cell pellet was obtained by 
centrifuging at 15,000rcf for 5 minutes. The pellet was washed once with pre-warmed PBS. 
Sample pellets were left on wet ice and 200µl CHAPS lysis buffer (TRAPEZE 1x CHAPS 
MILLIPORE Company) per 105-106 cells was used to re-suspend the pellets. All samples 
were retro-pipetted several times and the cell suspension was transferred to a new tube. The 
suspension was incubated on the ice for 30 minutes before centrifugation at 12,000 rcf for 20 
minutes at 4ᵒC. 150µl of the supernatant was transferred into a fresh tube and determined 
the protein concentration for all the samples including the one was going to be used as the 
standard curve. The remaining extract was aliquotted and immediately stored at -80ᵒC until 
required. 
2.8.2 Determination of protein concentration 
The protein concentration of samples was measured using the Pierce BCA Protein Assay Kit 
(Thermo Scientific). Pierce BCA Protein Assay is a detergent-compatible formulation based 
on Bicinchoninic Acid (BCA) for the colorimetric detection and quantitation of total protein. 
The assay was performed according to manufacturer’s guidelines. A standard calibration 
curve was set up using BSA diluted in CHAPS lysis buffer, ranging from concentration 0-
2µg/ml (Figure 2.8, Table 2-3). All unknown sample protein concentrations were measured 
against the standard curve (data not shown).  
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Figure ‎2-8. BSA standard curve for protein estimation.  
 
Table ‎2-3. Preparation of diluted BSA standards for BCA analysis. 
Tube Final BSA 
concentration 
Volume of BSA Volume of dH2O 
A 1500 µg/ml 30 µl 10 µl 
B 1000 µg/ml 20 µl 20 µl 
C 750 µg/ml 20 µl of A 20 µl 
D 500 µg/ml 20 µl of B 20 µl 
E 250 µg/ml 20 µl of C 20 µl 
F 125 µg/ml 20 µl of D 20 µl 
G 25 µg/ml 40 µl of E 40 µl 
H 0 µg/ml 40 µl of F 40 µl 
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A total of 200µl of Working Reagent (BCA protein assay reagent A/B diluted 50:1) was 
prepared for each aliquot of protein extract and BSA protein standard concentration. To each 
5µl of protein lysate, 200µl of the Working Reagent was added and the samples were 
vortexed thoroughly on a shaker for 30 second. The tube was incubated at 37ᵒC for 30 
minutes in the incubator and then allowed to cool at room temperature. The A562 of the 
standards and protein lysates was then measured using a plate reader (BP 800, BioHit). A 
standard curve was prepared by plotting the blank-corrected measurement for each BSA 
standard against its concentration. The standard curve was then used to determine the 
protein concentration of each study sample. 
2.8.3 TRAP PCR reaction set-up 
Telomerase activity was measured using a quantitative TRAP assay (Paraskeva, Atzberger 
et al.1998). Bench-top surfaces and pipettes were cleaned with RNAse Zap (Ambion) in 
preparation for the assay. Samples to be analysed were thawed on ice and diluted to a final 
concentration of 200ng/µl in CHAPS lysis buffer. Stock solutions were immediately quick-
frozen and stored at -80ᵒC to prevent protein degradation. Reaction mixtures for each of the 
samples to be analysed were made up using the following components and volumes: 
Component and volume of reaction mix: 
5µl 10X TRAP reaction Buffer 
1µl 50X dNTP Mix 
1µl telomerase primer (TS primer) (0.1µg/µl) (5`-AATCCGTCGAGAGTT-3`) 
1µl telomerase primer (ACX primer mix) (0.05µg/ml)(5`-GCGCGG (CTTACC) 3CTAACC-3`) 
0.4µL Taq Polymerase 
39.6µl dH2O 
2µl protein samples 
Total volume = 50µl 
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Reaction mixtures were thawed on ice to prevent protein degradation, vortexed and 
centrifuged briefly. Samples were assayed in triplicate and each assay run included a 
telomerase positive, negative and non-template control. As an additional negative control, 
10µl of each target sample was heat-treated to inactivate the enzyme by incubating at 85ᵒC 
for 10 minutes. The microtitre plate was then placed into the thermocycler block and PCR 
amplification carried out with the following reaction conditions. The reaction mixture was first 
incubated at 25ᵒC for 20 minutes. PCR was then started at 95ᵒC for 10 minutes, followed by 
a two-step PCR amplification of 35 cycles at 95ᵒC for 30s and 60ᵒC for 90s. 
The 10% Native (non-denaturing) PAGE gel was made using the following ingredients:  
10% Native (non-denaturing) PAGE gel ingredients: 
32.2ml distilled water 
12.5ml 40% Acrylamide mix (19:1 acrylamide/bisacrilamide) (Protogel EC890) 
5ml 10X TBE 
100µl 10%ammonium persulphate (APS) freshly made 
75µl TEMED 
 
The above formula will give a 10% gel that is poured into the gel glass plate. The gel glass 
plate was set up following the manufacturer`s protocol. The above gel was loaded 
immediately onto the gel tank, and left for 30 minutes to set with a separation comb in place.  
2.8.4 PAGE-gel electrophoresis and data analysis 
A total of 1µl of loading dye containing bromophenol blue and xylene cyanol (0.25% each in 
50% glycerol/ 50mM EDTA) was added into each reaction tube. Samples were loaded with 
25µl of the telomerase PCR assay on a 10% non-denaturing PAGE (no urea) in 0.5X TBE 
buffer. A 25bp DNA ladder (Lifetechnologies, CA, USA) by diluting the stock concentration 
1:10 in dH2O (2µl DNA ladder, 17µl dH2O, 1µl loading dye). 
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We used extreme care to prevent sample carry-over into adjacent wells, which may produce 
false-positive results. For optimal interpretation of results, we loaded heat-treated and non-
heat-treated samples in alternating lanes (i.e., extract 1+heat, extract 1-heat, extract 2+heat, 
etc.). The TSR8 quantitation control was added on the last lanes of the gel including 
CHAPS-only buffer. 
All samples were run at 300volts until the xylene cyanol runs 70-75% the length of the gel. 
This took on average between 3 to 3.5 hours. The smallest telomerase product band should 
be 50bp and the S-IC internal control band is 36bp. After electrophoresis, we stained the gel 
with SYBR Green according to the manufacturer’s instructions. For SYBR Green we diluted 
the stock solution 1:10,000 in deionized water. The gels were stained for 30 minutes at room 
temperature on a shaker set at low speed to prevent breakup of the gel (Figure 2.9). 
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Figure ‎2-9. Workflow used for TRAP measurement. 
2.8.5 Quantitation and data analysis using Image-Lab software 
The Image-Lab software (Bio-rad) was used to quantify pixel intensities from the TRAP gels. 
We followed the manufacturer’s guideline in estimating band intensity for this purpose. In 
brief, each lane was detected using the automated lane detection function and then adjusted 
to contain all samples in the gel. Each lane was then assessed for bands and band intensity 
using the automated function of the Image-Lab. Background correction was applied and the 
average background was subtracted from the intensity value. The intensity values for all 
bands were then summed up and the total sum of all bands in each lane used in the formula 
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to measure relative telomerase activity. The manufactures’ guideline was followed in 
estimating the levels of telomerase activity in each sample. 
𝑇𝑒𝑙𝑜𝑚𝑒𝑟𝑎𝑠𝑒 𝑎𝑐𝑡𝑖𝑣𝑡𝑦 =
(𝑥−𝑥0)/𝑐
(𝑟−𝑟0)/𝑐𝑅
 ×  100    
Whereby,  
x = product ladder bands from all samples including non-heat-treated 
xo = heat-treated sample extracts  
ro = 1X CHAPS lysis Buffer only control (primer-dimer/PCR contamination control)  
r = TSR8 quantitation control (0.2 amole) 
c = signal from the internal standard (S-IC) in non-heat-treated samples 
cR = TSR8 quantitation control 
2.9 C-Circle assay for detection of Alternative Lengthening of 
Telomeres (ALT) activity 
ALT+ cancer cells have several characteristics that are unique and are not found telomerase-
positive cancer or mortal cells. These unique characteristics make identification of ALT 
activity in cells particularly robust. They include, i) association of telomeric sequence with 
promyelocytic leukemia nuclear bodies (known as APBs), ii) heterogeneous telomeric 
lengths as a result of rolling mechanism such as rolling circle amplification (RCA), iii) 
recombination-dependant DNA replication, iv) low levels of  ARTX protein  activity, and v) 
circular c-rich single stranded DNA known as C-circle (CC). The levels of CC is measured 
through a two-step process: DNA amplification using phi29 DNA polymerase and nucleotide 
lacking dCTP followed by radio-labelled (P32) probing and hybridization using (CCCTAA)3 
oligonucletoide. 
2.9.1 Genomic DNA extraction 
Total genomic DNA was extracted from cell pellets of various cell lines using Qiagen QIAmp 
DNA Mini Kit by following the manufacturer’s guideline. This is a column-based technique 
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that does not require phenol-chloroform and DNA specifically binds to the QIAmp silica-
based membrane while other contaminant from cell extract passes through. The washing 
steps removes all PCR contaminants such as divalent cations and proteins leaving pure 
gDNA. The detail step of DNA extraction is shown below: 
1. Cell pellets were collected by spinning at 800g for five minutes. 
2. The media is removed and cells are washed with 1ml of phosphate buffered saline 
(PBS) twice to remove any residual medium and proteins that could inhibit the action 
of DNA extraction mini kit. Cells were pelleted again at 800g for five minutes. 
Supernatant is removed carefully without disturbing the cell pellet. 
3. Cell pellets are then suspended in 200µl of PBS. 20µl of protein K followed by 4µl of 
RNAse A. These ensure that RNAs and proteins are degraded in the cell pellets. 
4. This is followed by the addition of 200µl of nuclear lysis solution (Buffer AL) and the 
samples were vortex for 15 seconds intermittently. It is important not to vortex the 
cells continuously as this may shear the gDNA. 
5. The samples are then heated for 10 minutes at 56°C in a heating block. 
6. Spin down the sample for ten second at 12000g to collect cellular debris.  
7. Add 200µl of ethanol to precipitate the nucleic acid followed by a short spin for 10 
seconds at 12000g. 
8. The supernatant is then transferred into QIAmp column attached to a collection tube 
and spun down for 60 seconds at 8000g. The DNA is now attached to the silica-
based membrane and the flow through is discarded. 
9. The DNA is now washed with 500µl of solution AW1 and AW2 separately and spun 
down for 3 minutes seconds at 8000g in each wash. The flow through is discarded in 
each step. 
10. Next new collection tube is placed and the column is spun down for additional 60 
seconds at 14000g to remove any residual washing solution. 
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11. Finally DNA is eluted with 50µl of elution buffer (AE) that contained Tris-EDTA 
(10mM, pH 7.6) at room temperature for one minute. TE buffer ensures that the DNA 
is stable and not digested as elution in water can shear DNA for long-term storage. 
Then the sample is collected by centrifuging at 8000g for 1 minute in a new 
Eppendorf (1.5ml) tube with led. 
12. Samples are frozen down at -80°C. 
2.9.2 DNA quantification 
The quality and quantity of extracted DNAs were measured using 1µl of total gDNA 
calibrated against the elution buffer using Nanodrop (lifetehcnologies). Table 2-4 below 
summarises the quality (A260/280) and quantity (ng/µl) of each sample. 
 
Table ‎2-4. DNA concentration of all samples 
Sample name DNA concentration in 
(ng/µl) 
DNA quality and purity 
(A260/280) 
U2OS 147.5 1.88 
HeLa 200.6 1.88 
SKLU-1 182.1 1.85 
G292 169.5 1.84 
HCC1937 546.3 1.88 
GM00893 50.4 1.86 
GM13705 439.9 1.86 
LY-R 464.4 1.87 
LY-S 92.3 1.84 
E14 146.5 1.84 
408 322.4 1.86 
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2.9.3 C-circle amplification 
The first step of the CC assay involves amplification of the C-circles utilising the RCA 
(Rolling Circular Amplification) of partially double-stranded C-circles by Φ29 DNA 
polymerase (NEB) is auto-primed by the partial G-strand ([TTAGGG]n) (from the leading 
strand of the DNA). DNA samples were diluted to 10ng/ul after quantification and 30ng of 
DNA was used in the amplification using the following reaction: 
Stock concentration Volume (µl) Final concentration 
1M DTT 0.8 4mM 
10x Φ29 buffer 2.0 1x Conc 
10mg/ml BSA 0.4 0.2 mg/ml 
10% Tween 0.2 0.1% 
1mM dATP/dTTP/dCTP/dGTP 0.8 0.1mM 
Φ29 DNA polymerase (10,000 U/ml) 1.5 15 U 
Nuclease-Free water 4.3  
Total volume 10ul 
 
10ul of the above reaction mixture is then added to 10ul volume containing 30ng of DNA. 
The samples were then incubated at 30°C for 8hrs followed by 65°C for 20 minutes. 
Samples were immediately slot-blotted or stored at -20°C. 
2.9.4 Slot-blotting 
Samples were slot-blotted using Amersham Biosciences Slot blot filtration manifolds. In brief, 
samples were diluted with 40µl of 2xSSC and mixed well. The slot-blot apparatus were 
assembled using 1x nitrocellulose membrane (GE Healthcare) and 1x Whatman filter paper 
pre-soaked in 2xSSC (see figure xx). Next, the suction unit was turned on to full and the 
samples were added gently on each slot. The location of each slots were recorded. Care 
was taken not to touch the nitrocellulose membrane. Samples were vacuumed for two 
minutes and laid with 100µl of 2xSSC to wash remaining sample. Following which the 
apparatus was dismantled and the membrane allowed to dry. The membrane was 
immediately cross-linked using UV cross-linker (GE Healthcare) at 1,200J twice. 
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2.9.5 Hybridization with P32-labelled telomeric probe    
2.9.5.1 Preparation of P32 probe 
The c-rich telomere specific (CCCTAA)3 (Thermo Fisher) oligonucleotide was end-labelled 
with ATP [γ-32P] (Perking Elmer) using DNA 5’ end labelling system (Promega) as follows: 
Stock concentration Volume 
Oligonucleotide 100µM 5µl 
T4 polynucleotide kinase buffer 10x 1µl 
T4 polynucleotide kinase enzyme  1µl 
ATP [γ-
32
P] 3000Ci/mmol 10mCi/ml 3µl 
Total volume 10µl 
 
 
 Incubate the above mixture at 37°C for ten minutes in water bath 
 Stop the reaction by adding 1µl of 0.5M EDTA 
 Add 40µl of saline TE (STE) buffer to the above 10µl probe buffer 
2.9.5.2 Purification of P32 probe 
The newly prepared probe must be washed to remove any unbound nucleotide or probe 
using column base chromatography (Perkin Elmer). The full protocols were as follows: 
 Re-suspend the resin in the column by vortexing for few seconds 
 Twist off the bottom cap of the column and spun down to remove solutions from the 
resin at 735xg for 1 minute 
 Immediately add the probe mix samples (50µl in total volume) to the resin before 
resin bed became dried 
 The column is placed into a new clean 1.5ml Eppendorf collection tube and the 
column spun down for 2 minutes at 735xg  
 The purified probe is then stored at -20°C 
2.9.5.3 Hybridization 
The nitrocellulose membrane containing slot-blotted CC assay amplified samples was 
placed in a glass hybridization bottle and incubated with 10ml of pre-warmed Hybridization 
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buffer (PerfectHyb Plus, Sigma-Aldrich) at 37°C for 15 minutes to block the membrane for 
unspecific binding. Finally, the freshly prepared P32-labelled C-rich telomeric probe was 
added to the Hybridization bottle and allowed to hybridize overnight at 37°C.  
The next day the membrane was washed with high stringency wash buffer containing 
0.5xSSC and 0.1%SDS at 37°C with shaking for three-times. After washing the membrane 
was wrapped in an hybridization bag and exposed overnight onto x-ray film in dark. The 
exposed x-ray film was then developed using automated system (Xograph) and images were 
scanned for analysis. 
2.9.5.4 Image analysis of CC assay (Quantification) 
Each X-ray film containing developed images of the CC assay was scanned and Image J 
software (NIH) was used to analyse slot-blot pixel intensity (Figure 2.10). 
 
 
 
  
Figure ‎2-10. CC quantification using Image J.  
A) Each X-ray film was scanned and each band were automatically recognised using the Image J software. B) 
The band intensity is then generated and the area under each peak is used to generate intensity value. This 
value is used and normalised to U2OS for human samples or E14 for the mouse cells.   
The Microsoft Excel was used to analyse data and generate mean CC activity for each 
sample.   
A B 
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2.10 Graphical display and Statistical Analysis 
Three major types of graphical representation used to display the data. These are: 
- Bar charts and line graphs. In all bar charts we used either standard deviation (SD) 
or standard error of mean (SEM) to display variation among the data.  
- Scatter plots. Used to display individual data point across samples. Average is shown 
using a green bar in all cases. No SD or SEM is displayed in these types of graphs 
since the spread of data can be visualised by the spread of the data represented by 
dots, but SD were used separately for t-test analysis. 
- Whisker box-plot. In some cases we used the box-plot to display the spread of data 
as well as the mini/max. The line across the box displays the median. SD was used 
separately to perform t-test. 
We only used the student’s t-test to perform full statistical analysis. We used the 95% 
confidence interval as our cut off point with α set at 0.05 and where indicated the exact p 
value is displayed. In some cases the significance of each compared data is represented 
using * (P < 0.05), ** (P <0.001) or *** (P < 0.0001). The latter means the difference between 
the mean is highly significant. 
All statistical analysis or graphical drawing was performed on GraphPad PRISM 6 version. In 
some rare cases we used Microsoft Excel 2007 software.  
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3 Analysis of Telomere Function in 
BRCA1 Defective Human Cell 
Lines 
3.1 Introduction 
BRCA1 plays major roles in DNA damage and repair through NHEJ and HR (Moynahan et 
al., 1999, Davalos and Campisi, 2003, Cao et al., 2003, Ohta et al., 2011). BRCA1 is 
recruited to the DNA damage sites through the damage sensor, the MRN complex, and it 
provides a scaffold for and recruits other proteins involved in the DNA DSB repair pathway 
(See Chapter 1 for details). BRCA1 is also involved as a regulator of key effectors in the 
G2/M phases of the cell cycle by with the final result of activating the checkpoint kinase 1 
(CHK1) prior to the onset of mitosis (Yarden et al., 2002). The earliest evidence linking DNA 
damage response and BRCA1 was in a research pertaining to Brca1-defecient fibroblasts 
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and tumours, which revealed evidence of extensive genomic instability, such as 
chromosomal aberrations, centrosomal amplification and aneuploidy (Tirkkonen et al., 1997, 
Xu et al., 1999b, Weaver et al., 2002). The co-localisation of BRCA1 with the various DNA 
damage response factors, and involvement of BRCA1 in DNA DSB repair via HR and NHEJ 
is well documented (Powell and Kachnic, 2003). For example, BRCA1 role in NHEJ is 
thought to include end-resection and interaction with Ku and DNA-PKcs. These and other 
proteins (discussed in detail in Chapter 1) are also located at telomeres and their absence 
leads to telomere dysfunction as reported previously (for a review of DNA damage response 
proteins at telomeres see Slijepcevic, 2006). Therefore, BRCA1 is involved in the genome 
stability maintenance through its interaction with DNA damage response proteins. 
Furthermore, BRCA1 is recognised as an important tumour suppressor as BRCA1 defects 
are associated with familial breast and ovarian cancers (Claus et al., 1996, Ford et al., 1994, 
Whittemore et al., 1997, Jiang and Greenberg, 2015). Recently published work has 
demonstrated that a BRCA1 mutation in immortalised human primary epithelial cell creates 
halpoinsufficiency leading to premature senescence with increased genomic instability, as 
well as increased rate of telomere erosion (Sedic et al., 2015), further highlighting the role of 
BRCA1 in cellular senescence, genome stability and telomere maintenance. Interestingly, 
BRCA1 is shown to play important role in response to DNA damage induced by IR. For 
example, cells from BRCA1 mutation carriers show increased sensitivity to IR, suggesting 
that genomic instability might occur even when a single copy of BRCA1 is mutated (Foray et 
al., 1999, Trenz et al., 2002, Sedic et al., 2015). The breast cancer cell line, HCC1937, 
containing defects in both BRCA1 alleles, is sensitive to IR (Abbott et al., 1999), it shows 
karyotypic alterations and loss of heterozygosity at many loci (Tomlinson et al., 1998). 
The earliest evidence linking BRCA1 to telomere maintenance was, however, provided by 
McPherson et al. (2004) after examination of Brca1 and Chk2 in murine tumourigenesis 
models. Results showed elevated frequencies of end-to-end chromosome fusion due to 
Brca1 disruption - an observation pointing towards the role of BRCA1 in telomere capping 
Chapter 3: Telomere analysis in BRCA1 defective human cells 
 79 
function (McPherson et al., 2004). Further evidence was provided by (Al-Wahiby and 
Slijepcevic, 2005) in the study of human cells lacking functional BRCA1 resulting in elevated 
levels of end-to-end chromosomal fusions (a phenotypic hallmark of dysfunctional telomeres 
due to loss of capping function). McPherson et al, provided more robust evidence for the 
involvement of BRCA1 in telomere maintenance using Brca1-/- murine T-cells. These cells 
were characterized by the presence of telomeric fusions (McPherson et al., 2006).  Similarly, 
knockdown of BRCA1 in the breast adenocarcinoma cell line, MCF7, and the non-
tumorigenic breast epithelial cell line, MCF10A, caused increased frequencies of anaphase-
bridge due to telomere dysfunction (Cabuy et al., 2008). Interestingly, BRCA1 interacts with 
TRF1 and TRF2 at telomeres (Ballal et al., 2009). BRCA1 has been implicated in regulating 
telomerase (Xiong et al., 2003) most likely through acting as its negative-regulator (Ballal et 
al., 2009). Recent evidence indicates that BRCA1, through its interacting partner CtIP, 
promotes telomere fusion via A-NHEJ in an ATM-independent telomere damage-signalling 
manner in mouse embryonic fibroblast (MEFs) lacking functional TRF2 (Badie et al., 2015). 
This suggests that BRCA1 may mediate telomere repair through A-NHEJ in telomerase-
positive cells through the MRN complex (Badie et al., 2015). It must be noted that uncapped 
telomeres are recognised by DNA damage sensing mechanism as broken ends and 
therefore mediate end-joining through the NHEJ mechanism; either through classical NHEJ 
(c-NHEJ) involving KU70/80 and LIG4 (Celli and de Lange, 2005, Celli et al., 2006) or the 
alternative NHEJ (A-NHEJ) involving PARP1 and LIG3 (Rai et al., 2010, Sfeir and de Lange, 
2012). 
The above observations strongly implicate BRCA1 in telomere maintenance through the 
conventional telomerase-based mechanisms. Given the role of BRCA1 in HR it is possible 
that it may play a role in the ALT pathway. It is known that BRCA1 interacts with APB (ALT 
associated PML bodies) in ALT positive cells (Wu et al., 2003) and that BRCA1 recruits 
recQ-like helicases WRN and BLM to facilitate intra-strand cross-link repair and DSB repair 
at telomeres (Cheng et al., 2006) (Gocha et al., 2014). The activities of BRCA1 and BLM at 
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telomeres has only been recognised recently (Acharya et al., 2014). BRCA1 is required for 
recombination proteins to promote strand processing and invasion, and to form 
recombination intermediates, and this process requires BLM during G2 phase of the cell 
cycle (Acharya et al., 2014). This role is different from the role played by the BRCA1-RAD50 
complex found at the S-phase (Zhong et al., 1999) (Davalos and Campisi, 2003). Although, 
BRCA1 may have important functional role in the ALT-positive cells (which utilise HR for 
telomere length homeostasis) this is not well understood.  
In this chapter, we set out to investigate the role of BRCA1 in HR mediated telomeric 
recombination through measuring levels of telomere-sister chromatid exchanges (T-SCE) in 
cell lines from BRCA1 mutation carriers. Moreover, we aim to characterise the consequence 
of BRCA1 defect on telomere length and assess the role of BRCA1 defect on telomere 
function through measuring frequencies of radiation-induced telomere dysfunction induced 
foci (TIF) as well as measuring the role of BRCA1 defect on genome instability and 
chromosomal aberrations following exposures to IR. 
 
3.2 Results 
3.2.1 Cell lines and rationale 
We used two human lymphoblastoid BRCA1 defective cell lines (BRCA1+/-), GM13705 and 
GM14090, obtained from BRCA1 mutation carriers and one control cell line, GM00893 
(BRCA1 +/+). The GM13705 cell line had a four base-pair deletion at positions 3875 (3875 
del 4) in exon 11 (frameshift mutation), resulting in a premature termination at codon 1252 
(http://ccr.coriell.org) (Coriell 2009). The cell line, GM14090 had double base-pair deletion at 
position 185 (185delAG) in exon 3 (frameshift mutation), resulting in a premature termination 
at codon 37 (http://ccr.coriell.org) (Coriell 2009). Both cell lines have been purchased form 
Coriell Cell Repositories. The GM00893 cell line originated from a normal individual, and 
was used as BRCA1 (WT) control. Furthermore, LY-R and LY-S mouse cell lines were used 
as calibration standards for telomere length measurements.  
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3.2.2 Telomere sister chromatid exchange in BRCA1 lymphoblastoid cell lines 
One of the frequent events occurring in eukaryotic chromosomes is the exchange of 
genetic/chromosomal material between two sister chromatids known as the sister chromatid 
exchange (SCE) (Wolff, 1977). This process occurs during DNA replication (S phase of the 
cell cycle) and it is dependent on HR (Bailey et al., 2004b). The technique known as CO-
FISH is capable of identifying SCEs occurring specifically within telomeres termed telomere 
SCEs (T-SCEs). It is well established that T-SCEs constitute one of the markers of the ALT 
pathway. This may serve as a means of recombination-based telomere length maintenance. 
In addition, a high level of T-SCEs has been associated with the ALT phenotype (Bailey et 
al., 2004b, Bechter et al., 2004b, Londono-Vallejo et al., 2004). However, high T-SCE 
frequencies have also been reported in some telomerase positive cells (Vera et al., 2008).  
One of the aims of this chapter is to investigate whether human lymphoblastoid cell lines that 
have BRCA1 mutations exhibit altered recombination rates at telomeres. Consequently, the 
frequencies of T-SCEs in the above lymphoblastoid cell lines were assessed by CO-FISH 
(Figure 3.1). A total of 100 metaphase cells per cell line were analysed by CO-FISH to 
delineate the number of T-SCE events (Figure 3.2). The experiment was performed twice to 
ensure reproducibility and precision of results. Statistical analysis revealed a significant 
increase (P<0.001) in T-SCE levels of the BRCA1 defective cell lines (GM13705 and GM 
14090) in comparison with the control (GM 00893) (Figure 3.2). Our results suggest that T-
SCE occur more frequently in the BRCA1 defective cells than the normal cells, thus 
implicating BRCA1 in ALT mechanism in these cells. 
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Figure ‎3-1. Examples of T-SCEs in lymphoblastoid cell lines after CO-FISH.  
a) A metaphase spread from the GM00893 control cell line with no T-SCEs. b) GM 13705, and c) GM 14090 
BRCA1 defective cell lines showed multiple T-SCE events indicated by arrows. 
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Figure ‎3-2. T-SCE analysis of human lymphoblastoid cells by CO-FISH.  
Both BRCA1 defective cell lines showed a significant increase in T-SCE levels compared to the control cell line. 
Error bars indicate standard error of the mean (SEM). T-test performed for all statistical analysis.  
 
3.2.3 Telomere length analysis in BRCA1 lymphoblastoid cell lines 
To measure the telomere length in our set of cell lines we used the IQ-FISH method which 
measures average telomere length in interphase cells. The method was described in a PhD 
thesis by another student from our laboratory (Ojani 2013). A total of 50 interphase cells per 
cell line were analysed and the mean telomere fluorescence intensity was determined for 
each cell line. Representative images of telomeres in interphase cells after this procedure 
are shown in Figures 3.3 and 3.4. The integral part of the method is the use of two mouse 
lymphoma cell lines, LY-R and LY-S, as calibration standards (Figure 3.5).  These cell lines 
have stable telomere lengths of 49kb and 7kb, respectively (McIlrath et al., 2001) (Cabuy et 
al., 2004, Yasaei and Slijepcevic, 2010). Using the values of telomere fluorescence obtained 
for LY-R and LY-S cells (Figure 3.5 A and B) corrected calibrated fluorescence (CCFL) was 
calculated for the three human lymphoblastoid cell lines (Figure 3.5C) BRCA1 defective cell 
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lines (GM13705 and GM14090) showed significantly decreased telomeric fluorescence 
compared to the control GM00893 cell line (Figure 3.5). 
 
Figure ‎3-3. Representative examples of telomere FISH in the interphase nuclei of human lymphoblastoid 
cell lines.  
A) GM00893 BRCA1 WT cell line (used as control). B) GM13705 BRCA
+/-
. C) GM14090 BRCA1
+/-
. In all cases 
telomere FISH probe is tagged with FITC (green) and the cell nuclei is counterstained with DAPI (blue). 
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Figure ‎3-4. Representative examples of telomere FISH in mouse LY-R (A and B) LY-S cells (C and D). 
Blue: nuclei stained with DAPI (A and C). Green: telomere staining by the FITC labelled probe (B and D).  
 
  
A B 
C D 
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Figure ‎3-5. Mean values of telomere fluorescence measured using IQ-FISH.  
A) Mean telomere fluorescence intensity from unmodified signals from LY-R and LY-S mouse lymphoma cell 
lines used here as calibration standards. B) A scattered plot of unmodified fluorescence intensity from 50 
cells/cell line. C) Corrected Calibrated FLuorescence (CCFL) of mean telomere length from the BRCA1 WT 
(GM00893) and two BRCA1 mutant cell lines, GM14090 and GM 13705. Error bars represent SE. Figures A and 
B are based on the analysis of 50 cell nuclei/cell line performed in five independent experiments to ensure 
consistency. All measurements are done using the exposure of 0.5 second (s). Figure C is based on the analysis 
of 100 nuclei/cell line in two independent experiments. T-test used for statistical comparison. 
 
3.2.4 Cytogenetic analysis of chromosomal aberrations in human lymphoblastoid 
BRCA1 defective cell lines  
It is known that genes participating in genome stability maintenance could also be affecting 
the function of telomeres. For instance, Ku and DNA-PKcs that take part in DNA DSB repair 
are situated at telomeres (Riha et al., 2006, Wang et al., 2009, Ruis et al., 2008, Indiviglio 
and Bertuch, 2009). Some other DDR proteins, such as ATM, NBSI, PARP and FANCA are 
also implicated in telomere maintenance (Cabuy et al., 2004). Since genes encoding the 
above proteins are also involved in cellular response to IR, we refer to the family of these 
A B 
C 
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genes as TERAGENE (Telomere and Radiosensitivity Gene Network) (Cabuy et al., 2004). 
Genes encoding RAD54, RAD51D and PARP2 are considered the most recent additions to 
the TERAGENE family (Jaco et al., 2003, Dantzer et al., 2004, Tarsounas et al., 2004a). 
Research suggests that the TERAGENE family will indeed grow further and that BRCA1 is a 
TERAGENE candidate (Al-Wahiby and Slijepcevic, 2005). Consistent with this notion, 
BRCA1 deficient cells show sensitivity to IR (Shen et al., 1998, Foray et al., 1999) (Abbott et 
al., 1999) (Trenz et al., 2002), while mouse cells with targeted truncation in exon 11 of 
BRCA1 show dicentric chromosomes (Xu et al., 1999b, Weaver et al., 2002), which possibly 
result from end-to-end chromosome fusions or telomeric fusions. That, in itself, represents a 
signature of telomere dysfunction. Furthermore, higher levels of end-to-end chromosome 
fusions are observed in BRCA1-/- P53-/- mouse T-cells in comparison with cells from P53-/- 
mice (McPherson et al., 2004). Therefore, we wanted to examine response to IR in our set of 
cell lines and determine the involvement of telomeres in this process. 
 
3.2.5 Chromosomal abnormalities in the BRCA1 defective human cells – the G1 
assay 
We started by analysing chromosomal abnormalities in G1 phase of the cell cycle after 
exposure to 0.5 Gy, 1.0 Gy and 2.0 Gy of gamma radiation. Representative images of 
radiation induced chromosomal aberrations in G1 phase (dicentric chromosomes) are shown 
in Figure 3.6. 
A total of 100 metaphases per cell line were analysed to examine the frequencies of 
spontaneous and induced chromosomal abnormalities in each cell line. The results obtained 
showed that the spontaneous chromosomal abnormalities as well as the radiation induced 
levels of chromosomal abnormalities were significantly higher (p<0.05, p<0.01, and p<0.001) 
in BRCA1 deficient cell lines (GM14090 and GM13705) compared to the control cell line 
(GM00893) (Figure 3.7). This observation indicates that BRCA1 defective cells have a defect 
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in DSB as radiation induced chromosomal aberrations result from IR induced DSBs 
(McPherson et al., 2006, Cabuy et al., 2008). 
 
Figure ‎3-6. Representative example of radiation-induced CA in G1 from the BRCA1 defective human cells. 
A) Un-irradiated metaphase cells of GM14090 stained with Giemsa. B) Examples of dicentric chromosomes 
(resulting from end-to-end chromosome fusions) and chromosome fragments in GM14090 shows with pink 
arrows, after exposure with 2.0Gy of gamma radiation, C) Enlarged examples of dicentric (red and purple boxes) 
and chromosome fragment (black box). 
 
Figure ‎3-7. Frequencies of chromosomal abnormalities in three human cell lines after exposure to 
various doses of gamma radiation.  
The total number of chromosomal aberrations (dicentric chromosomes, fragments and ring chromosome) are 
shown above from a total of 100 metaphases/cell line/dose. Each analysis is based on at least two independent 
experiments. Error bars represent SEM. *P<0.05, **P<0.01, and ***P<0.001. 
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3.2.6 Chromosomal abnormalities in the BRCA1 defective human cells – the G2 
assay 
In order to assess chromatid damage following exposure to IR we performed the so-called 
G2 assay, which captures only chromosomal damage induced in the G2 phase (Terzoudi et 
al., 2009, Hatzi et al., 2009). 
Cells have been exposed to a single dose of 0.5 Gy and a total of 100 metaphase 
cells/sample were analysed 1.5 hours, 3 hours and 4 hours after exposure to gamma-rays 
(Figure 3.9). The average frequencies of chromatid breaks and gaps were significantly 
higher (P<0.05, P<0.01, and P<0.001) in the BRCA1 defective cell lines (GM13705 and 
GM14090) than in the control cell line (GM00893) (Figure 3.8). The persistence of chromatid 
damage in the BRCA1 defective cells after 0.5 Gy gamma-irradiation suggests a deficiency 
or imbalance in DNA repair or processing of the radiation- induced DNA DSBs. In other 
words, DNA damage during induced in G2 is potentially irreparable suggesting a deficiency 
or deficiencies in DNA repair which results in the enhanced radiosensitivity and cancer 
proneness characterizing BRCA1 gene carriers. Representative examples of IR induced 
chromatid breaks are shown in Figure 3.9. 
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Figure ‎3-8. Frequencies of radiation induced chromatid breaks and gaps (G2 assay) in the BRCA1 
defective cell lines (GM13705 and GM14090) and the control cell line (GM00893).  
*=P<0.05, **=P<0.01, ***=P<0.001, Error bars represent SEM. 
 
 
Figure ‎3-9. An example of chromosomal abnormalities in the G2 phase of the cell cycle in a human 
lymphoblastoid cell line.  
A) Chromatid break in BRCA1 defective lymphoblastoid cell line GM14090, B) Enlarged image from A. 
 
3.2.7 Establishment of micronucleus assay for assessing chromosome damage in 
BRCA1 defective cell lines 
One of the most important events in carcinogenesis is chromosomal damage that occurs via 
DNA damage (DSBs) at the chromosome level. Therefore, investigating DNA damage at the 
Chapter 3: Telomere analysis in BRCA1 defective human cells 
 91 
chromosome level is an essential part of genetic toxicology. The micronucleus assays come 
into view as one of the approved methods for estimating chromosome damage. This assay 
is important due to its ability to detect chromosome loss, chromosome breakage and 
chromosome rearrangement (nucleoplasmic bridges). The technique is now applied to 
various cell types for population monitoring of genetic damage, screening of chemicals for 
genotoxic potential and for specific purposes, such as the prediction of the radiosensitivity of 
tumours and the inter-individual variation in radiosensitivity (Fenech, 2000). Initially, several 
parameters were analysed to establish the optimal experimental conditions for using 
micronuclei tests to determine the level of chromosomal damage after exposure to gamma 
radiation (it is important to note that this test is not used routinely in our laboratory, hence we 
need to ensure that it will work in our hands consistently). 
First, multiple flasks were prepared for each cell line to determine the optimal concentration 
of Cyt-B (3µg/ml or 6µg/ml) and optimal harvesting time (24 h or 48 h) after Cyt-B treatment. 
After Giemsa staining, the microscope analysis revealed that the optimal bi-nucleated cells 
and visible cytoplasm formed after 48hrs with the optimal concentration of Cyt-B being 
6µg/ml (Figure 3.10). Since these results were consistent repeatedly we used the above 
concentration and timing in subsequent experiments.  
A total of 500 bi-nucleated cells were scored to determine the presence or absence of MN in 
all cell lines after exposure to 0.5Gy, 1.0Gy, 2.0Gy and 4.0Gy of gamma rays. We observed 
a difference in spontaneous MN frequency between cell lines (Figure 3.11). Surprisingly, the 
amount of IR-induced MN was not particularly high at higher doses as reported in the 
literature (Slavotinek et al., 1993, Stopper and Lutz, 2002). This could be due to our 
inexperience with the methodology. Nevertheless, statistical analysis revealed that no 
significant difference in mean MN frequency was observed between untreated cells 
(GM00893, GM13705, and GM14090) and low dose rate (0.5Gy) (Figure 3.11 B) whereas at 
higher doses the difference was significant. 
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Figure ‎3-10. Analysis of binucleated cells in BRCA1 human lymphoblastoid cell lines.  
A) a normal binucleated cell after the cytokinesis block MN assay; B) bionucleated cell containing one MN; C) a 
binucleated cell with a group of  MN;  D and E) tri- and quadrinuclear cells; F) multinucleated cell. 
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 0.5Gy 1.0Gy 2.0Gy 4.0Gy 
 MN/cell MN/cell MN/cell MN/cell 
GM00893 (WT) 0.216 (p=0.167) 0.290 (p=0.0038) 0.404 (p=4.85E-07) 0.584 (p=2.86E-14) 
GM13705 (BRCA1+/-) 0.374 (p=0.482) 0.472 (p=0.015) 0.65 (p=0.0003) 0.822 (p=1.96E-13) 
GM14090 (BRCA1+/-) 0.514 (p=0.173) 0.61 (p=0.0056) 0.78 (p=4.26E-06) 0.972 (1.69E-09) 
 
Figure ‎3-11. Mean frequency of micronuclei in un-irradiated and irradiated cell lines.  
A) Graph showing average MN per cell in untreated and irradiated cells. B) T-test analysis comparing the 
untreated with irradiated. The were no significant differences between the untreated MN frequency per cell and 
0.5Gy IR in all three samples. Error bar represent SEM. **=P<0.01, ***=P<0.001. T-test used in all statistical 
comparison.  
 
3.2.8 Immunofluorescence‎analysis‎of‎γ-H2AX in human lymphoblastoid cell lines 
3.2.8.1 Analysis of γ-H2AX kinetics in human lymphoblastoid cell lines 
 
In order to confirm cytological results at the more sophisticated level we examined IR 
induced DNA damage by measuring γ-H2AX levels. Frequencies of spontaneous DNA 
damage foci were higher in BRCA1 defective cell lines (Figure 3.12 A). All normal cell lines 
usually show some DNA damage foci. In our case the normal line had on average 2 foci/cell, 
whereas BRCA1 defective lines showed ~ 4-5 foci/cell (Figure 3.12 A). We then exposed 
cells to 1.0 Gy of gamma rays and quantified IR induced DNA damage foci at several time 
A 
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intervals post-exposure (Figure 3.12 B). Statistical analysis shown in the Figure 3.12 C 
suggests persistence of IR induced DNA damage in BRCA1 defective lines relative to the 
control line. This observation is consistent with the notion that BRCA1 deficiency causes 
radiosensitivity due to ineffective repair processes. 
Representative examples of IR-induced DNA damage foci are shown in Figure 3.13. 
 
 
 0.5hrs 5.0hrs 24hrs 48hrs 
 H2AX/cell H2AX/cell H2AX/cell H2AX/cell 
GM00893 (WT) 11.00 (p=6.51E-38) 10.70 (p=1.03E-42) 5.02 (p=4.58E-17) 2.70 (p=0.072) 
GM13705 (BRCA1+/-) 15.74 (p=7.78E-55) 13.96 (p=2.60E-40) 10.38 (p=5.07E-51) 6.68 (p=1.43E-18) 
GM14090 (BRCA1+/-) 16.86 (p=9.80E-59) 15.28 (p=8.37E-35) 11.56(p=4.26E-44) 7.52 (p=3.83E-11) 
 
Figure ‎3-12.‎Frequencies‎of‎γ-H2AX foci induced with 1.0Gy of gamma-rays.  
A) Average frequencies of spontaneous -H2AX foci.  B) Time-course experiment from a total of 50 nuclei scored 
based on two independent experiments, C) T-test analysis comparing untreated -H2AX foci per cell in each 
sample with 1.0Gy irradiation. Asterisks indicate the level of significance (***P<0.001). Error bars represent SEM. 
T-test used in all statistical comparison. 
A 
B 
C 
Chapter 3: Telomere analysis in BRCA1 defective human cells 
 95 
 
 
Figure ‎3-13.‎ Representative‎ example‎ of‎ γ-H2AX foci detected by immunofluorescence in human 
lymphoblastoid cell line GM14090 (BRCA1
+/-
) induced with 1.0Gy gamma radiation. 
 
3.2.8.2 Analysis of γ-H2AX after exposure to different doses of gamma rays 
 
We also wanted to establish if radiosensitivity of BRCA1+/- cells detectable through defective 
repair kinetics (Figure 3.12) can be observed by generating dose response curves. To that 
end we exposed cells to 0.5 Gy, 1.0 Gy, and 2.0 Gy of gamma radiation and quantified γ-
H2AX foci 30 min following exposure. Statistical analysis revealed that significant difference 
was observed between high dose (2.0Gy) and low doses (0.5Gy) of gamma radiation (Figure 
3.14). This suggests that increasing of gamma radiation doses can cause accumulation of 
DDR markers in mono-allelic mutant BRCA1 cell lines. Therefore, our results indicate that 
the BRCA1 defective cells accumulate higher rate of DNA damage compare to wild type 
when exposed to IR, pointing to the fact that BRCA1 is an important DNA DSB protein even 
in a heterozygous BRCA1 situation. Figure 3.15 shows microscope analysis of γ-H2AX foci 
induced by IR. 
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Figure ‎3-14.‎Frequencies‎of‎γ-H2AX and TIF foci after exposure to 0.5Gy, 1.0Gy, and 2.0Gy of gamma rays 
in BRCA1 defective cell lines (GM14090 and GM13705) and the control cell line (GM00893). A) Average 
frequencies of spontaneous γ-H2AX foci. B) The difference in the levels of γ-H2AX was significant between the 
two BRCA1 defective (GM14090 and GM13705) cell lines and the BRCA1 WT control (GM00893) (***P<0.001). 
Asterisks indicate significant differences between the BRCA1 and control cell lines (*P<0.5; **P< 0.001; ***P< 
0.0001). T-test used in all statistical comparison.  
 
 
Figure ‎3-15.‎ Immunofluorescence‎ microscopy‎ showing‎ γ-H2AX foci formation in nuclei of human 
lymphoblastoid cell line GM14090.  
A) γ-H2AX foci in un-irradiated cells B) γ-H2AX foci after irradiation with 0.5Gy, C) γ-H2AX foci after exposure to 
1.0Gy, and D) The cells exposed with 2.0Gy of gamma radiation. 
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3.2.9 Telomere dysfunction-induced foci (TIF) analysis in human lymphoblastoid cell 
lines 
3.2.9.1 Analysis of TIF kinetics in human lymphoblastoid cell lines 
Next, in order to evaluate contribution of telomeres to the observed radiosensitivity in cell 
lines from BRCA1 carriers we used TIF assay as a marker for telomere dysfunction. 
Telomere dysfunction or loss of telomere function can be caused by telomere uncapping that 
occurs when either shortened telomeres or telomere-protective factors are impaired, and 
subsequently cell cycle arrest, senescence, apoptosis, and chromosome end fusions. TIF 
assay detects DNA damage exclusively at telomeres by counting dual staining: γ-H2AX 
(FITC) and telomere probe (Cy3) (for details see Chapter 2). Representative TIF images are 
shown in Figure 3.16. Our analysis revealed that slower processing of repair kinetics occurs 
at telomeres in cells from BRCA1 carriers (GM13705 and GM14090) compared to the 
control cell line (GM00893). However, previous study revealed that the co-localisation of 
DDR foci with telomeric signal gradually increases because telomeres are potentially 
irreparable (Fumagalli et al., 2012). Our data support this finding only to a degree because 
we observed evidence of repair at telomeres in both normal and BRCA1+/- cells (Figure 
3.17). 
 
Figure ‎3-16. An example of TIF foci in BRCA1 carrier (GM14090).  
Microscope analysis shows co-localisation of y-H2AX and telomere. Interphase cells were permeabilised and 
stained with anti-γH2AX (green) and telomeric Cy3-labeled PNA probes (red). Nuclei were counterstained with 
DAPI.     
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 0.5hrs 5.0hrs 24hrs 48hrs 
 TIF/cell TIF/cell TIF/cell TIF/cell 
GM00893 (WT) 1.68 (p=7.86E-11) 1.24 (p=2.90E-05) 0.74 (p=0.15) 0.58 (p=0.65) 
GM13705 (BRCA1+/-) 2.78 (p=1.43E-19) 2.44 (p=1.21E-14) 1.94 (p=5.21E-07) 1.80 (p=3.24E-06) 
GM14090 (BRCA1+/-) 3.38 (p=1.44E-18) 2.88 (p=8.45E-15) 2.38 (p=5.62E-09) 1.96 (p=2.78E-05) 
 
Figure ‎3-17. Average frequencies of TIF foci in each cell line irradiated with 1.0Gy.  
A) Levels of TIFs per cell nuclei measured in the un-irradiated lymphoblastoid lines. B) A total of 50 nuclei scored 
for each time point and cell line in two independent experiments. C) Repair of TIFs in the WT samples riches 
normal status within 24hrs after 1.0Gy of IR whereas in the BRCA1-defective cells there is a significant difference 
in the levels of TIFs after 48hrs when compared to the un-irradiated counterparts. Asterisks indicate significant 
differences between the BRCA1 defective cell lines and control cell lines at all time-points post-irradiation 
(**P<0.001; ***P<0.0001). Error bars represent SEM. T-test used for all statistical comparison. 
 
3.2.9.2 Analysis of TIF response after acute dose response in human lymphoblastoid 
cell lines. 
Detection of TIFs was carried out in BRCA1 defective cell lines (GM14090 and GM13705) 
and control cell line (GM00893) following low dose (0.5 Gy) and high dose (1.0Gy and 2.0 
Gy) of gamma radiation (Figure 3.18). A total of 50 nuclei were analysed to assess the mean 
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of TIFs foci in each cell lines. As is evidenced, the frequencies of TIF foci were significantly 
higher in BRCA1 defective cells in comparison with the control (P<0.001) (Figure 3.18). To 
conclude, TIF results in cells with deficiency in BRCA1 could reveal telomere dysfunction 
and subsequently lead to genome instability during tumourigenesis. 
 
 
 
Figure ‎3-18 Average TIFs in BRCA1 defective cell lines (GM14090 and GM13705) and control cell lines 
(GM00893) exposed to various doses of IR.  
A) Levels of TIFs measured per cell in the un-irradiated samples showing levels of spontaneously generated 
TIFs. B) TIFs were scored 30 minutes post-irradiation for each dose level. Asterisks indicate significant 
differences between the BRCA1 and control cell lines (*P<0.5; **P< 0.001; ***P< 0.0001). T-test used in all 
statistical comparison. 
3.3 Discussion 
Numerous researchers have highlighted the fact that in the mammalian cells DDR proteins 
also affect telomere maintenance (Verdun and Karlseder, 2007, d'Adda di Fagagna et al., 
*** 
*** 
*** 
A 
B 
 
Chapter 3: Telomere analysis in BRCA1 defective human cells 
 100 
2004). The co-operation between DNA damage response mechanisms and telomere 
maintenance is required to protect telomeres so that they are distinguished from DNA DSBs 
(Slijepcevic, 2006),(De Lange, 2005b), suggesting that DDR and telomere maintenance are 
functionally related.  
The aim of this chapter was to evaluate the effect of BRCA1 defect on telomeres in the 
human lymphoblastoid cells using various telomere-specific techniques. The first results 
indicate elevated frequencies of T-SCEs in the two BRCA1 carrier cell lines as compared to 
the normal BRCA1 cell line. The dysfunctional copy of the BRCA1 gene in two human 
lymphoblastoid cell line GM13705 (3875del4 in exon 11) (Castilla et al., 1994) and GM14090 
(185delAG in exon 2 causing a premature termination codon at position 39) (Struewing et 
al., 1995) cause an elevation in the T-SCE frequencies, and an alteration in telomere length 
regulation which was evidenced via telomere length analysis in these cell lines (Figures 3.2 
and 3.5C).  
We have also shown that a lymphoblastoid cell line from a BRCA1 carrier showed elevated 
levels of spontaneous dicentric chromosomes resulting from end-to-end chromosome 
fusions (G1) and chromatid breaks (G2) (Figures 3.7 and 3.8). We have also shown that the 
exposure to IR causes CAs, resulting from interaction between telomeres and DSBs in the 
above cell lines. Our findings are in agreement with previous studies showing increased 
chromosomal radiation sensitivity of BRCA1 mutation carriers (Ernestos et al., 2010). The 
same results were observed by (Barwell et al., 2007). Another published study by (Kote-
Jarai et al., 2006) and colleagues used M-FISH to show increased levels of radiation-
induced chromosomal aberration in heterozygous BRCA1 mutation carriers compared with 
controls. They found that all chromosomes were equally involved in translocations or breaks 
when the data were corrected for chromosomal length. In contrast to these data, other 
investigators have not found an association between BRCA1 heterozygosity and 
radiosensitivity (Baria et al., 2001, Nieuwenhuis et al., 2002, Baeyens et al., 2004). 
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MN assay was another cytogenetic technique we used to assess radiosensitivity in 
heterozygous BRCA1 mutation carriers. Surprisingly, we observed low frequencies of MN 
induced by IR in BRCA1 carrier cell lines, which is not in the line with previous work that had 
shown high level of MN at higher doses (Slavotinek et al., 1993, Stopper and Lutz, 2002). In 
contrast to these data, other study (Trenz et al., 2002) have found no systematic difference 
in radiation sensitivity between lymphoblastoid cell lines with and without a BRCA1 mutation. 
Spontaneous and gamma radiation-induced MN frequencies were in same range. 
Additionally, it is clear that telomere dysfunction is critically involved in the deficiency of DNA 
damage response in these cells. Our examination of γ-H2AX foci frequencies as a marker of 
DNA damage after exposure to IR in BRCA1 carrier cell lines (GM13705 and GM14090) 
revealed that part of DNA damage foci placed at telomeres, is caused by dysfunctional 
telomeres. This assessment of DNA damage kinetics suggests that damage at telomeres, in 
the form of TIFs, are reparable at all-time points post-exposure in two BRCA1 carrier cell 
lines (GM13705 and GM14090). On the other hand, our data are not in the line with other 
study (Fumagalli et al., 2012) that support telomeric DNA are irreparable and trigger 
persistent DDR and cellular senescence. 
Previously, it has been revealed that there could be a potential mechanism for BRCA1 due 
to its effects on telomeres and DNA damage response (McPherson et al., 2004, Deng and 
Wang, 2003). It was also reported that BRCA1 regulates telomerase activity (Xiong et al., 
2003); therefore, BRCA1 deficiency can lead to an alteration of normal telomerase function, 
resulting in telomere shortening similar to that observed in (Figure 3.5). Additionally, it was 
found that BRCA1 knockdown resulted in increased telomerase activity and significant 
telomere lengthening in tumour cells (Ballal et al., 2009). Also, studies have suggested an 
interaction and co-localization of BRCA1 with shelterin proteins TRF1 and TRF2, and 
RAD50 (a component of the MRN complex) (Ballal et al., 2009). Furthermore, it was 
demonstrated that the length of the 3`G-rich overhang regulated via BRCA1, and also over-
expression of BRCA1 caused lengthening, and knockdown of BRCA1 or RAD50 caused 
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shortening of the 3`overhang (Ballal et al., 2009). All these observations clearly suggest the 
role of BRCA1 in DNA damage response and subsequently on telomeres, providing further 
confirmation that DNA damage response and telomere maintenance are closely associated.  
In conclusion results presented in this chapter clearly indicate BRCA1 mutation carriers 
show telomere dysfunction as evidenced by altered telomere length, increased TIF 
frequencies and elevated levels of T-SCE. Thus our results are in line with some earlier 
studies (Al-Wahiby and Slijepcevic, 2005, McPherson et al., 2006) (Wang et al., 2007, 
Ernestos et al., 2010).  
An additional function of BRCA1 with regards to DSB repair may result from the up-
regulation of the activity of base excision repair (BER) via a transcriptional mechanism, 
which in turn involves the stimulation of the expression of several key BER enzymes (OGG1, 
NTH1, and REF1/APE1) (Ballal et al., 2009). All in all, BRCA1 plays a vital role in the error-
free repair of DSBs of DNA through HR. This role is indeed very critical for the tumour-
suppressing nature of BRCA1. Nevertheless, the role of BRCA1 in non-homologous end 
joining remains to be settled (Rosen, 2013). 
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4 DNA damage response in mouse 
embryonic stem cells 
4.1 Introduction 
The ability of mouse embryonic stem cells (mESC) to maintain pluripotency and 
differentiation into all somatic cell types is well documented and can be characterised by a 
high proliferation of activity. One of the significant factors in mouse and monkey embryonic 
stem cells is an unusual cell cycle; they have a very short G1 phase (~ 1.5 h) and lack a G1 
checkpoint (Aladjem et al., 1998) (Malashicheva et al., 2000, Fluckiger et al., 2006). Owing 
to the defect of wild type p53 and low levels of CDK inhibitor p21/Waf1 expression (Aladjem 
et al., 1998) (Malashicheva et al., 2000) (Stead et al., 2002) (Burdon et al., 2002), ESCs do 
not undergo cell cycle arrest following exposure to DNA damaging agents and stress factors 
(Fluckiger et al., 2006) (Schratt et al., 2001), (Malashicheva et al., 2002). Therefore, this 
raises the question: how do mESCs maintain genome integrity when p53 is not activated? Is 
there any other mechanism involved in the activation of DNA damage response and 
4 
 
C
H
A
P
T
E
R
 
Chapter 4: DNA damage in mouse ESC 
 104 
genomic integrity? There are several possibilities that have been described to provide such 
protection to the mouse ESCs. These include: (i) p53-independent apoptosis (Aladjem et al., 
1998) (Malashicheva et al., 2000) (ii) lower mutation rates in the mouse ESCs as compared 
to the adult somatic cells or mouse embryonic fibroblasts (MEFs) by a factor of 100-fold, 
eliminating the need for constant monitoring of the genome for stability (Stambrook, 2007). 
Two DNA damage responses is activated by ATM (ataxia-telangiectasia mutated) and ATR 
(ATM-and Rad3-related) (Bakkenist and Kastan, 2004) (Lavin and Kozlov, 2007) which 
subsequently activate other proteins such as: Chk1 and Chk2 kinase, p53, MDM2, H2AX, 
proteins of the MRE11 complex, and many others (Helt et al., 2005a), (Shiloh, 2006) (Hurley 
and Bunz, 2007) (Lin et al., 2005). One question that needs to be explored is whether these 
pathways are functional in mESC in the same was as in somatic cells. Recently, some 
studies have suggested that p53 can be activated by DNA damage following the 
suppression of Nanog promoter activities; therefore, differentiation and DDR must be 
coordinated (Lin et al., 2005). Moreover, the similarity of the mESC and the mouse 
embryonic carcinoma cell line F9 (ECC) in terms of short cell cycles, reduced duration of the 
G1 phase, as well as a high proliferation rate has been reported (Chuykin et al., 2008a). 
Ideas relating to how stem cells are over sensitive to DNA damage and easily undergo 
apoptosis or differentiation which eliminates impaired cells from the pluripotent pool are well 
documented (Van Sloun et al., 1999) (de Waard et al., 2003). It is clear enough that the loss 
of impaired self-renewing cells effectively maintains genetic integrity of the proliferating cell 
population. Consistent with this view, ESCs lack a functional G1 checkpoint, partially due to 
the sequestration of P53 in the cytoplasm. Therefore, an absence of the G1 checkpoint in 
the cells with DNA damage results in the transit from G1 into S phase and accumulation of 
damage (Aladjem et al., 1998, Prost et al., 1998) (Hong and Stambrook, 2004). Recently, 
some studies demonstrated that differentiation can be promoted by p53 translocation to the 
nucleus and also the transcription of p53 is inhibited through the Nanog promotor, 
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suggesting that the role of p53 is more important during differentiation than in responding to 
DNA damage in ESCs (Lin et al., 2005).  
The most toxic DNA lesions are DSBs (Valerie and Povirk, 2003). ESCs show extremely 
high frequency of spontaneous γ-H2AX foci relative to non ESCs (Giachino et al., 2013). 
One of the possible reasons for this could be the replication fork collapse or reactive oxygen 
species (ROS) from oxidative metabolism. However, (Saretzki et al., 2004) have 
demonstrated that ESCs can be grown in hyperoxic conditions (40% O2) with little effect on 
cell proliferation compared with cells grown under normoxic culture conditions. It, therefore, 
seems likely that spontaneous γ-H2AX foci observed in ESCs do not result from DNA 
damage but rather from the physiological interplay between different factors in these cells 
aimed at balancing DDR and differentiation.   
Generally, two major mechanisms are associated with DNA DSB repair: HR and NHEJ. The 
HR pathway is active in the late S to G2 phases of the cell cycle where sister chromatids are 
available to serve as templates (Morrison et al., 2000) (Takata et al., 1998, Haber, 2000), 
whereas the NHEJ pathway requires little or no homology sequence for repair; it can also be 
error-free or error-prone. In contrast to HR, NHEJ takes place in the early G1 and S phases 
of the cell cycle (sister chromatids are not accessible during this stage). 
It is noticeable that ESCs utilize HR rather than NHEJ as the principle mechanism of repair 
(Donoho et al., 1998) (Hasty et al., 1992) (Smih et al., 1995). This theory has been proven 
by gene targeting experiments. The introduction of a DSB into the targeting vector increases 
significantly HR activity in ESCs (Donoho et al., 1998, Hasty et al., 1992) (Smih et al., 1995). 
Also, prolonged S phase in ESCs might stimulate the HR pathway rather than NHEJ 
preferentially. Moreover, a short G1 phase can lead to the majority of ESC genomes having 
sister chromatids which would be more efficient for the recombination mediated repair. 
Clarity of research has been hampered by the fact that genetically modified mice frequently 
suffer from an early embryonic lethality (Friedberg and Meira, 2006). This suggests that 
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affected proteins may be essential for the continued proliferation of ESCs. Additionally, 
Rad51 plays an important role in the strand invasion process, an integral part of the HR 
mechanism (Baumann et al., 1996). Mice nullizygous for Rad51 die in the early stages of 
development. Doubly targeted ESCs lacking Rad51 cannot be obtained, and cells derived 
from Rad51 null blastocysts do not proliferate, suggesting that Rad51 protein plays an 
essential role either in cell proliferation or in the repair of DSBs generated by the 
endogenous processes (Tsuzuki et al., 1996, Lim and Hasty, 1996). A deletion of Rad51 on 
the p53 deficient backgrounds yielded similar results, although development proceeded to 
embryonic day 8.5 (Lim and Hasty, 1996). Consistent with the contention that HR is a major 
repair pathway in ESCs, Rad51 protein levels are approximately 20-fold higher in ESCs than 
in MEFs where NHEJ predominates.  
The aim of this chapter is to investigate the effect of Brca1 on telomeres in mESCs where 
both copies of Brca1 were disrupted by gene targeting (Snouwaert et al., 1999). As 
explained earlier, telomere maintenance mechanisms and DDR appear to be functionally 
related providing us with a further possibility to examine this relationship. 
We focused on investigating repair of IR induced DSBs in mESCs: 408 (Brca1-/-) and E14 
(Brca1+/-) cell lines.  Also, we performed analysis of chromosomal aberration induced in G1 
and G2 phases of the cell cycle after exposure of the cells to IR. Furthermore, we have 
conducted experiments similar to that in the previous chapter, namely an analysis of 
micronuclei to identify the frequencies of chromosomal damage induced by IR. 
4.2 Results 
4.2.1 Establishment of an immunofluorescence assay protocol in mESCs cells 
It is now well accepted that mESCs have high spontaneous levels of γ-H2AX positive foci 
even without exposure to genotoxic agents (Turinetto et al., 2012). Our first aim was to show 
that this is the case with the 408 E14 cell lines. However, the first obstacle we encountered 
was related to growth properties of mESCs. These cells do not grow as a monolayer but 
rather form multilayers of cells, thus preventing an accurate analysis of individual cells. In 
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order to quantify γ-H2AX positive foci in individual cells 3D multilayers of cells must be 
disrupted and cells separated from each other. In order to facilitate this we disrupted 
monolayers by trypsinization, re-suspended cells and used the Shandon Cytospin to deposit 
a thin layer of individually separated cells on microscope slides. However, establishing the 
right conditions for the cytospin protocol required time and frequent changes in the protocol. 
Table 4-1 shows a summary of changes in experimental conditions required to establish 
optimal conditions for the analysis of γ-H2AX positive in mESCs. 
Table ‎4-1- Establishment of the H2AX assay protocol. 
All experiments were performed on mESC lacking functinal Brca1(408) and normal Brca1(E14). Cells were 
attached to polyprep slides using a cytospin centrifudge at 800 rpm for 5min (see Chapter 2 for the methodology). 
Experiment 
no. 
Aim Method used Change (s) to 
the method 
Outcome 
Experiment 1 To test the Cytospin 
speed  
Immunohistochemistry Reduce the 
speed from 
1200 to 800 
Positive 
Experiment 2 Blocking buffer Immunohistochemistry Incubate the 
cells with 1% 
BSA instead 
of Milk 
Positive 
Experiment 3 To test the new 
antibody (γ-H2AX) 
Immunohistochemistry N/A Positive 
Experiment 4 To test the new 
Secondary antibody 
Immunohistochemistry Reduce the 
dilution from 
1:500 to 
1:1000 
Positive 
Experiment 5 Complete 
immunohistochemistry 
followed by FISH 
Immunohistochemistry 
and then hybridization 
with PNA 
N/A PNA and 
γH2AX signal 
weak 
Experiment 6 Modified experiment 5 
protocol 
Immunohistochemistry 
and then extra fixation 
with 4% formaldehyde, 
then leave at room 
temperature 
overnight, following by 
hybridization with PNA 
Washing with 
TBST instead 
of PBS 
Positive γH2AX 
signal, positive 
telomeric PNA 
signal. Protocol 
suitable for 
further 
experiment. 
 
 
After establishing the γ-H2AX assay suitable for mESCs (Table 4-1), a total of 50 nuclei 
were analysed twice to evaluate the frequency of spontaneous γ-H2AX foci. Results of this 
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analysis are shown in Figure. 4.1 A. In line with previous studies we observed dramatically 
higher spontaneous levels of γ-H2AX positive foci in mECS than for example in human 
lymphoblastoid cells lines (see previous chapter). Examples of mECS stained with the H2AX 
antibody without any treatment are shown in Figure 4.1 B. The average number of γ-H2AX 
positive foci was 31.42 cells with the 408 cell line showing significantly more foci than the 
E14 cell line 23.56 (Figure 4.1 A). 
We then exposed both cell lines to 1.0 Gy of gamma rays and quantified γ-H2AX positive 
foci 30min, 5hrs, 24hrs and 48hrs post exposure (Figure 4.2). Results of this analysis are 
shown in Figure 4.1 C. Also, it is important to indicate that we performed a statistical analysis 
in two different ways. First, we compared Brca1-/-(408) against the control cell line E14 at 
each individual point (control, 0.5hrs, 5hrs, 24hrs and 48hrs); the results of this analysis are 
demonstrated by asterisks placed immediately above the bars in Figure 4.1 C. The results of 
the second analysis are presented in the table (Figure 4. 1 D). The Table contains a 
statistical comparison between control (spontaneous) frequencies of DNA damage foci and 
their counterparts at each time point post-irradiation (30min, 5hrs, 24hrs and 48hrs) for each 
individual cell line. The frequencies of DNA damage foci 0.5hrs and 5hrs after being exposed 
in Brca1-/- (408) cells were significantly higher than spontaneous frequencies, as these time 
intervals were insufficient for the repair processes to remove large amounts of induced DNA 
damage. However, a significant difference between frequencies of spontaneous DNA 
damage and that observed 24hrs and 48hrs post-exposure in the 408 cell line indicates the 
presence of unrepaired DNA damage. Therefore, this may imply a DNA damage defect in 
this cell line. 
By contrast the control E14 cell line repaired DNA damage effectively, judging by the lack of 
statistical differences between DNA damage 24hrs and 48hrs after exposure relative to the 
spontaneous DNA damage. 
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 0.5hrs 5.0hrs 24hrs 48hrs 
 H2AX/cell H2AX/cell H2AX/cell H2AX/cell 
E14 (WT) 39.60 (p=7.13E-21) 35.94 (p=1.77E-11) 24.48 (p=0.128) 33.82 (p=0.712) 
408 (BRCA1
-/-
) 45.32 (p=4.17E-14) 43.54 (p=5.41E-20) 39.92 (p=2.55E-11) 37.02 (p=8.11E-09) 
 
Figure ‎4-1. Analysis‎of‎γ-H2AX foci in mESCs.  
A) Spontaneous levels of γH2AX foci in un-irradiated E14 and 408 cells. B) Examples of the γH2AX levels in E14 
(top picture) and 408 cells (bottom picture). C) Repair kinetics in E14 and 408 cells irradiated with 1.0 Gy.  T-test 
analysis was done to compare E14 with 408 cells (***P<0.001). (D) T-test analysis comparing the untreated 
samples with irradiated samples. There were no significant differences between the average frequency of H2AX 
foci in the E14 cell line 24hrs and 48hrs post-irradiation when compared to the untreated E14 cells, whereas 408 
Brca1 defective mESCs showed significantly elevated levels of H2AX at all time points compared to the un-
irradiated 408 sample. Results were obtained from two independent experiments with an average of 50 cell 
nuclei scored per cell line. 
 
*** *** 
A 
C 
E14 E14 
408 408 
B 
D 
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Figure ‎4-2. Detection‎of‎γ-H2AX by immuno-FISH in mouse embryonic stem cell line (408 Brca1
-/-
) after 
different time post 1.0 Gy gamma irradiation. 
 
4.2.2 Telomere dysfunction-induced foci (TIF) analysis in normal and homozygous 
Brca1 mESCs 
We next performed the TIF assay to assess telomere function in the above cell lines. The 
TIF assay allows detection of γ-H2AX foci and telomeres  simultaneously (Takai et al., 
2003). We used a synthetic PNA (peptide nucleic acid) telomere probe to detect telomeres. 
Our analysis showed that 408 cells had greater spontaneous TIF frequencies in comparison 
to the cell line E14 (P<0.001) (Figure 4.3 A). However, after treatment with IR frequencies of 
TIFs returend to normal levels 24hrs and 48hrs later in E14 cells (Figure 4.3 B and C). By 
contrast, there were significant differences between spontaneous frequencies of TIF before 
and those observed 24 h and 48 h after IR in the 408 cell line (P<0.001) (Figure 4.3 B and 
C). A representative image of a TIFs observed in mESCs are shown in Figure 4.4. Thus, our 
results suggests that 408 cells show  telomere dysfunction relative to control E14 cells. 
 
30min 5hrs 24hrs 48hrs 
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 0.5hrs 5.0hrs 24hrs 48hrs 
 TIF/cell TIF/cell TIF/cell TIF/cell 
E14 (WT) 2 (p=4.46E-07) 1.46 (p=0.0002) 0.96 (p=0.088) 0.8 (p=0.500) 
408 (BRCA1-/-) 3.86 (p=6.36E-17) 3.56 (p=2.42E-12) 3.06 (p=7.43E08) 2.4 (p=0.0044) 
 
Figure ‎4-3. Average frequencies of TIF foci in each cell line after 0.5hrs, 5hrs, 24hrs and 48hrs post-
irradiation. A) levels of TIFs per cell nuclei measured in the un-irradiated E14 and 408 cell lines. B) a total of 
50nuclei scored for each time point and cell line (E14 and 408) in two independent experiments. C) T-test 
analysis comparing the untreated samples with irradiated samples. There were no significant differences 
between the average frequency of TIF foci in the E14 cell line 24hrs and 48hrs post-irradiation when compared to 
the untreated E14 cells, whereas 408 Brca1 defective mESC showed significantly elevated levels of TIF at all 
time points compared to the un-irradiated 408 sample but to a lesser extent at 48hrs. Error bars indicate SEM 
and asterisks indicate significant differences between the 408 and the control cell line (E14) (***P<0.001). 
 
*** 
*** 
A 
B 
C 
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Figure ‎4-4. Detection of TIF in mESC: Brca1+/+ and Brca1-/- (E14 and 408 respectively). Interphase cells 
were permeabilised and stained with antiphospho-histon γ- H2AX (green) and telomeric Cy3-labeled PNA probes 
(red). Nuclei were counterstained with DAPI. 
 
4.2.3 Radiation induced chromosomal abnormalities in Brca1 mutant mouse 
embryonic stem cells 
To investigate whether Brca1 defecincy results in IR sensitivity, the G1and G2 assay was 
performed in the E14 (Brca1+/+) and 408 (Brca1-/-) cell lines after exposure to increasing 
doses of IR. IR induces DSBs effectively and these may convert in cytologically visible 
chromosoml damage. Some studies have reported that BRCA1 mutant HCC193 carcinoma 
cell line is hypersensitive to IR, and that this sensitivity is partlly relieved by the expression of 
wild-type BRCA1. Morover, Brca1 mutant mESC, 236.44, is also sensitive to IR  (Moynahan 
et al., 2001). Also, mouse cells with targeted deletion in exon 11 of Brca1 show severe 
genomic instability including the presence of multiple chromosomal aberrations (CAs) in 
individual cells (Xu et al., 1999b, Weaver et al., 2002). Mouse embryos carrying a Brca1 null 
mutation and mouse thymocytes lacking functional Brca1 are hypersensitive to IR (Shen et 
al., 1998, Mak et al., 2000). This idea suggests that Brca1 deficiency results in chromosome 
instability in mESCs, however, this is different to the dramatic instability detected in MEFs. 
4.2.4 Analysis of CAs induced by IR in mESCs 
Cell lines were subjected to 0.5 Gy, 1.0 Gy, 2.0 Gy and 4.0 Gy of gamma rays for the G1 
assay, while cells were exposed to 0.5 Gy for the G2 assay. The protocols for G1 and G2 
γ-H2AX Telomere Merged 
 
Chapter 4: DNA damage in mouse ESC 
 113 
assay are used routinely in our laboratory and are based on the following references (Al-
Wahiby and Slijepcevic, 2005). We used the clasical Giemsa staining method to identify 
CAs, such as dicentric chromosomes, chromosome fragments (Figure 4.5). As expected, the 
statistical analysis of the mouse embryonic Brca1-/- stem cell line (408) showed significantly 
higher frequencies of CAs, relative to the control cell line Brca1+/+ (E14) in the G1 assay 
(P<0.05, P<0.01, and P<0.001) (Figure 4.6).  
Similarly, the G2 assay showed same results. A statistical analysis after 1.5hrs post-
radiation of both cell lines (E14 and 408) showed a significantly higher level of chromosome 
breaks relative to the untreated cell lines (P<0.05) (Figure 4.7). A similar situation was also 
observed after 3hrs and 4hrs of post-radiation which is also statistically significant (P<0.05, 
P<0.01). Our results clearly demonstrate that the 408 cell line is IR sensitive relative to the 
E14 cell line pointing further in the direction of a defective DNA damage response. 
 
Figure ‎4-5. Examples of chromosomal abnormalities in mouse embryonic stem cells. A) Untreated cells, 
with classical Giemsa staining method, B) chromosomal abnormalities in 408 cell line (dicentric and fragment) 
after exposure with IR. 
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Figure ‎4-6. Frequency of chromosomal abnormalities in mouse embryonic stem cell lines: E14 (Brca1+/+) 
and 408 (Brca1-/-) induced by IR in the G1 phase. *=P<0.05, **=P<0.01, ***=P<0.001. The error bars represent 
SEM. 
 
Figure ‎4-7. Relative frequencies of chromatid breaks in mouse embryonic stem cell lines (E14 and 408): 
all cells collected at 1.5hrs, 3hrs and 4hrs after exposuere to 0.5Gy IR. The error bars represent SEM. 
 
Chapter 4: DNA damage in mouse ESC 
 115 
4.2.4.1 Setting up a modified micronuclei assay protocol for assessing chromosome 
damage in mouse BRCA1 homozygous embryonic stem cells  
In the previous chapter, we attempted to optimise the MN assay in BRCA1 carrier 
lymphoblastoid cell lines. Here, we also attempted to investigate DNA damage at the 
chromosome level in mESCs using the MN assay. Therefore, we carried out a series of 
experiments (Table 4-2) to optimize the MN assay in mESCs. Figures 4.8 and 4.10 illustrate 
differences between initial results (Figure 4.8) which indicated poorly stained cells, lack of 
differentiation between nuclei and cytoplasm, lack of accuracy in detecting MN and results 
after the protocol optimization (Figure 4.10) showing clear distinction between nuclei and 
cytoplasm, clarity of identifying MN and clarity of identifying binucleate cells. The final results 
(Table 4-2) revealed that the optimal binucleated cells and clear cytoplasm formed 48hrs 
after treating cells with 6µg/ml of Cyt-B. 
 
Figure ‎4-8. Examples of initial images generated by the MN assay in mESCs A) after 24hrs with 3µg/ml of 
Cyt-B, B) after 24hrs with 6µg/ml Cyt-B, C) after 48hrs with 3µg/ml of Cyt-B. 
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Table ‎4.2- Establishment of a micronucleus assay. 
All experiments were performed on normal (E14) and mutant mouse embryonic stem cells (408). 
Experiment no. Aim Method used Outcome 
Experiment 1 To test the dose of Cyt-
B (3 or 6 µg/ml) 
Both doses of Cyt-B 
were added 
Visible and clear MN of 
6 µg/ml dose 
Experiment 2 To test the optimum 
time for radiation-
induced MN 
MN was found 
between 24 hrs and 48 
hrs post-radiation 
Increase the level of 
MN 48 hrs post-
radiation 
Experiment 3 Modified Experiment 2 
protocol as the 
optimum experimental 
conditions 
Micronuclei assay and 
then Giemsa staining 
Positive MN 
measurement at 48 hrs 
in the presence of 6 
µg/ml Cyt-B 
 
It is now established that micronuclei are derived from acentric chromatid fragments, 
acentric chromosome fragments or whole chromosomes that fail to segregate properly in 
anaphase (Fenech, 2010).  
Our analysis revealed a clear distinction regarding the spontaneous level of MN frequencies 
between E14 and 408 cell lines as shown in Figure 4.9. The level of MN formed following IR 
was higher in the 408 cell line compared to the normal E14 cell line. The highest level of MN 
was observed after exposure to 2.0 Gy and 4.0 Gy in 408 cells. The statistical analysis 
revealed frequencies of MN are higher in the 408 cell line (P<0.05) than in the normal E14 
cell line after 2 Gy and 4 Gy (Figure 4.6). Taken together these results show greater 
sensitivity to IR in 408 cells relative to E14 cells, suggesting a DDR defect. 
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Figure ‎4-9. Mean MN after irradiation in mouse embryonic stem cell lines: E14 (Brca1+/+) and 408     
(Brca1-/-). The basal levels of MN induced by IR 48hrs after  exposure to different Gy in cultures of normal Brca1 
cell line (E14) and Brca1 homozygous cell line (408) treated with cytochalasin B. Mean + SEM from 500 scored 
binucleated cells. T-test used for statistical analysis. * (P<0.05); ** (P<0.001).   
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Figure ‎4-10. Scoring binucleated cells in mESC. A) an examlpe of a MN; B and C) binucleated cells with three 
MN; D, E and F) viable mono, di and quadrinuclear cells. 
4.3 Discussion 
 Previous investigations showed that telomere dysfunction induces a DNA damage response 
in mammalian cells (Takai et al., 2003). Also γ-H2AX, 53BP1, RAD17, RAD51D, and ATM 
as DNA damage response factors, were discovered to become associated with 
dysfunctional, uncapped telomeres (Takai et al., 2003) (d'Adda di Fagagna et al., 2003, 
Herbig et al., 2004), (Tarsounas et al., 2004b). Moreover, it has been reported that 
embryonic tissue with BRCA1 deficiency revealed IR hypersensitivity, consistent with a 
defect in DSB repair (Sharan et al., 1997) (Deng and Brodie, 2000).   
The first aim of this chapter was to evaluate the influence of BRCA1 defect on DDR 
mechanisem in mESCs (E14 and 408). It was shown previously that mESCs show very high 
basal levels of γH2AX without exposure to any genotoxic agents (Turinetto et al., 2012, 
Fernandez-Capetillo et al., 2002, Banath et al., 2009) argued that this could be due to 
chromatin decondensation rather than pre-existing DNA damage which potentially explains a 
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new role for γ-H2AX in mECCs. We have also observed the high level of γ-H2AX foci in both 
un-treated mouse ESCs (E14 and 408) which are consistent with their results.  
Additionally, it is well documented that γ-H2AX is essential for the recruitment of BRCA1 and 
other DNA repair and damage-response factors like 53BP1, MDC1, and the MRN complex 
to the site of DNA damage (Fernandez-Capetillo et al., 2002, Stewart et al., 2003). Similar to 
the previous study by (Shen et al., 1998), we also know that murine BRCA1 is responsible 
for genomic integrity and murine embryos carrying a Brca1 null mutation exhibited 
hypersensitivity to γ-irradiation and chromosomal abnormalities, suggesting an involvement 
of BRCA1 in DDR. The DNA damage kinetics analysis in mESCs after exposure to IR shows  
full repair in the control cell line (E14) 24hrs post-radiation, whereas, the Brca1-/- cell line 
(408) shows a defect in DNA repair kinetics as exemplifed by the presence of residual 
damage 48 hrs after (Stewart et al., 2003) exposure to IR (Figure 4.1). Analysis of DNA 
damage at telomeres also suggests lack of repair in the 408 cell line but not its full 
absences(Figure 4.3). The normal cell line, E14, was able to repair TIFs effectively (Figure 
4.3). Thus our evaluation of DNA damage kinetics suggests that damage at telomeres (TIFs) 
is not irreparable in the case of the normal cell line. Our results contrast recent published 
resulsts suggesting that DNA damage at telomeres is irreparable irrespective of the genetic 
status of the cells (Fumagalli et al., 2012).  
A high level of γH2AX has also been associated with the single-strand breaks occuring in the 
S phase of the ESC population, as rapidly dividing cells have increased proportion of cells in 
S phase, compared to many somatic cells (Chuykin et al., 2008b). Many studies have 
reported on the differences in sensitivity to DNA damaging agents between telomeric 
sequences and the rest of the genome. Furthermore, a number of studies have also 
demonstrated that the absence of a G1 checkpoint leads to cell death in S phase; it is also 
well documented that HR is the predominant DSB repair pathway in mESCs but when ESC 
cells start to differentiate, the HR levels are reduced whereas the NHEJ levels are increased 
(Tichy and Stambrook, 2008).  
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 The second aim of this chapter was to determine whether the Brca1 defect in mESCs leads 
to IR sensitivity. Our results clearly show that this is the case as shown by elevated 
frequencies of CAs in both G1 and G2 phases of the cell cycle (Figures 4.6, 4.7). The first 
evidence of elevated CAs in the 408 cell lines as a result of telomere dysfunction was 
presented by Al-Wahiby and Slijepcevic  (2005). Their analysis revealed significantly higher 
levels of CAs after being exposed to bleomycin in 408 cells relative to E14  cells. It is clear 
that both cell lines showed CAs involving telomere-DSB interaction after treatment with 
blemycin, however, the percentage of CAs due to dysfunctional telomeres in the wild type 
ES cell line can be explained by the fact that this cell line, also named E14TG2a, is not 
completely normal; i.e., it lacks the 5` portion of the Hprtgene and may have some other 
abnormalities (Snouwaert et al., 1999). 
A study has examined the DSB repair at the molecular level in the Brca1-/- 236.44 mESC 
line to determine the nature of the repair defect. It is worth mentioning that this cell line was 
designed by several rounds of gene targeting, such that both Brca1 allels are mutated by 
deletion of the 5` end of exon 11 (Gowen et al., 1996). Their results demonstrated that the 
236.44 cell line has defective HR which induced chromosome breaks and reduced gene 
targeting; the results also support the notion that wild type Brca1 enables functional HR. In 
addition, Moynahan et al. (2001) established that the Brca1-/- genetic status results in 
chromosome instability in mESCs, while no dramatic instability can be detected in MEFs 
(mouse embryonic fibroblasts). Notably, Brca1 deficient cells show sensitivity to mitomycin-C 
which is more profound than the previously published IR and cisplatin sensitivities (Gowen et 
al., 1998, Bhattacharyya et al., 2000).  
In conclusion, results in this chapter indicate that when both copies of Brca1 are 
dysfunctional, as in the case of the 408 cell line, this leads to dysfunctional DNA damage 
response and subsequently dysfunctional telomere maintenance. 
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5 Analysis of ALT markers in 
mESCs 
 
5.1 Introduction 
It has been documented the nuclear protein, BRCA1, is classified as a tumour 
suppressor based on the fact that deficiency of BRCA1 gene can cause about 80-90% risk 
for breast or ovarian cancer (Ford et al., 1994, Miki et al., 1994). However, the BRCA1 
protein has been shown to interact with other proteins; it can also play a supporting role in 
several cellular processes, such as transcription (Chapman and Verma, 1996, Monteiro et 
al., 1996), cell cycle transition (Xu et al., 1999a, Larson et al., 1997) and DNA repair (Scully 
et al., 1997, Gowen et al., 1998, Shen et al., 1998, Zhong et al., 1999). It is interesting that 
telomere maintenance mechanisms also act as a tumour suppression mechanism (Cesare 
and Reddel, 2008). Therefore, analysis of telomere maintenance in cells with null BRCA1 
could potentially shed light on how this protein exerts its tumour suppression properties. 
Also, it has been demonstrated that BRCA1 is expressed in only a subset of tissues (Miki et 
al., 1994); however, some studies that used the murine homologue Brca1 (Bennett et al., 
1995, Sharan et al., 1995) have demonstrated that the expression can be detected early in 
the development of the embryo and continues to be expressed in a large spectrum of tissues 
throughout the development and into adulthood (Marquis et al., 1995, Lane et al., 1995). 
Other studies have also revealed that BRCA1 can be expressed in all dividing cells 
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throughout the cell cycle in a specific manner; the maximal expression has been shown to 
occur in the S phase (Chen et al., 1996, Ruffner and Verma, 1997). Functionally, BRCA1 
has been examined using a number of mouse lines with disruption of Brca1 gene-by-gene 
targeting (Gowen et al., 1996, Hakem et al., 1996, Liu et al., 1996, Ludwig et al., 1997, Shen 
et al., 1998). Unlike humans, mice with null Brca1 do not show an increased risk of tumour 
formation (Cressman et al., 1999). However, mice heterozygous mutants for both Brca1 and 
P53 have been shown to develop tumours after exposure to IR (Cressman et al., 1999). 
Using mice with deficiency of Brca1 as a source of primary cell lines has been restrictive 
because these animals die in early embryogenesis. Therefore, the mECS cell line 
homozygous for a mutant Brca1 allele has been generated by two rounds of gene targeting 
(Snouwaert et al., 1999). 
Also, two additional studies confirmed that BRCA1 plays a role in telomere maintenance. 
French et al. (2006) revealed that the expression of a dominant negative BRCA1 mutation in 
breast epithelial cells leads to changes in telomere length (elongation) and an increase of 
anaphase bridges. Moreover, previous studies using mouse Brca1-/- cells (McPherson et al., 
2006) showed the level of telomeric fusion increases relative to control cells. On the other 
hand, study of the effect of telomere shortening on chromosome stability, and analysis of 
telomere length in two individual chromosomes (2 and 11) derived from mice lacking the 
telomerase RNA (mTR) gene by using quantitative fluorescence in situ hybridization, 
indicate that telomere length at both chromosomes decreased with increasing generations of 
mTR-/- mice. 
Promyelocytic leukemia (PML) nuclear bodies regulate cellular processes, such as DNA 
replication, tumour suppression, gene transcription and DNA repair (Pearson et al., 2000, 
Salomoni and Pandolfi, 2002, Bernardi and Pandolfi, 2007). Consistent with the multi–
functional role in cells, PML bodies contain a variety of regulatory proteins including PML, 
SP100, p53, pRb, HP-1, ATRX, DAXX and SUMO-1. Generally, in human ALT cancer cell 
lines PML bodies known as the ALT-associated PML bodies (APBs) are readily identifiable. 
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It is well documented that telomeric DNA, telomere binding proteins (TRF1, TRF2) and DNA 
repair protein (NBSI, Mre11, RAD50) co-localize with the APBs (Cesare and Reddel, 2010, 
Wu et al., 2003). Although it is still unclear whether APBs directly drive ALT activity, there is 
evidence that they promote ALT activity. The disassembly of APBs as a result of RNAi-
mediated knockdown of either PML or Mre11/RAD50/Nbs1 (MRN) proteins leads to 
inhibition of telomere elongation in ALT cells (Jiang et al., 2005, Jiang et al., 2007, Wu et al., 
2000). Furthermore, it has been demonstrated that NBS1 plays a key role in the recruitment 
of Rad50, Mre11 and BRCA1 (the latter through the binding of NH2-domain of NSB1 with 
the COOH-terminal domain) to the APBs (Wu et al., 2003). Thus, the study suggests the 
direct association of BRCA1 with APBs. 
It is now well documented that mutations in the ATRX gene correlate with the ALT activity 
making this gene one of the best ALT markers (Lovejoy et al., 2012). The activation of the 
ALT pathway occurs in pancreatic neuroendocrine cancers, pediatric glioblastomas, and 
other tumours of the central nervous system when ATRX is mutated (Lovejoy et al., 2012). 
The molecular bases for ALT activation in human cancer cells are not yet fully known. The 
ALT activation occurs relatively infrequently in vitro during conversion of virally-transformed 
(p53/Rb deficient) human cells and may take months following a telomere mediated crisis 
(Yeager et al., 1999, Lovejoy et al., 2012). The low frequency of ALT activation in 
mammalian cells is thought to be due to a mechanism that requires mutation and/or 
epigenetic modification of the genome to unleash the ALT pathway (Lovejoy et al., 2012). 
The ALT pathway is suppressed in telomerase-positive mammalian cells due to the 
component of shelterins, such as TRF2, Rap1 and POT1 as well as KU70/80 heterodimers 
(Lovejoy et al., 2012, Celli et al., 2006) (Sfeir et al., 2010). ATRX and DAXX participate in 
chromatin remodelling at telomeres within histone H3.3; recently it has been shown that 
inactivating mutations in ATRX or DAXX are a common phenotype of human pancreatic 
neuroendocrine tumors (Heaphy et al., 2011) and cause telomere dysfunction phenotype 
resembling that of ALT activation in 61% of the tumours (Heaphy et al., 2011). These ALT-
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associated phenotypes include increasing TTAGGG repeat containing telomeric transcripts 
(known as TERRA), reducing telomeric loading of HP1α and elevated DDR (Osterwald et al., 
2015). Although the exact mechanism of ATRX or DAXX mutation in ALT activation is not 
yet known, ATRX or DAXX mutation is thought to serve as a good marker of ALT activity in 
vitro, as a recent study has shown that 90% of ALT-positive immortalised lines are ATRX 
deficient (Lovejoy et al., 2012).  
 
In this chapter, we examined telomere maintenance in the same set of mECSs as in the 
previous chapter (E14, 408) in order to assess contribution of BRCA1 deficiency to this 
process. We analysed T-SCEs by CO-FISH, telomere length by IQ-FISH and the frequency 
of end-to-end chromosome fusions by conventional cytological methods. We also probed 
telomere association with APBs and ATRX in order to assess contribution of ALT to telomere 
maintenance in the BRCA1 negative environment. 
5.2 Results 
5.2.1 CO-FISH analysis of BRCA1-defective mouse embryonic stem cells 
We started by analysing frequencies of T-SCEs. A total of 100 metaphases per cell line were 
analysed. Our results indicate a significant increase (P<0.001) in T-SCE levels in the 408 
cell line relative to the E14 cell line (Figure 5.1). These results suggest that the BRCA1 
defect affects recombination rates at telomeres, and subsequently could be a contributory 
factor to the defective DNA damage response observed in these cells. Additionally, the 
results further confirm the existence of the ALT pathway in mouse Brca1-/- ESCs as T-SCEs 
represent one of the ALT markers (Chapter 6). Figure 5.2 shows microscopy examples of T-
SCEs observed in mESCs. 
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Figure ‎5-1. Mean value of T-SCEs in mESCs. Error bars indicate SEM. A total of 100 metaphases were scored 
for the presence of T-SCE in two independent experiments. 
 
 
Figure ‎5-2. Examples of T-SCEs in the mESCs. A) A metaphase spread from the E14 cell line. B) A 
metaphase spread from the 408 cell line. The yellow arrows indicate examples of T-SCEs and enlarged on the 
right.  
 
5.2.2 Analysis of end-to-end telomeric fusion in mouse embryonic stem cells 
Chromosomal instability has been characterised as a one the major classes of genetic 
instability, which occurs at a very early stage of tumorigenesis (Shih et al., 2001). Some 
studies have revealed that disorder of telomere maintenance is related with end-to-end 
chromosome fusion in many organisms. For instance, in the fission yeast S. pombe, deletion 
of ATM homologous (tel1+ and rad3+) or telomerase reverse transcriptase gene (trt+) affects 
A B 
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telomere shortening and leads to eventual loss of growth. To directly determine whether 
telomere dysfunction can induce genetic instability, we measured end-to-end chromosome 
fusions in E14 and 408 cell lines. We measured frequencies of end chromosome fusions 
(ECFs) in metaphase cells. For this purpose, we scored 100 metaphase cells by using the 
telomeric PNA probe. The results indicated a significant increase (P<0.05) in frequencies of 
telomeric fusion in 408 cells compared to the control E14 cell line (Figure 5.3). Our results 
support the idea that functional telomeres are required to maintain chromosome stability and 
prevent chromosome fusions. Figure 5.4 shows examples of ECFs observed. 
 
Figure ‎5-3. Frequencies of telomeric end-to-end fusions in E14 and 408 cell lines. The error bar indicates 
SEM. A total of 100 metaphases were scored for the presence of ECFs in two independent experiments. 
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Figure ‎5-4. Detection of telomeric fusion in mouse embryonic stem cells: A) control cell line (E14), and B) 
Brca1
-/-
 (408). 
 
5.2.3 Telomere length analysis using IQ-FISH in mouse embryonic stem cells 
Next, we analysed telomere fluorescence intensity in 408 and E14 cell lines using the IQ-
FISH technique (see the Chapter 2). A total of 100 interphase cells per cell line were 
captured, and the mean telomere fluorescence intensity per cell was used to determine 
potential differences between cell lines. In order to ensure reproducibility of results, telomere 
lengths were measured in two mouse lymphoblastoid cell lines: the parental radio-resistant 
L5178Y-R cell line (known as LY-R) and its subtype, the radiosensitive L5178-S cell line (LY-
S) (see Chapter 3; Figure 3.5 A and 3.5 B). Statistical analysis of our results revealed that 
the mouse Brca1-/- cell line (408) had significantly decreased telomeric DNA sequences (P< 
0.001) compared to the control Brca1+/+ cell line (E14) (Figure 5.5). Therefore, these results 
are similar to those observed in cell lines from BRCA1 carriers (Chapter 3). 
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Figure ‎5-5. Telomere fluorescence analysis by IQ-FISH. CCFL. corrected calibrated fluorescence after 
calibration using LY-R and LY-S cells. Error bars indicate SEM. 
 
Figure ‎5-6. Telomere fluorescence analysis using IQ-FISH. A and B) Radioresistance LY-R and 
Radiosensitive LY-S in interphase; C and D) show mESCs: 408 and E14, respectively. 
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5.2.4 Co-localization of PML bodies and telomeres in mouse embryonic stem cells 
Elevated frequencies of T-SCEs in 408 cells suggest on the presence of the active ALT 
pathway (Figure 5.1). To investigate whether these cells show further evidence of the active 
ALT pathway we assessed another ALT marker, APBs, in each cell line. For this purpose we 
used well-established positive controls: human ALT + and ALT - cell lines (U2OS as ALT 
positive and HeLa as ALT negative) (Figure 5.7). In addition, we included the human BRCA1 
defective HCC1937 cell line and two mouse lymphoma cell lines, LY-R and LY-S (Figure 
5.7). The difference in the average numbers of APBs/nuclei, were statistically significant 
between U2OS cells on one side and HeLa and HCC1937 on the other side (Figure 5.7). 
This suggests that BRCA1 deficiency present in the HCC1937 cell line does not lead to the 
ALT activation. However, the difference between HeLa and HCC1937 cells is significant 
(Figure 5.7) adding some uncertainty to our results. We have also observed statistically 
significant differences between 408 cells on one side and all other mouse cell lines on the 
other side (Figure 5.7) suggesting that the BRCA1 defect may have some effect on APBs as 
the ALT marker.  
The analysis of co-localisation of the telomeres and APBs is shown in Figure 5.8. This 
analysis excludes the BRCA1 deficiency as a potential activator of ALT in human cells as the 
HCC1937 cell line did not show co-localisation between APBs and telomeres (Figure 5.8). 
Similarly, there was no difference between 408 and E14 cells in terms of co-localisation 
(Figure 5.8) further supporting the lack of correlation between the ALT activation and a 
BRCA1 defect. Interestingly, mouse lymphoma cells showed some differences relative to 
408/E14 cells (Figure 5.8).   
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Figure ‎5-7. Total number of APBs in human and mouse cells. Frequency of APBs counted in: BRCA1-
positive human cells (U2OS and HeLa) and BRCA1-defective human cells (HCC1937); and mouse Brca1-
positive ESC (E14) and Brca1-defective ESC (408) cells; mouse Brca1-positive lymphoblastoid (LY-R and LY-S) 
cells. Data from 50 nuclei counted in two independent experiments. T-test used for statistical analysis.   
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Figure ‎5-8. Co-localisation of APBs with telomeres in human and mouse cell lines. Green lines indicate the 
means. T-tests were used for statistical analysis. 
 
 
Examples of images obtained after the immunofluorescence analysis with PML antibodies 
and telomeric probe are shown in Figures 5.9 and 5.10. 
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Figure ‎5-9. Immuno-FISH analysis in ALT
+
 (U2OS) and ALT
-
 (HeLa and HCC1937). U2OS was used as the 
positive control while HeLa served as the negative control. Interphase cells were permeabilised and stained with 
anti-PML (green) and telomeric Cy3-labeled PNA probes (red). Nuclei were counterstained with DAPI. 
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Figure ‎5-10. Detection of APBs by immuno-FISH in mESCs, LY-R and LY-S cells. Interphase cells were 
permeabilised and stained with anti-PML (green) and telomeric Cy3-labeled PNA probes (red). Nuclei were 
counterstained with DAPI. 
5.2.5 ATRX as a marker of ALT activity 
Next, we used another ALT marker, the antibody against ATRX, to check if there is a link 
between the ALT activation and BRCA1 defect. We looked for the presence of ATRX using 
immunofluorescence in the two mESC lines, as well as in human ALT+ U2OS (BRCA1+/+), 
ALT- HeLa (BRCA1+/+) HCC1937 (BRCA1-/-), mouse LY-R and LY-S cells. We measured the 
total number of ATRX foci per cell in two independent experiments in all samples (Figure 
5.11). As expected, the human U-2OS ALT+ cell line had no ATRX foci as reported 
previously (Lovejoy et al., 2012), whereas there were on average between 10-11 ATRX foci 
per cell in both HeLa and the HCC1937 human breast cancer cell line (Figure 5.11). Also 
there were on average 7 ATRX foci in the two mESC lines (Figure 5.11). Therefore, judging 
by the presence of ATRX signals in all cell lines except the ALT positive cell line, U2OS, we 
have to conclude that the BRCA1 defect per se is not linked to the ALT activation. 
Next, we analysed co-localisation of ATRX with telomeres, if any, in all cell lines (Figure 
5.12). A total of 50 cell nuclei were randomly analysed in each cell line in two independent 
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experiments. In general, the level of co-localisation was low (Figure 5.12) and interestingly, 
there was a statistical difference between 408 cells and LY-R cells (p<0.0001) (Figure 5.12). 
 
Figure ‎5-11. Total number of ATRX signals in human and mouse cells. Data is from 50 nuclei from two 
independent experiments. T-test is used for statistical comparison. 
Chapter 5: ALT markers in mESCs 
 135 
 
Figure ‎5-12. Co-localisation of ATRX with telomeres. The green bar indicates mean. T-test is used for 
statistical analysis. 
 
Examples of images of cells stained with ATRX antibodies and telomeric probe are shown in 
Figures 5.13 and 5.14. 
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Figure ‎5-13. ATRX (green) is absent in U2OS cells and present in HeLa and HC1937 cells. Telomeres 
shown in red. 
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Figure ‎5-14. ATRX signals (green) present in all mouse cells. Telomeres shown in red. 
 
5.3 Discussion 
Mutations in breast and ovarian cancer susceptibility gene 1 (BRCA1) can cause about 40-
45% of hereditary breast cancer cases. BRCA1 is a multi-functional protein, which is not fully 
understood, however, research has shown BRCA1 functions in DDR, HR, NHEJ and 
regulation of telomere length (Tirkkonen et al., 1997, Xu et al., 1999b, Weaver et al., 2002, 
Baldeyron et al., 2002, Zhong et al., 2002b, Bau et al., 2004, Moynahan et al., 1999, 
Moynahan et al., 2001, Merel et al., 2002, Acharya et al., 2014) (Wang et al., 2001). In 
mammalian cells, telomere dysfunction induces DDR. For example, a study has shown that 
the TRF2 deletion leads to uncapped telomeres and an association with DDR factors 
including 53BP1, γ-H2AX, Rad17, ATM and Mre11, and subsequent telomere dysfunction 
(Takai et al., 2003). The co-localisation of BRCA1 with MRN complex following DNA damage 
Chapter 5: ALT markers in mESCs 
 138 
was also reported (Zhong et al., 1999, Wang et al., 2000, Wu et al., 2003) proposing that 
BRCA1 plays a role in telomeres. Moreover, the results of an initial study on cultured 
embryonic stem cells revealed that Brca1-deficient cells in addition to hypersensitivity to γ-
irradiation also showed numerical and structural chromosomal aberrations which may be a 
direct consequence of unrepaired DNA damage (Deng and Scott, 2000). Therefore, 
deficiency in BRCA1 gene affects many cellular pathways.  
Results presented in this chapter indicate that the Brca1 defect in mESC line, 408, caused 
elevated T-SCE frequencies (Figure 5.1) as revealed by the CO-FISH assay (Bailey et al., 
2004a)Baily and Eberle 2001). This finding is in the line with a previous study (Al-Wahiby 
and Slijepcevic, 2005) which revealed that after treatment with bleomycin the Brca1 deficient 
cell line (408) shows a higher level of T-SCEs than the parental wild type ES cell line (E14). 
Furthermore, we observed increased end-to-end chromosome fusion and significant 
telomere shortening relative to the control cell line (E14) (Figures 5.2 and 5.3).  
Elevated T-SCE frequencies (Figure 5.1) may represent the sign of ALT activation. However, 
no clear difference was detected in the number of APB or ATRX signals in the set of several 
relevant cell lines (Figures 5.8 and 5.12) suggesting the lack of association between the ALT 
activation and BRCA1 defect. The observed elevated T-SCE frequencies in 408 cells 
probably reflect the HR deficiency as a result of BRCA1 absence rather than the ability of 
BRCA1 to affect HR at telomeres.  
We also measured telomere length by IQ-FISH techniques (see Chapter 2). We found a 
significant difference between Brca1-/- (408) and the matching control cell (E14) (Figure 5.5). 
This result suggests that telomeres in mouse Brca1-/- degraded more rapidly than telomeres 
in Brca1+/+ (E14) due to telomere dysfunction. Our measurements are in agreement with 
previously published studies, which analysed telomere maintenance in mESCs deficient in 
Brca1, which revealed accelerated telomere shortening and mild telomere dysfunction in 
comparison to control cells (Cabuy et al., 2005). Furthermore, their results revealed 
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accelerated telomere shortening in cells defective in ligase I, ligase IV, Artemis, AT, NBS, 
FA, patient with a defect in DNA DSB repair and patient diagnosed with Xeroderma 
Pigmentosum (Cabuy et al., 2005). However this accelerated telomere shortening was 
accompanied by signs of telomere dysfunction including anaphase bridges (formation of 
bridge during anaphase separation of chromosomes), end-to-end chromosome fusions and 
early loss of telomere capping function (Cabuy et al., 2005). 
In conclusion, results presented in this chapter indicate (i) elevated T-SCE frequencies and 
some other signs of telomere dysfunction in the mouse Brca1 deficient cell line (408) and (ii) 
lack of correlation between the ALT and the BRCA1 defect. 
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6 Assessment of additional ALT 
markers in mouse and human 
cells 
6.1 Introduction 
In the previous chapter we used markers of ALT (T-SCE, APBs, and ATRX) in human 
cells and mESCs to detect correlation between BRCA1 deficiency and ALT activity. 
However, none of the ALT markers we used gave us enough confidence to think that Brca1 
is actively involved in the ALT pathway. For example, even though frequencies of T-SCEs 
were elevated in Brca1 defective mECSs (Figure 5.1) other ALT markers (APBs and ATRX) 
could not be correlated with the Brca1 mediated defect (Figures 5.8-5.12).  Therefore, we set 
out to use a more robust marker of ALT activity to clarify this uncertainty. At present the most 
reliable indicator of ALT activity is the C-Circle (CC) assay (Henson et al., 2009). The CC 
assay provides a rapid and sensitive measure of the ALT activity (Henson and Reddel, 
2010).  
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Human and rodent cells maintain their telomere length through the use of telomerase 
enzyme (Greider and Blackburn, 1985). However the fundamental difference between the 
two types of cells is that most human somatic cells have a repressed telomerase activity - 
apart from mitotically active cells such as skin, hair follicle cells, lymphocytes and 
endometrial cells that shows low levels of telomerase (Hiyama et al., 1995, Härle-Bachor 
and Boukamp, 1996, Yasumoto et al., 1996). Nevertheless, telomerase enzyme is found 
active in human germ cells (Hahn et al., 1999) and 85% of human tumour cell lines (Kim et 
al., 1994). Interestingly, recent evidence has suggested that ALT may indeed be active in 
mouse somatic cells in vivo, but the level of the activity is insufficient to maintain or elongate 
telomere lengths and that during in vitro immortalisation or in cancers this level is increased 
(Neumann et al., 2013). So far, there is no evidence that ALT activity is present in normal 
human somatic cells. ALT is specific to some forms of tumors such as osteosarcomas 
(Cesare and Reddel, 2010).  
Rodent cells including mouse do not shut down telomerase activity in transition from stem to 
differentiated cells and therefore possess longer telomeres (20kb) compared to the human 
cells (9-12kb) (Hemann and Greider, 2000, Newbold, 2002, Rangarajan and Weinberg, 
2003, Calado and Dumitriu, 2013). Mouse cells have longer telomeres and inhibition of 
telomerase enzyme in these cells, like the mTR-/- mouse embryo fibroblast (MEFs), stop cell 
division only after 10-15 population doublings long before appreciable telomere shortening 
occurs (Blasco et al., 1997), indicating that mouse cells do not use telomere lengths as a 
mechanism to limit cell division and therefore, other events may exist (Wright and Shay, 
2000). Could the other factor be the co-existence between the telomerase and ALT in 
maintaining telomere lengths dynamics in mouse cells? Indeed, in experiments whereby 
telomerase was exogenously activated through the hTERT transfection in ALT positive 
GM847 human cells, data showed that telomerase did not abolish ALT activity and only 
when the GM847 telomerase+/ALT+ cells were fused with telomerase-positive tumour cell 
lines this caused inhibition of ALT activity (Perrem et al., 2001), suggesting that other factors 
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could be responsible for inhibition of the ALT pathway (Perrem et al., 2001). These intriguing 
observations show that both telomerase and ALT can co-exist in the same cell and their 
activities depend on unknown factors. However, it is not clear whether there could exist 
human tumour cells with both ALT and telomerase activity, suggesting that one mechanism 
is sufficient to combat the process of telomere erosion in cancer cells.  
However, the co-existence between telomerase and ALT activity in the mouse cells have 
been reported recently (Neumann et al., 2013). Therefore, the aim of this chapter is to probe 
for the activity of ALT in the same set of cell lines as in Chapter 5 (extended by two more 
ALT+ human cell lines) using the CC assay. Other aims include (i) measuring telomerase 
activity and (ii) analysis of colocalisation of BRCA1 and BLM with telomeres as a recent 
study has suggested that BRCA1 and BLM co-localise with RAD50 in ALT positive human 
cells (Acharya et al., 2014). 
6.2 Results 
6.2.1 Cell lines 
A total of eleven cell lines were analysed in this chapter including: U2OS, HeLa, G292, 
SKLU-1, HCC1937, mESCs E14 and 408, human lymphoblastoid cells lines GM00893 and 
GM13705 (BRCA1+/-) and mouse lymphoma cell lines LY-R and LY-S. All cell lines were 
analysed using (i) the CC assay (ii) the telomerase activity TRAP assay and (iii) 
immunofluorescence with the BLM antibody combined with other relevant antibodies or 
telomeric PNA probes.  
6.2.2 Detection of ALT activity by C-circles assay  
Results presented in Chapter 5 were inconclusive regarding the link between BRCA1 and 
ALT activity. For example, although we observed significant differences in the number of 
APBs between the 408 and E14 cell lines (Figure 5.7) there was no difference between the 
cell lines in terms of co-localisation of APBs and telomeres (Figure 5.8). Similarly, we 
observed identical situation with human HCC1937 (Figures 5.7 and 5.8) known to be 
defective in BRCA1. 
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However, to assess the presence of ALT in the most accurate way we measured ALT 
activity using a sensitive CC assay. This assay measures levels of self-priming circular 
telomeric C-strand templates for rolling circle amplification (RCA) (Henson et al., 2009, 
Henson and Reddel, 2010) that is shown to be 1000-fold overexpressed in ALT+ cells 
relative to ALT- cells and therefore provides the most accurate measure of ALT activity 
available at present. However, it must be pointed out that it is not yet clear whether CC’s are 
integral part of the ALT pathway and therefore the data must be interpreted with caution 
(Henson and Reddel, 2010). Furthermore, it must be noted that the CCs are different to the 
t-circles found in ALT+ cells that contain nicks and gaps in both strands and therefore unable 
to sustain RCA. The CC assay protocol is described in detail in Chapter 2 (Materials and 
Methods). 
The CC assay was carried out using 30ng of gDNA from the ALT+ human cell lines (U2OS, 
G292 and SKLU-1), ALT- cell lines (HeLa and HCC1937) and human lymphoblastoid lines 
(GM00893 and GM13705) as well as mESCs (E14 and 408) and mouse lymphoblastoid cell 
lines, LY-R and LY-S (Figure 6.1A). 
 
Figure ‎6-1. The CC assay in human and mouse cells. A) Slot-blot examples of the CC assay using 30ng of 
gDNA. B) The human ALT-positive U2OS cells used to create a standard curve with concentrations of DNA 
ranging from 3.75ng-60ng. C) Standard curve of the CC assay of the ALT-positive U2OS. The R
2
 was equal to 
0.9207. The CC assay unit is calculated based on arbitrary unit (a.u.). 
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The gDNA from all samples were slot blotted onto a nitrocellulose membrane and probed 
with P32-labelled C-rich telomeric oligonucleotide (CCCTAA)3 (Figure 6.1). To establish that 
the increases in the ALT activity measured through CC assay are dependent on the gDNA 
concentration we performed a serial dilution experiment using various concentrations of the 
ALT+ U2OS (Figure 6.1B). Regression analysis showed a linear correlation (R2=0.9207) 
between concentrations of gDNA of U2OS and CC activity (Figure 6.1C) suggesting that the 
activity of CC assay is dependent on the input gDNA and consistent with the published data 
(Henson and Reddel, 2010).  
Data from the CC assay showed ALT activity in both mESCs in the range similar for the 
human ALT+ cell lines with the exception of (i) the 408 cell line which had the highest ALT 
activity and (ii) the LY-S cell line which lacked ALT activity completely (Figure 6.2). To 
confirm this observation further and to assess the differences is not due to the input gDNA, 
we repeated the CC assay using 20ng of freshly extracted gDNA from the mouse ES cells 
and the LY-R and LY-S on two independent experiments and measured the average ALT 
activity by quantifying the blot images as before. Data showed similar results in that the 
mouse ES 408 had higher activity on average 1.5 fold more CC activity than the isogenic 
E14 (not shown). This confirms that the Brca1 defective mESC line, 408, has the highest 
level of ALT activity in our set of mouse cell lines (Figure 6.2) (p= 0.0341). 
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Figure ‎6-2 CC assay on 30ng genomic DNA. A) from U2OS (ALT
+
), HeLa, GM00893, GM13705 (BRCA1
+/-
), 
HCC1937 (BRCA1
-/-
), SKLU-1, G292. B) E14 (Brca1
+/+
), 408 (Brca1
-/-
), LY-R, and LY-S. The quantitation was 
done using the Image J software. Error bars indicates SD. T-test used for statistical analysis. *P= 0.0341, 
**P=0.0169. 
 
The complete lack of ALT in LY-S cells is surprising, as normal mouse somatic cells have 
readily detectable ALT activity (Neumann et al., 2013). Interestingly, the levels of ATRX in 
the LY-S cell line was significantly lower than in the LY-R line (Figure 5.11). This reduction of 
ATRX in the LY-S cell line apparently does not affect ALT which is contrary to results of 
(Clynes et al., 2014) showing that the complete absence of ATRX activates ALT. Therefore, 
ablation of ATRX alone is not sufficient to trigger ALT in mouse cells possibly suggesting the 
involvement of other factors in ALT activation. It has been reported that mouse cells with 
reduced ATRX activity show DNA damage at telomeres and higher levels of γH2AX (Clynes 
et al., 2014, Lovejoy et al., 2012). This is true in respect to the radio-sensitive LY-S cells and 
could suggest an important role of ATRX in the DNA damage response.    
6.2.3 Detection of Telomerase activity in mESCs 
As discussed previously, mammalian cells maintain their telomere length through two major 
known pathways: telomerase or ALT (Cerone et al., 2001, Bednarek et al., 1995, 
Chadeneau et al., 1995, Blasco et al., 1996, Broccoli et al., 1996). To assess whether the 
ALT activity observed mESCs (Figures 6.1 and 6.2) has an effect on the telomerase levels 
* 
** 
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we measure telomerase activity using the gold standard PCR-based Telomerase Repeat 
Amplification Protocol (TRAP) assay (Kim et al., 1994, Harley et al., 1994, Kim and Wu, 
1997). Using this assay we measured telomerase activity in all mouse cell lines (E14, 408, 
LY-R and LY-S) with two different concentrations of protein (200ng and, 400ng data doesn’t 
shown) (Figure 6.3). Two human cell lines, HeLa (telomerase positive) and U2OS (ALT+; 
telomerase negative) served as controls (Figure 6.3). Since the TRAP assay is enzyme 
based we heat-treated each sample to inactivate the telomerase enzyme and to identify 
false positive reactions. The data revealed high telomerase activity in the HeLa cells as 
expected and consistent with previously published observations (Shay et al., 2001, Ivankovic 
et al., 2007) and low telomerase activity in U2OS cell line as expected (Bryan et al., 1997b, 
Vonderheide et al., 1999, Tilman et al., 2009, Lovejoy et al., 2012) (Figures 6.3 and 6.4). 
Interestingly, the two mESC lines showed ~5 fold and ~3 fold less telomerase activity 
relative to HeLa cells respectively (Figure 6.4), when quantified using Image J. Although the 
408 cells had slightly higher levels of telomerase activity compared to E14 cells the 
difference was not significant (p=0.149), whereas, we observed significant difference 
(p=0.0026) in telomerase activity between LY-S and LY-R cells (Figures 6.3 and 6.4). To 
confirm these observations we repeated the TRAP assay using 400ng of total Chaps-lysed 
protein and quantified the telomerase levels (data doesn’t show). The levels of telomerase 
activity in the U2OS, E14, 408 and LY-R were largely consistent with the previous TRAP 
assay in terms of levels of telomerase activity (200ng in Figure 6.3). However, the levels of 
telomerase activity in the HeLa and LY-S cells increased significantly when the 
concentrations of the telomerase were doubled (data doesn’t show) possibly suggesting the 
importance of the activity of telomerase in the maintenance of telomeres in these two cell 
lines. 
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Figure ‎6-3. Telomere Repeat Amplification Protocol (TRAP). 200ng of CHAPS lysed proteins used in all 
samples. The heat-treated samples were heated at 85C for 10 minutes to inactivate the telomerase enzyme. 
The Standanrd Internal Control (SI-C) at 36bp is indicative of complete PCR amplification. In high telomerase 
samples the SI-C is weaker than in low telomerase samples since the SI-C competes proportionaly with the 
telomerase enzyme. The 25bp DNA ladder is shown in the first lane. The last lanes are TSR8 (2 units of 
telomerase quantitation positive control. TSR8 is an oligonucleotide with a sequence identical to the TS primer 
extended with 8 telomeric repeats AG(GGTTAG)7. This control serves as a standard for estimating the amount of 
TS primers with telomeric repeats extended by telomerase in a given extract provided by the kit manufacturer) 
and CHAPS buffer used as internal positive and negative controls respectively. 
SI-C 
HeLa U2OS E14 408 LY-R LY-S 
50bp 
75bp 
100bp 
Heat treated     -        +          -         +          -          +       -          +        -          +       -         +        -         -       - 
TSR8   CHAPS 
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Figure ‎6-4 Telomerase activity in the human and mouse cell lines. U2OS (ALT
+
), HeLa (ALT
-
), LY-R, LY-S, 
E14 (Brca1
+/+
), and 408 (Brca1
-/-
) calculated using the TRAP gels from the 200ng protein . The artibtary unit of 
telomerase units calcualted using the formula described in chapter 2. T-test is used for statistical analysis. The 
200ng data is based on three independent experiments from two independent CHAPS lysed proteins.  
 
6.2.4 Investigation of BRCA1 protein in ALT and non ALT cell lines 
Given the differences observed in terms of ALT activity between mESCs and mouse 
lymphoma cell lines we thought that it is important to verify presence/absence of BRCA1 in 
all cell lines before moving further. First, we performed immunoblot analysis to measure 
levels of Brca1 in the mouse and human cells (Figure 6.5). Protein lysates were extracted 
from 1.6x106 cells from each cell line and total protein lysate (60µl from human cells and 
30µl from mouse cells) were separated on a 4-20% a gradient gel (See Chapter 2 for detail). 
The Brca1 immunoblot confirmed the lack of Brca1 activity in the mouse ES cell 408 
compared to the E14 (Brca1 WT) and slightly lower Brca1 activity in the LY-S cells 
compared to the LY-R (45% and 75% respectively) (Figure 6.5A-C). The immunoblot 
revealed some BRCA1 activity (7%) in human BRCA1 defective breast cancer line HCC1937 
compared with the BRCA1 WT HeLa and U2OS lines (Figure 6.5B).  
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Figure ‎6-5  Immunoblotting of BRCA1 in the human and mouse cell lines. A) Western blot showing the 
BRCA1 expression. B) Protein bands were quantified by densitometry, expressed relative to actin, and 
normalized to the control (HeLa). C) Protein bands were quantified by densitometry, expressed relative to actin, 
and normalized to the control (E14). 
    
6.2.5 Immunofluorescence analysis of BRCA1, BLM and ATRX 
A recent study shows that BRCA1 interacts with the BLM helicase exclusively in ALT+ cells 
(Acharya et al., 2014). Although the exact mechanism of ALT activation in human tumor 
lines are not yet clear, it is suggested to involve several proteins central to the HR pathway 
including BRCA1 and BLM helicase (Acharya et al., 2014). This is interesting in the present 
context as we have shown that the ALT activity is extremely high in mouse Brca1 defective 
408 cells (Figure 6.1 and 6.2). To study the possible role of BLM interactions with BRCA1 in 
the ALT pathway we set out to use immunofluorescence experiments to assess co-
localisation between BLM, BRCA1, ATRX and telomeres in our set of cell lines. Thus, this 
section is divided into 4 parts examining interactions between: 
 BRCA1 and telomeres 
  HeLa         U2OS     HCC1937                        E14 408            LY-R          LY-S 
BRCA 1 
Actin 
260 
Mr (K) 
220 
43 
A 
B C 
B C 
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 BLM and telomeres 
 BRCA1 and BLM 
 BRCA1 and ATRX. 
BRCA1 and telomeres 
First, all cell lines were examined for the presence of BRCA1 foci using immunofluorescence 
(Figure 6.6). As expected significant differences were observed in the number and 
distribution of BRCA1 foci in human ALT+ (U2OS) and human ALT- (HeLa and HCC1937) 
(Figure 6.7 and 6.8) (p<0.0001). For example, U2OS cells showed on average 18.14 foci per 
cell compared to HeLa (13.38 foci per cell) and HCC1937 (4.14 foci per cell) (Figure 6.7). 
Similarly, we observed significant difference between the Brca1 foci in the E14 and 408 
(p<0.0001) (Figure 6.8) with E14 showing on average 11.78 foci per cell and 408 showing 
1.56 foci per cell of Brca1. These data are in agreement with the immunoblot shown in the 
previous section (Figure 6.5). However, we did notice a small number of Brca1 foci in the 
Brca1-/- mouse ES 408 cells (1.56 foci per cell) and we believe this could be due to the 
unspecific binding of Brca1 antibody to other transcript variants of the Brca1 gene (in human 
cells these are reported to be 5 BRCA1 gene isoforms with molecular weight range of 70-
220 kDa) (Monteiro et al., 1996, Bork et al., 1997). This unspecific binding of the Brca1 
antibody was also observed in the immunoblot image at ~ molecular weight of 120 kDa (data 
not shown). Due to the extremely low occurrence of these unspecific Brca1 foci in mouse ES 
408 cells we decided to continue with analysing for the colocalisation of the Brca1 with 
telomeres.  
Next we probed the BRCA1 immunostained slides with telomeric PNA FISH probes to scan 
for colocalisation between BRCA1 and telomeres (Figure 6.6 and 6.7). The results of our 
analysis are shown in Figures 6.8 and 6.9. The low levels of BRCA1 staining in HCC1937 
and 408 cells are most likely due to non-specific staining.  
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Figure ‎6-6- BRCA1 co-localise at telomere in human cell lines. Examples of immunofluorescence 
colocalisation of BRCA1 with telomeres in the human HCC1937 BRCA defective and HeLa and U2OS BRCA1 
positive cells. . Interphase cells were permeabilised and stained with anti-BRCA1 (green) and telomeric Cy3-
labeled PNA probes (red). Nuclei were counterstained with DAPI. 
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Figure ‎6-7- BRCA1 co-localise at telomere in mouse cell lines. Examples of BRCA1 colocalisation with 
telomeres. 408 cell line served as the negative controls, and E14 was used as the positive control. Interphase 
cells were permeabilised and stained with anti-BRCA1 (green) and telomeric Cy3-labeled PNA probes (red). 
Nuclei were counterstained with DAPI.  
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Figure ‎6-8- Total number of BRCA1 foci per cell in the human and mouse cells. Immunofluoresence of the 
total number of BRCA1 foci in the human ALT-positive (U2OS) and ALT-negative (HeLa and HCC1937) cells and 
the mouse ES cells (E14 and 408) and lymphoblastoid (LY-R and LY-S) counted in 50 cell nuclei in two 
independent experiments. T-test is used for statistical analysis. 
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Figure ‎6-9- Co-localisation of BRCA1 with telomeres in the human and mouse cells and human cell lines. 
Number of BRCA1 foci colocalised with telomeres in the human ALT-positive (U2OS) and ALT-negative (HeLa 
and HCC1937) cells and the mouse ES cells (E14 and 408) and lymphoblastoid (LY-R and LY-S) cells. In total 50 
cell nuclei counted in two independent experiments. The green bar indicates mean. T-test is used for statistical 
analysis. 
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BLM and telomeres 
Images of BLM staining in different cell lines are shown in Figures 6.10 and 6.11. The ALT+ 
U2OS cells had on average 6.5 BLM foci per cell whereas the ALT-/telomerase+ HeLa and 
HCC1937 had on average 8.24 and 9.8 foci per cell respectively (Figure 6.12 and 6.13). 
U2OS had significantly lower levels of BLM foci per cell when compared to both HeLa 
(p=0.0024) and HCC1937 (p<0.0001). However, when levels of BLM associated with 
telomeres were analysed in the human cells, the U2OS ALT+ cells showed higher levels of 
colocalisation (3.06 foci per cell) as compared to the ALT- HeLa (0.62) and HCC1937 (0.62) 
further indicating the involvement of BLM in the ALT activity (Figure 6.12 and 6.13). This 
difference was highly significant (p<0.0001). In the mESCs, level of average BLM foci per 
cell was slightly higher in the E14 cells (7.32) compared to 408 (6.68 foci per cell) but not 
significant (p=0.2287) (Figure 6.12). Interestingly, when BLM colocalisation with telomere 
was assessed in the two mESCs, E14 cells had much higher levels of BLM-telomere 
colocalisation (2.32 foci per cell) than 408 cells (0.44 foci per cell) (Figure 6.13). This 
significant difference (p<0.0001) backs up similar observation seen in the human ALT+ cells 
where BRCA1 was crucial in maintaining BLM association with telomeres further suggesting 
and important role of BLM, BRCA1 and ALT activity and in line with the recently published 
data (Acharya et al., 2014). Furthermore, LY-R and LY-S cells had the highest levels of 
average BLM foci per cells 10.44 and 11.72 respectively (Figure 6.12), but showed similar 
levels of BLM-telomere colocalisation (1.70 foci per cell in LY-R and 1.78 foci per cell in LY-
S) (Figure 6.13).  
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Figure ‎6-10- BLM (green) co-localisation with telomeres (red) in the human cell lines. . Interphase cells 
were permeabilised and stained with anti-BLM (green) and telomeric Cy3-labeled PNA probes (red). Nuclei were 
counterstained with DAPI. 
 
 
Figure ‎6-11- BLM (green) co-localisation with telomeres (red) in the mouse cell lines.  
Chapter 6: Additional ALT markers in mESCs 
 157 
      
 
Figure ‎6-12- Number of BLM foci per cell in the human and mouse cells. A total of 50 cell nuclei in two 
independent experiments were analysed. Statistical analysis carried out by T-test. 
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Figure ‎6-13- Co-localisation of BLM with telomeres in the human and mouse cells. A total 50 cell 
nuclei/sample counted in two independent experiments. The green bars indicate the means. T-test is used for 
statistical analysis. 
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BRCA1 and BLM  
Bloom syndrome (BS) is an uncommon cancer-predisposing autosomal recessive disorder 
characterized by genomic instability, immunodeficiency, infertility, and small stature 
(German, 1993, Ellis and German, 1996). BLM, the gene mutated in Bloom syndrome 
encodes a DNA helicase of the RecQ family (Ellis et al., 1995). Moreover, BLM associates 
with numerous proteins involved in DNA repair including BRCA1, DNA mismatch repair 
proteins, DNA topoisomerases, and Fanconi anemia proteins. BLM is a component of the 
BRCA1-associated genome surveillance complex (BASC) (Wang et al., 2000, Chaudhury et 
al., 2013, Wu et al., 2001). Interestingly BLM also associated with several telomere-specific 
proteins, such as POT1, TRF1 and TRF2 (Stavropoulos et al., 2002, Sun et al., 1998), 
(Temime-Smaali et al., 2008, Bhattacharyya et al., 2010). 
Next, we carried out immunofluorescence analysis using combination of BLM and BRCA1 
antibodies (Figures 6.14 and 6.15). Number of foci per cells and mean number of co-
localisation are shown in Figures 6.16. Our results indicate that HeLa as telomerase-positive 
cells contained a high frequency of BLM-BRCA1 co-localised foci (Figure 6.16A), but none 
are found at telomeres. Whereas only in ALT cells BLM and BRCA1 co-localise at 
telomeres. Interestingly all mouse cell lines (E14, LY-R, and LY-S) show less than 10% of 
co-localisation of BLM with BRCA1 (Figure 6.16B). Also data shows that BLM and BRCA1 
physically interact. 
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Figure ‎6-14- Examples of immunofluorescence showing co-localisation of BRCA1 with BLM in human cell 
lines. Interphase cells were permeabilised and stained with anti-BRCA1 (green) and anti-BLM (red) antibodies. 
Nuclei were counterstained with DAPI. 
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Figure ‎6-15- Examples of immunofluorescence showing co-localisation of BRCA1 with BLM in mouse cell 
lines. Interphase cells were permeabilised and stained with anti-BRCA1 (green) and anti-BLM (red) antibodies. 
Nuclei were counterstained with DAPI. 
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Figure ‎6-16- A) Co-localisation of BRCA1 with BLM in the human and mouse cells. B) Quantitation of 
percentage of cells with BRCA1-BLM co-localisation. A total 50 cell nuclei/sample counted in two independent 
experiments. The green bar indicate the means. T-test is used for statistical analysis. 
 
BRCA1 and ATRX 
To investigate whether ATRX co-localises with BRCA1 in our set of cell lines the Abcam 
antibody against ATRX was used in co-localisation experiments (Figures 6.17 and 6.18). 
The results of our analysis are presented in Figure 6.19. It is likely that the BRCA1 positive 
signals observed in HCC1937 (Figure 6.19) are the result of non-specific staining. The rest 
A 
B 
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of results are in line with expectation. In particular, we would like to highlight LY-S cells 
which showed the lowest level of co-localisation between BRCA1 and ATRX (Figure 6.19). 
At the end of this analysis it is important to provide some kind of summary which is 
presented in Figure 6.20. This Figure combines the result of APB analysis (Figure 5.8), 
ATRX analysis (Figure 5.12) with all Figures presented in this Chapter (Figures 6.9 and 
6.13).  
 
Figure ‎6-17- Examples of immunofluorescence showing co-localisation of BRCA1 with ATRX in the 
human cell lines. Interphase cells were permeabilised and stained with anti-BRCA1 (green) and anti-ATRX (red) 
antibodies. Nuclei were counterstained with DAPI. 
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Figure ‎6-18- Examples of immunofluorescence showing co-localisation of BRCA1 with ATRX in the 
mouse cell lines. Interphase cells were permeabilised and stained with anti-BRCA1 (green) and anti-ATRX (red) 
antibodies. Nuclei were counterstained with DAPI. 
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Figure ‎6-19- Co-localisation of BRCA1 with ATRX in the human and mouse cells. A) Number of BRCA1 and 
ATRX colocalisation in the human ALT-positive (U2OS) and ALT-negative (HeLa and HCC1937) cells and the 
mouse ES cells (E14 and 408) and lymphoblastoid (LY-R and LY-S) cells. B) Quantitation of percent of cells with 
ATRX-BRCA1 colocalisations in the human and mouse cells. In total 50 cell nuclei counted in two independent 
experiments. The green bar indicates mean. T-test is used for statistical analysis. 
 
 
A 
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Figure ‎6-20- Co-localised foci of APBs, ATRX, BRCA1 and BLM with telomeres in human and mouse 
cells. 
 
6.3 Discussion 
In previous chapters (4 and 5) we provided some evidence for the presence of ALT-like 
activity associated with the Brca1 defect but this was not conclusive. For example, we have 
shown elevated frequencies of T-SCEs in 408 cells relative to control cells (Figure 5.1) and 
increased numbers of APBs (Figure 5.7). However, the rest of ALT markers used indicated 
lack of differences between 408 and E14 cells (Figures 5.8, 5.12).  
The aim of this chapter was to use a more sensitive ALT marker known as the CC assay to 
assess the presence of ALT activity in the mESCs and other cell lines more accurately. The 
most accurate method for assessing the ALT activity at present is the CC assay that 
quantifies the levels of rolling circles generated as a result of recombination at telomeres 
(Henson et al., 2009, Henson and Reddel, 2010). Using this method we identified elevated 
levels of CC activity in the mouse ES cells E14, 408 and the lymphoblastoid LY-R cells 
(Figure 6.2). Further examination and quantification of the CC activity revealed that the 
Brca1 defective 408 cells had 50% more CC activity than the isogenic control counterpart 
E14 (Figure 6.2). We have also identified CC activity in the LY-R cells but no such activity 
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was observed in the LY-S cells (Figure 6.2). To our knowledge this is the first reported 
evidence of CC activity in the pair of mouse LY cells and ESCs, E14 and 408.  
It must be mentioned that the ALT activity in the mouse tissues has been reported previously 
(Neumann et al., 2013) suggesting that normal mouse somatic cells use the ALT pathway. 
However, it is not clear whether ALT activity in the mouse tissues have any telomere 
lengthening function. For example, it has also been demonstrated quite clearly that in some 
strains of laboratory mice telomere lengths are much longer (30-150kb) as compared to the 
wild-derived mouse strains with shorter telomere lengths of about 10-25kb (Hemann and 
Greider, 2000). Whether, the differences in the mouse telomeres are due to ALT activities is 
not known at present. The low activity of ALT was suggested to inhibit the elongation of 
telomeres by telomerase by trimming the long telomeres through recombination and 
production of t-circles (Neumann et al., 2013). To identify whether the high levels of CC 
activity in the mouse cells and subsequently ALT-type activity has replaced telomerase, we 
measured the levels of telomerase enzyme activity using the TRAP assay. Quantifying the 
TRAP data revealed some interesting points: (i) that levels of telomerase enzyme in E14 and 
408 were similar and (ii) levels of telomerase were significantly higher in LY-S cells than in 
the LY-R cells (Figure 6.4; p=0.0026). Interestingly, we observed differences in the level of 
enzyme activity between 200ng and 400ng protein extract concentrations between LY-R and 
LY-S cells (Figure 6.4). However, this was replicated in the case of the telomerase positive 
HeLa cell line (Figure 6.4) possibly suggesting that the importance of the activity of 
telomerase in the maintenance of telomeres in this two cell lines. 
This suggested that the co-existence of ALT and telomerase in the mouse cells might serve 
different functions depending on the type of cells. For instance, the elevated levels of 
telomerase in the LY-S cells may serve to maintain the shorter telomere lengths of the LY-S 
whereas in the LY-R the low levels of telomerase may have canonical function other than 
telomere length elongation and maintenance since ALT in the LY-R cells, may be the 
prominent mechanism of telomere length maintenance. Alternatively, functional activity of 
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ALT and telomerase in the mESCs, regardless of the levels of Brca1 activity, might serve 
independent roles. It would be of interest to study the telomere length role of telomerase and 
ALT in mESCs by inhibiting telomerase enzyme using specific telomerase inhibitor such as 
Imetelstat (GRN163L; Geron) and subsequently measuring telomere length. However, due 
to lack of time this hypothesis was not followed. 
We also measured levels of Brca1 protein using western blotting to check whether Brca1 
was fully expressed in all cell lines and to define the levels of Brca1 activity in the mutant 
lines, especially in the mutant human BRCA1-defective cell line (HCC1937) and the mouse 
ES cell line 408. The results further confirmed the published observation that there is a leaky 
expression of BRCA1 protein in the human HCC1937 extracts as previously described 
(Figure 6.5) (Tulchin et al., 2013). The 408 cell line did not have any detectable levels of 
Brca1 expression. Once we were confident of the levels of Brca1 activity, we set out, in a 
series of single and double immunofluorescence experiments, to measure the co-localisation 
of Brca1 with telomeres, BLM, and ATRX in all seven human and mouse cell lines (Figures 
6.15-6.20).  
When assessing the co-localisation of BRCA1 with ATRX and we found that two mouse cell 
lines, E14 and LY-R (both ALT-positive) showed significantly higher level of co-localisation in 
comparison with 408 (ALT-positive) and the LY-S (ALT-negative) respectively (Figure 6.18; 
p<0.0001 and p=0.0002). These are the first ever-reported data, to our knowledge, of 
colocalisation amongst Brca1 and ATRX in the mouse cells and our data clearly suggest that 
the ATRX and Brca1 co-localises at higher levels in the ALT-positive cells. However, these 
data are in contradiction to the functional role of ATRX in the human cells. It has been shown 
that the level of ATRX is diminished in 90% of human ALT-positive cells and that ATRX can 
be a marker of ALT activity in the human cells (Lovejoy et al., 2012). In the mouse cells we 
have found that ATRX is much lower in the LY-S cells and this low levels of ATRX does not 
correlate to the ALT activity whereas the LY-R and E14 have elevated levels of ATRX as 
well as ATRX co-localisation with Brca1. Why the ATRX levels are lower in the LY-S cells 
Chapter 6: Additional ALT markers in mESCs 
 169 
and not in the 408 cells are puzzling. However, in ALT-negative human cell lines; HeLa and 
HCC1937 (BRCA1-/-); the high frequencies of co-localisation were observed. 
It is now clear that only in ALT cells, BRCA1 and BLM co-localise with RAD50 (Acharya et 
al., 2014). We presented evidence that in mESCs, LY-R and LY-S cells only a fraction of 
BRCA1 co-localises with BLM at telomeres (10% percentage) (Figure 6.16B). Our data from 
the human cells HeLa and U2OS are in agreement with the results obtained by Acharya et 
al. (2014), which shows HeLa cells have higher frequency of co-localisation than the U2OS 
cells. 
Perhaps, the most interesting observation in this Chapter was the highest level of ALT 
activity in 408 cells (Figure 6.2). This finding suggests that, at least in the context of mouse 
cells, defective Brca1 may contribute to increase in the ALT pathway. In the human BRCA1 
negative cells, HCC1937, the ALT activity was absent (Figure 6.2). Further investigation is 
required to expand upon these initial findings and assess their relevance. In the same 
context, it is important to highlight the situation with the pair of well characterized mouse 
lymphoma cell lines, LY-R and LY-S cells (Figure 6.2). Surprisingly, the only mouse cell line 
with no evidence of ALT was the LY-S cell line (Figure 6.2) thus contradicting observations 
by Neumann et al. (2013) that mouse somatic cells use ALT regularly as a method for 
telomere maintenance. It will be of importance to understand the nature of this observation in 
the context of LY-S cells radiosensitivity. All known components of DSB repair, that mediate 
radiosensitivity, are normal in LY-S cells (McIlrath et al., 2001). Given that telomere 
maintenance and DDR mechanisms are functionally linked (d'Adda di Fagagna et al., 2003) 
it would be of interest to assess to which extent potentially defective telomere maintenance 
in LY-S cells contributes to radiosensitivity. By the same token, our results argue that 
defective BRCA1 alters telomere homeostasis in favour of ALT perhaps acting as its de-
repressor. This finding may have implications for cancer therapy based on targeting 
telomere maintenance. 
Chapter 6: Additional ALT markers in mESCs 
 170 
 
Chapter 7: General Discussion 
 171 
 
 
 
 
 
 
 
 
 
7 General Discussion and Future 
Research Direction 
 
7.1 Introduction 
BRCA1 is an important tumour suppressor protein that plays a key role in the DDR and DNA 
repair (Roy et al., 2011, Jiang and Greenberg, 2015). Germline mutations in BRCA1 
increase the life-time risk of developing breast (40-80%) and ovarian cancer (11%-50%) 
(Roy et al., 2011, Petrucelli et al., 2013). The main role of BRCA1 in DNA repair is fulfilled 
via the HR mechanism, an important DNA repair pathway that uses the undamaged sister 
chromatid to carry out high-fidelity repair of predominantly replication-associated DSB (Roy 
et al., 2013). BRCA1 also has a critical role in sensing DNA damage and therefore it is vital 
to the DDR and cell cycle checkpoint activation (Roy et al., 2013), making the role of BRCA1 
in the genome integrity indispensible in the mammalian cell. More recently, it has been 
suggested that BRCA1 plays an active role in ALT-positive cancer cells but not telomerase-
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positive cancer cells with the help of BLM and RAD50 (Acharya et al., 2014). However, the 
exact role of BRCA1 in telomere maintenance in ALT-positive cells is still unclear. 
In this thesis we explored the role of BRCA1 from a telomere biology point of view by 
assessing markers of telomere dysfunction and ALT activity in the human and mouse cells. 
Our data revealed additional evidence for the role of BRCA1 in telomere dysfunction in the 
mammalian cells (Chapter 3; 4). Furthermore our data provided a new line of evidence for 
the relationship between BRCA1 and ALT activity in the mouse cells (Chapter 5; 6). These 
results are briefly summarized below. 
7.2 Telomere dysfunction in BRCA1 mutation carriers 
Telomere dysfunction can lead to premature senescence (de Lange, 2006) and cancer 
(Blackburn et al., 2006, Donate and Blasco, 2011) if left unrepaired. The current known 
mechanisms behind telomere dysfunction are (a) disrupted shelterin proteins leading to 
unprotected telomeric ends (de Lange, 2006), (b) telomere length shortening and loss of the 
t-loops (Blackburn et al., 2006), (c) defective DNA damage repair and sensing proteins 
(d'Adda di Fagagna et al., 2004). To assess the role of BRCA1 in telomere dysfunction in the 
human cells, we used two markers of telomere dysfunction i.e. T-SCE and telomere length 
using human cell lines from BRCA1 carriers. Our findings specific to cells from BRCA1 
carriers, described in detail in Chapter 3, indicate (i) higher frequencies of T-SCE, (ii) 
significantly shorter telomeres and (iii) defective DDR that also affects telomeres. Previous 
studies have shown that BRCA1 deficiency leads to telomere dysfunction, as evidenced by 
elevated chromosome fusions and translocations involving telomeres and telomere 
shortening (Cabuy et al., 2008, McPherson et al., 2006). To our knowledge in this thesis we 
reported first evidence of elevated T-SCEs in the two BRCA1 mutation carrier human cell 
lines and our observation of telomere shortening is consistent with the function of BRCA1 on 
telomeres that has been previously demonstrated (McPherson et al., 2006). However, the 
exact role of BRCA1 in telomere length homeostasis is conflicting. For example, Ballal et al. 
(2009) has shown that knock-down of BRCA1 protein using siRNA in two breast cancer cell 
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lines (MCF7 and T47D) led to increases in telomere length by an average of 3.45kb with 
45% increase in the activity of the telomerase enzyme. The same study also showed that co-
knock-down of the hTERT (the catalytic subunit of the telomerase enzyme) and BRCA1 did 
not result in telomere shortening suggesting that the mechanism of telomere lengthening by 
BRCA1 may be independent of the telomerase enzyme. In contrast, in another study, Cabuy 
et al., (2008) did not find changes in telomere length or the telomerase enzyme activity when 
BRCA1 was knocked down in the mammary epithelial cells, although the frequencies of 
anaphase-bridges (normally is indicative of dysfunctional telomeres) was elevated in those 
cells. The authors, therefore, suggested that the role of BRCA1 on telomeres might have a 
protective function rather than affect telomere length maintenance. Moreover, increased 
frequency of TIFs observed in cells from BRCA1 carriers shown in Chapter 3, further 
highlights the role of BRCA1 in telomere integrity maintenance. Taken together, our data 
presented in Chapter 3 seems to be in agreement with the published data (Cabuy et al., 
2008, Ballal et al., 2009, Al-Wahiby and Slijepcevic, 2005, McPherson et al., 2006) pointing 
towards the active role of BRCA1 in telomere maintenance and length stability. However, the 
exact mechanism behind BRCA1 function in telomere length maintenance remains unclear. 
7.3 Evidence for ALT activity in BRCA1 defective mESCs 
ALT is another mechanism used in mammalian cells to maintain or increase telomere 
lengths. Roughly 15% of human cancers use ALT as the preferred mechanism of telomere 
length maintenance (Bryan et al., 1995, Bryan et al., 1997b, Bryan and Reddel, 1997, Hande 
et al., 1999). The currently accepted explanation for telomere elongation in the ALT positive 
cells is through the HR mechanism (Dunham et al., 2000). Interestingly, it has been 
proposed that recombination-mediated telomere synthesis was the archetypal telomere 
lengthening mechanism when eukaryotes first evolved linear chromosomes and that this 
was permanently repressed when it was superseded by telomerase in later eukaryotes (de 
Lange, 2004). It has recently been shown that the ALT activity is present in normal mouse 
tissues but this activity may be repressed in the mouse germline cells (Neumann et al., 
2013). The exact molecular mechanism behind ALT repression or derepression in the 
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mammalian cells is not fully understood. A recent study have suggested that BRCA1, 
through its interaction with BLM and RAD50, accumulates and co-localises at telomeres in 
the ALT+ human cells but not in telomerase+ cells (Acharya et al., 2014). Our results 
presented in Chapters 4, 5 and 6 of this thesis, provided novel insights into the mechanism 
of ALT in mammalian cells. We demonstrated that levels of T-SCE (one of the markers of 
ALT activity) were significantly higher in the mESC line, 408 (Brca1-/-) and lymphoblastoid 
cells from BRCA1 carriers. These initial observations suggested that at least one recognized 
ALT marker (T-SCEs) was positive. However, when we looked at other markers, such as 
ATRX and APBs we did not find significant differences between Brca1 defective cells and 
the control cells suggesting lack of association between Brca1 and ALT in these cells.  
Nevertheless, when we assayed for the occurrence of ALT using a more sensitive assay (the 
CC assay) we found ALT activity in both mESCs and mouse lymphoblastoid LY-R cells. The 
ALT activities in these cells were accompanied with telomerase and this data confirm the 
previous finding that ALT may be expressed at low levels in all mouse somatic tissues 
(Neumann et al., 2013). However, to our surprise, the 408 cells had 1.5 fold higher activity 
than the isogenic normal counterpart. This clearly provided additional evidence for the 
involvement of Brca1 in ALT derepression mechanism in the mouse cells. However, we 
believe factors might be at play in addition to Brca1. Our results indicate the non-canonical 
role of ALT in the mouse cells. For example, higher activity of ALT in the 408 cells may serve 
a different function possibly more related to the DNA repair and the HR than telomere length 
synthesis whereas, the activity of ALT in the LY-R cells may serve as telomere length 
maintenance. Our results strongly suggest that the ALT activity is suppressed in the LY-S 
cells. This finding is of great interest for future research. We therefore, provided first strong 
evidence of higher ALT activity in the Brca1 defective mESCs on the absence of ALT in LY-
S cells. But it must be pointed out that, that we do not have direct evidence for some of the 
hypotheses we postulated above, namely the different functional role of ALT. We believe 
these can be the basis for further investigation. 
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7.4 Future Research Direction 
As mentioned above the novel findings of this thesis are: 
 Identification of elevated levels of T-SCE in the human BRCA1 defective cells; 
 Telomere dysfunction phenotype in the human and mouse Brca1 defective cells; 
 Elevated ALT activity in the mouse Brca1 defective cells; 
 Absence of ALT activity in the LY-S mouse lymphoma cells. 
As a result of the above findings several line of new research could be pursued. Firstly, it 
would be of interest to further investigate, at molecular level, the mechanism behind BRCA1 
and ALT derepression in the mammalian cells to identify whether BRCA1 cooperates with 
other factors such as BRCA2, BLM, WRN, Rad50 etc in providing ALT repression and if so 
to what extent. These can be performed using shRNA library screening or with the help of 
genome editing using CRISPR/Cas9. For example, conditional in vitro knock-out of BRCA1 
and BRCA2 in normal human and mouse cells may provide further insight into the 
biochemical and functional activities of BRCA1/BRCA2 from telomere maintenance 
perspective. These cells can be subjected to detailed cytogenetic analysis using double 
colour CO-FISH to measure the levels of chromatid exchanges and imbalances or telomere 
probe STORM imaging to quantify levels of t-loop formation. 
Secondly, the alternative functions of the ALT in mouse cells could be further investigated. 
For example, the co-existence of telomerase and ALT in the mouse cells provides a nice 
model to study telomere length synthesis role of ALT in the mouse 408 and LY-R/LY-S cells 
by inhibiting the telomerase activity either through inhibitor of the telomerase enzyme or 
knock-down of the mouse Tert gene. This will enable identification of the role of ALT on 
telomere length maintenance. Telomere length measurement could quickly be performed 
using qPCR or IQ-FISH methods. 
Of particular importance would be examination of the nature or radiosensitivity in LY-S cells 
in light of ALT absence. A strong body of data indicate functional link between DDR and 
telomere maintenance (d'Adda di Fagagna et al., 2004).  
Finally, it would be of interest to identify genes that may play important roles in ALT 
derepression by performing large-scale RNAi screening coupled with transcriptomics 
(RNAseq) to identify genes that may activate ALT phenotype in normal human cells. Data 
generated here will enable identification of functional role of set of gene(s) that can further 
be investigated through single-gene knock-outs experiment. Finding out the exact 
mechanism of ALT derepression and activity in maintaining the telomere length will have 
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important clinical uses. For example, it can be used to design novel anti-ALT inhibitors as an 
anti-tumour drugs.       
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